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  Infertility is a worldwide epidemic often treated with in vitro fertilization. The 
success of in vitro fertilization is directly dependent upon the quality of oocytes 
produced during the controlled stimulation of the patient’s ovaries.  There is a need 
for improved methods to allow embryologists to select the most viable embryos 
with the highest probability of leading to live births since in vitro fertilization success 
is far from optimal.  
 Oocyte and subsequent embryo quality are intimately influenced by the 
granulosa cells which surround the oocyte during follicular maturation.  The 
oocytes require proper signaling and energy production form the surrounding 
granulosa cells for ideal maturation which will allow the oocyte to fertilize and 
produce a viable embryo.  We hypothesize that mRNA levels of certain genes in 
granulosa cells will allow for the identification oocytes that will produce euploid 
embryos and the most viable embryos within a cohort.  Secondly, we hypothesize 
that the rate by which mitochondria from granulosa cells are able to utilize certain 
metabolic substrates will be able to identify patients that have increased probability 
of producing high quality embryos leading to live births.
This dissertation attempts to identify a group of genes within individual 
cumulus cells that show differential mRNA gene expression between oocytes of 
euploid embryos and oocytes leading to live birth compared to oocytes that do not.  
From these genes we further attempt to create a model using multiple genes to 
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identify the most viable oocytes within a cohort.   This dissertation also attempts to 
identify metabolic substrates differentially utilized by granulosa cell mitochondria 
based on patient demographics or embryo development and determine if individual 
substrates can be used as mitochondrial biomarkers for assisted reproduction.  As 
a whole, the work in this dissertation seeks to provide a panel of biomarkers that 
can be used by clinicians to better identify embryos that will help improve overall 
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1.1 Significance of Study 
In vitro fertilization (IVF) is a common intervention for treating women 
struggling with infertility.  IVF involves hormonally priming a woman’s ovaries to 
mature multiple follicles, retrieving oocytes from the follicles, inseminating the 
mature oocytes with the partner’s or donor sperm, and after several days selecting 
cultured embryos for transfer to the patient’s uterus.  Most IVF cycles fail to lead 
to a live birth.  Each round of IVF has a tremendous cost to the patient ranging 
from $10,000 to $20,000 per fresh oocyte retrieval and around $4,000 for 
subsequent frozen embryo transfers (FETs).  The low take-home baby rate means 
that many patients will incur each of these costs multiple times.   
To improve live birth outcomes, the use of preimplantation genetic testing 
for aneuploidy (PGT-A) has been employed to identify genetically euploid embryos 
before uterine transfer.  In some cases, PGT-A has been shown to increase 
implantation, ongoing pregnancy, and delivery rates (Chen et al., 2015a, 
Schoolcraft et al., 2010, Scott et al., 2013, Yang et al., 2012).  However, PGT-A is 
also an invasive method that requires the removal of several cells from the 
embryo’s trophectoderm layer of the blastocyst.  Using euploid embryos for uterine 
transfer does not guarantee implantation, however, and some studies have 
indicated there is a decreased pregnancy rate following PGT-A  (Kushnir et al., 
2016, Chang et al., 2016).  One study has shown that only certain age groups 
benefit from PGT-A testing (Kang et al., 2016).  Additionally, implantation failure 
has been positively correlated with the number of cells removed during the biopsy 
procedure (Zhang et al., 2016).  There is also concern that mosaicism (two distinct 
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cells lines within the same embryo) will give rise to erroneous PGT-A results and 
that some embryos which would lead to genetically normal live births will not be 
transferred because of these misleading results (Kushnir et al., 2018, Gleicher et 
al., 2016, Taylor et al., 2014).  Therefore, finding a non-invasive and reliable 
method to select the most viable oocytes and subsequent embryos for uterine 
transfer would be highly desirable in the field of IVF.  
 The ultimate success of an IVF cycle is determined by ovarian stimulation 
protocols and patient characteristics that control the quality of the oocytes retrieved 
(Adriaenssens et al., 2010a).  These various factors will influence the development 
of the somatic cells of the ovarian follicle, specifically, the granulosa cell (GC) 
population.  In turn, the GCs will impact the developing oocytes they enclose 
(Eppig et al., 1996, Gilchrist et al., 2008, Matzuk et al., 2002).  In an ideal IVF 
stimulation, the interactions of the GCs and oocytes will result in optimal conditions 
for oocyte maturation (Tanghe et al., 2002, Uyar et al., 2013).  Since the GCs are 
readily obtained as a by-product of the IVF process, they are an ideal source of 
materials for non-invasive analysis of oocyte potential.  Techniques which assess 
mRNA biomarker levels and mitochondrial substrate utilization in GCs allow rapid 
profiling that could potentially identify the most viable oocytes and subsequent 
embryos and still be incorporated into the standard workflow of an IVF laboratory 
without much difficulty.  mRNA expression analysis and mitochondrial metabolic 
assessment of GCs can be performed before embryo transfer (ET) allowing for the 
selection of the embryo with the highest implantation potential.  Several recent 
studies suggest that GC mRNA biomarkers can be used to generate models that 
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can identify oocytes/embryos with the highest probabilities of leading to 
pregnancies and live births (Borup et al., 2016, Ekart et al., 2013, Iager et al., 2013, 
Wathlet et al., 2011, Wathlet et al., 2012, Wathlet et al., 2013). Mitochondrial 
function and mitochondria content have also been shown to be related to oocyte 
maturation and IVF pregnancies as well (Dalton et al., 2014, Huang and Wells, 
2010, Tsai et al., 2010). 
The developing ovarian follicle is comprised of an oocyte, follicular fluid, and 
distinct somatic cell populations.  The preovulatory follicle, whose cells are 
harvested during the IVF procedure, contains two distinct GC types: the cumulus 
granulosa cell (CC) and the mural granulosa cell (MGC). The CCs surround and 
share gap junctions with their individual oocytes.  Cumulus cells remain attached 
to their oocytes following oocyte retrieval and must be mechanically and 
enzymatically removed before intracytoplasmic sperm injection (ICSI) of 
spermatozoa for insemination in male factor and PGT-A cases.  Cumulus cells will 
remain attached to the oocyte during conventional insemination procedures.  
Cumulus cells have bi-directional communication with the oocytes and tend to 
reflect the oocyte’s overall health (Huang and Wells, 2010).  Biomarkers of GCs 
associated with individual oocytes could potentially be used in assisted 
reproduction procedures to indicate which embryos have the best chance of 
implanting in the uterus and completing gestation.   
Successful embryo development relies upon sufficient energy metabolism 
generated by adenosine triphosphate (ATP) processed through the mitochondria.  
Cumulus cells produce ATP and augment oocyte ATP supply during follicular 
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growth.  The CCs also provide pyruvate for the oocyte, generated from glycolysis, 
via gap junctions. Pyruvate is converted by pyruvate dehydrogenase to acetyl-CoA 
which enters the tricarboxylic acid cycle where it is metabolized and ultimately 
produces ATP through the process of oxidative phosphorylation (OXPHOS) within 
the mitochondria of the oocyte (Su et al., 2009, Sutton-McDowall et al., 2010).  
Several studies have evaluated CCs, MGCs, and trophectoderm cells from 
blastocysts, and it appears there is a high correlation between the mitochondrial 
DNA (mtDNA) content found in oocytes and CCs indicating that CC mtDNA levels 
might serve as a biomarker for oocyte competence (Boucret et al., 2015, 
Desquiret-Dumas et al., 2017, Diez-Juan et al., 2015, Fragouli and Wells, 2015, 
Ogino et al., 2016, Taugourdeau et al., 2019).   
We hypothesize that specific biomarkers in GCs can be used to select 
individual oocytes and their subsequent embryos that have the best chances of 
leading to viable pregnancies and resulting in live births.  We propose a series of 
studies to determine if (1) a set of CC mRNA biomarkers and (2) GC mitochondrial 
metabolic substrate utilization can be used to improve IVF outcomes.  Successful 
completion of the first study will result in a mRNA biomarker model that can be 
used to select the embryos for uterine transfer that have the best chance of 
resulting in a live birth. Accomplishment of our second goal will result in 
determination if mitochondrial metabolic substrate utilization in pooled MGCs and 
CCs can be used as biomarkers relating to patient demographics and embryo 
development.   A future goal would be to utilize a small subset of mitochondrial 
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substrates as biomarkers to analyze individual CC masses to choose individual 
embryos for uterine transfer.  
1.2 Ovarian Structure 
The female gonad is called the ovary, and it is analogous to the testis in the 
male.  The ovary’s primary function is oocyte production or oogenesis.  It will store 
oocytes arrested at the primordial stage of development until they are recruited to 
initiate maturation.  After puberty and through menopause, the ovary will mature a 
cohort of oocytes each reproductive cycle and ovulate one or more oocytes each 
cycle. The ovary also acts as an endocrine gland producing hormonal secretions 
such as steroids prior to ovulation and from the luteinized cells of the follicle which 
remain in the ovary and form the corpus luteum (CL) following ovulation.   
 A single ovary is located on each side of the uterus and attached with an 
ovarian ligament (Figure 1.1).  Each ovary lies near the fimbriae of each oviduct or 
Fallopian tube.  The Fallopian tube acts as a conduit to transport spermatozoa 
from the male, oocytes from the female, and the resulting embryo following 
fertilization.  The Fallopian tubes will also provide a nutrient-rich environment for 
the gametes and embryos.  A spermatozoon will fertilize the oocyte in the ampulla 
of the Fallopian tube and the resulting fertilized oocyte, also known as the zygote, 
will be transported to the uterus for implantation.  The uterus has an external wall 
called the perimetrium, a muscular middle layer called the myometrium, and an 
inner layer called the endometrium.  Both the myometrium and endometrium are 
responsive to hormones of the reproductive cycle.  The endometrium has two 
layers the stratum functionalis and the stratum basalis.  The stratum functionalis 
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lines the inside of the uterus and is where the embryo will attach and grow into a 
fetus or it will be shed during menstruation if the embryo does not implant. 
The ovary (Figure 1.2) is a complex structure containing multiple cell types 
with diverse and dynamic functions.  The innermost layer is the ovarian medulla 
and the outermost layer is the ovarian cortex. The outer cortex, known as the tunica 
albuginea, is composed of only dense connective tissues which protect the ovary. 
The ovary contains female gametes, termed oogonia or oocytes, and somatic cells 
within the ovarian follicles and specialized dense connective tissue, termed 
stroma, and blood vessels. Ovarian nerves, as well as blood and lymphatic 
vessels, reside within the medulla.  The main difference between the medulla and 
cortex is that ovarian follicles are only present in the cortex.  
The main functional components of the ovary are the ovarian follicles.  The 
follicles consist of oocytes, GCs, and theca cells (TCs).  The GCs and TCs provide 
the oocyte they surround with a protected environment in which they grow and 
mature, allowing for fertilization by a spermatozoon following ovulation (Buccione 
et al., 1990). There is bi-directional communication between the GCs and oocytes, 
which promotes oocyte maturation (Tanghe et al., 2002, Uyar et al., 2013).   This 
close association between the oocytes and their GCs make the GCs good 
candidates for research related to oocyte developmental competence.   
1.3 Oogenesis 
Oogonia are derived from primordial germ cells (PGCs). In humans, PGCs 
appear early during the second week of embryonic development from the  primary 
ectoderm (Larsen, 2001, Wylie, 1999).  PGCs can travel to various locations 
  
  8 
throughout the embryo and yolk sac but will finally colonize the gonadal ridges 
(Richardson and Lehmann, 2010). Human PGCs migrate from the primary 
ectoderm to the extra-embryonic yolk sac after their formation.  Around week 5 of 
embryonic development, human PGCs travel back to the embryo where they 
colonize the epithelial-derived sex cords within the gonadal ridges, which ultimately 
form the primordial gonads.  Concomitant with cortical sex cords proliferation, the 
epithelial cells which surround the PGCs will eventually transform into somatic GCs 
within the ovarian follicles and ovarian TCs will derive from the mesenchyme of the 
genital ridge.   
In humans, PGCs will undergo mitosis until around the seventh month of 
fetal development.  At that point, they will begin meiosis and give rise to the 
oogonia within the ovary.  PGCs are unique as they are the only cells that can 
initiate and undergo meiosis.  The oogonia experience incomplete cytokinesis and 
remain linked through cellular bridges and will cluster together into nests 
surrounded by a single layer of pre-granulosa cells (Pepling and Spradling, 1998).  
It has been suggested that most of the oocytes within an individual nest will not 
ultimately undergo folliculogenesis but undergo atresia, so only the most 
competent oocytes from each nest will survive (Hernandez-Ochoa et al., 2009).   
At birth, female humans will have approximately 1 million oogonia.  All the 
oogonia will undergo arrest at the diplotene stage of meiotic prophase I (MPI), as 
primary oocytes, where they will persist until the onset of sexual maturity 
(Whitaker, 1996).  The primary oocytes will remain in a quiescent state until a small 
cohort of primary oocytes is recruited with each reproductive cycle, due to 
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hormonal signals from the pituitary gland, and transform into secondary oocytes 
(McGee and Hsueh, 2000).  Secondary oocytes will mature and gain meiotic 
competence to form a viable metaphase II (MII) oocyte throughout the follicular 
stage of the reproductive cycle.  In response to the luteinizing hormone (LH) surge, 
the oocyte will be expelled from the follicle and ovulated into the oviduct in 
preparation for fertilization by a spermatozoon.  The ovary will reabsorb the 
remaining oocytes of the cohort that do not gain competence and complete 
ovulation.  Follicular oocyte quantity dwindles with increasing age and it is widely 
accepted that the supply is finite and females will stop ovulating when the stock of 
oocytes is depleted (Gosden et al., 1983, te Velde et al., 1998). However, there is 
growing evidence that germline stem cells could potentially replenish part of the 
ovarian oocyte pool and form new primordial follicles; this is still a topic of debate. 
Surface epithelial cells from tunica albuginea in human ovaries have been shown 
to differentiate into GCs and oocytes, which combine form new follicles (Bukovsky 
et al., 2004, Bukovsky, 2005). 
During oogenesis mitochondria, other organelles, RNA, proteins, and 
energetic repositories will accumulate in the oocytes in preparation for the early 
stages of pre-embryonic development.  Mitochondria will proliferate within the 
oocyte and a bottleneck appears to exist where the healthiest mitochondria with 
minimal mutations are preferentially selected to be passed to the next generation 
(Figure 1.3) (May-Panloup et al., 2016, Marlow, 2017).  Estimates suggest pre-
migratory PGCs have 10 mitochondria, increasing to 100 when the PGCs migrate  
to the gonadal ridges, and nearly 10,000 in the primordial follicle in the human 
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(Jansen and de Boer, 1998) with other estimates suggesting up to 250,000 
mitochondria or more in the oocyte (Barritt et al., 2002, May-Panloup et al., 2005b, 
Reynier et al., 2001, Santos et al., 2006).  It has been proposed that the bottleneck 
serves to maintain a uniform genome of mtDNA, termed homoplasmy, and reduce 
multiple mtDNA genomes, termed heteroplasmy (Cummins, 2001).  Mitochondria 
are also found within the early flattened GCs which surround the oocyte at this 
early stage of development.  Regions of concentrated mitochondria and other 
organelles, termed Balbiani bodies, are found in the cytoplasm near the nuclei of 
primary oocytes humans (Motta et al., 2000).  Multiple metabolic pathways are 
present during oocyte maturation.  Primordial follicles utilize both glucose and 
pyruvate as substrates meaning they use both glycolysis and OXPHOS to 
generate ATP (Shoubridge and Wai, 2007).  Additionally, pyruvate is supplied to 
the oocyte from the breakdown of glucose by the CCs through gap junctions 
(Jansen and Burton, 2004). 
Following a period of dormancy, which can last for several years in humans, 
the primary oocyte begins to grow and prepare for fertilization.  The nucleus of the 
oocyte is termed the germinal vesicle (GV).  The GCs and TCs surrounding the 
oocyte will transform through varying stages, beginning with a single layer of 
flattened squamous pre-GCs into a multilaminar antral follicle containing both GCs 
and TCs (Lintern-Moore and Moore, 1979). Germinal vesicle breakdown (GVBD) 
is a necessary first step in the resumption of meiosis by the oocytes and the 
process is initiated in several animal species by maturation [M-phase] promoting 
factor (MPF) following the LH surge (Eppig et al., 1983, Jones, 2004). It has been 
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postulated that within the antral follicle that the CCs, MGCs, and TCs all generate 
adenosine 3’,5’-cyclic monophosphate (cAMP) which is shuttled into the oocyte.  It 
has been shown that gap junctions are the gateways by which cAMP is transferred 
from the somatic cells to the oocyte leading to the redeployment of the catalytic 
subunit of adenylyl cyclase/cAMP/protein kinase A (PKA) (Webb et al., 2002).  The 
cAMP keeps MPF in its inactive form, maintaining the oocyte in the diplotene 
phase of meiosis I (Dekel et al., 1981).   
The causal mechanism behind the resumption of meiosis is a marked 
decrease of cyclic guanosine monophosphate (cGMP) in GCs following the LH 
surge.  There is also a concomitant decrease of cGMP levels in the oocyte 
increasing phosphodiesterase 3A enzyme activity which promotes conversion of 
cAMP to adenosine 5’-monophosphate (AMP) resulting in lower cAMP levels and 
triggers MPF to resume meiotic development (Celik et al., 2015, Jaffe and Egbert, 
2017, Mehlmann, 2005). It has been demonstrated that when oocytes from 
vertebrates and mammals are removed from antral follicles and cultured in control 
media and somatic cell conditioned media, the oocytes in the somatic cell media 
exhibit reduced GVBD which suggest CCs and MGCs play a role in maintaining 
oocytes in the arrested meiotic state (Liang et al., 2007).  When an oocyte is 
removed from the follicle, spontaneous maturation will occur because the 
communication between the somatic cells and the oocyte ceases (Conti et al., 
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1.4 Folliculogenesis 
The pre-antral phase of folliculogenesis is gonadotropin independent, while 
the antral phased is governed by the gonadotropins of the reproductive cycle 
(Figure 1.4). At any point in time, the ovary contains follicles at many stages of 
development.  The reproductive cycle begins with the follicular phase when a small 
cohort of primary oocytes within small (~2 mm) antral follicles resume growing in 
response to follicle stimulating hormone (FSH), the critical regulator of 
folliculogenesis, from the anterior pituitary.  Follicles will grow for several months 
in the primordial, pre-antral, and early antral stages of folliculogenesis prior 
reaching the small antral stage.  In addition to the oocytes, the somatic cells 
surrounding each primary oocyte also grow and transform in response to the 
hormones of the reproductive cycle.  Throughout the follicular phase, the somatic 
cells differentiate into distinct cell types.  The cells near the oocyte will become the 
GCs (CCs and MGCs) while those most distal from the oocytes will become 
internal and external TCs.  Both sets of cells will support the oocyte as it matures 
and provide nourishment for the oocyte (McGee and Hsueh, 2000, Suh et al., 
2002).  The oogonia impact the development of both the GCs and the TCs.  The 
somatic cells, in turn, also influence the nuclear and cytoplasmic maturation of 
oogonia (Eppig, 2001).  This interaction implies that the developmental 
competence of the oocyte relies on the complete ultrastructure of the follicle, 
indicating that CCs and MGCs are ideal for assessing oocyte and embryo quality.   
The various types of follicles exhibited throughout the reproductive cycle 
include oocyte nests, primordial follicles, primary unilaminar pre-antral follicles, 
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primary multi-laminar pre-antral follicles, antral follicles, and pre-ovulatory or 
Graafian follicles (Figure 1.4).   The distinguishing property of primordial follicles is 
a solitary layer of flattened pre-GCs that surround dormant primary oocytes 
(Fortune, 2003).  When primary oocytes enter the growth phase, the follicles 
become primary unilaminar pre-antral follicles as a single layer of pre-granulosa 
cells transforms into cuboidal granulosa cells (Hirshfield, 1989).  Granulosa cells 
are unlike other somatic cell types, both phenotypically and transcriptionally.   
As the follicle continues to develop, cuboidal granulosa cells proliferate into 
a primary multi-laminar pre-antral follicle and give rise to primary and secondary 
follicles.  During this time, each follicle will continue to add GC layers.  The somatic 
cells at the developing follicle’s periphery, originating from mesodermal embryonic 
tissue and exterior to the basement membrane termed the basal lamina, will 
transform into TCs (Fortune, 2003).  Theca cells produce androgens that diffuse 
across the basement membrane to GCs where they are converted into estrogen 
(E2).   
The pre-antral follicle will contain the oocyte surrounded by multiple distinct 
somatic cells layers.  The TCs differentiate into both internal and external stratums 
at the periphery of the follicle.  Within the basement membrane, there are also two 
strata of GCs surrounding the oocytes, the MGCs and CCs.  The CCs reside 
closest to their individual oocyte and they share gap junctions.  When the oocyte 
is ovulated in a natural reproductive cycle or aspirated during assisted reproductive 
technologies (ART) the CC layer, also termed the corona radiata, will remain 
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associated with the oocyte.  Collectively, the oocyte and the CCs that surround it 
are referred to as the cumulus-oocyte complex (COC).   
As the follicle continues to increase in size, fluid will collect in the space 
between the GCs creating a fluid-filled cavity, or antrum.  Oocytes isolated from 
smaller antral follicles have been shown to have decreased meiotic competence 
and are less likely to undergo final maturation (Hunter et al., 2000).  The capacity 
for an oocyte to recommence meiosis I is referred to as meiotic competence and 
will occur following the LH surge.  The antrum will increase in size until it becomes 
a pre-ovulatory or Graafian follicle, just before ovulation.  The size of Graafian 
follicles in human ovaries between 22 to 25 mm. The LH surge will cause the follicle 
to rupture releasing the COC and triggering the final maturation of the oocyte from 
the GV stage to the MII stage in preparation for fertilization (Stocco et al., 2007).  
The MGCs and TCs remaining in the post-ovulatory follicle will become the CL due 
to luteinization.  In most higher mammals, the TCs transform into small luteal cells 
and the GCs will become large luteal cells (Murphy, 2000). The follicular blood 
supply of the pre-antral follicles originates from the ovarian stromal cells.  During 
the antral stage of development, the TCs also develop their own separate blood 
supply (Stouffer et al., 2001).  When the oocyte ruptures from the follicle, the blood 
vessels that surround the follicle will bleed forming a post-ovulatory structure 
known as the corpus hemorrhagicum (CH).  The CH will quickly transform into the 
CL (Niswender et al., 2000).  The CL is a temporary endocrine gland that, in 
humans, produces both progesterone (P4) and E2.  The hormones are produced 
for the first few months of the pregnancy, if established, and are needed until the 
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placenta takes over production of the hormones.  If pregnancy fails to transpire, 
the CL will degenerate into a corpus albicans (CA) which over time will be 
reabsorbed into the stroma of the ovary.    
Two distinct granulosa cell populations exist in the mature follicle, the MGCs 
and the CCs.  Cumulus cells surround the oocyte during follicular maturation and 
ovulation and remain attached to the oocyte following oocyte retrieval during ART.  
Mural granulosa cells and CCs share many similarities but also have individual 
transcriptional patterns consistent with their specialized relationship with the 
oocyte (Huang and Wells, 2010) and differential responsiveness to pituitary 
gonadotropins (Khamsi and Roberge, 2001).  Both MGCs and CCs are under the 
influence of oocyte secreted factors, most notably growth-differentiation factor 9 
(GDF9), bone morphogenetic protein 15 (BMP15) and possibly bone 
morphogenetic protein 6 (BMP6).  These factors influence CCs and MGCs by 
controlling apoptotic activities as well as metabolism and steroidogenesis (Su et 
al., 2008).  These factors regulate MGC and CC functions by activating the SMAD 
and/or mitogen-activated protein kinases (MAPK) intracellular cascade pathways 
through Transforming Growth Factor beta (TGF-β) superfamily receptors (Gilchrist 
et al., 2008, Liang et al., 2007).  Oocyte-secreted factors influence the stem cell 
factor (SCF), which binds to the c-KIT receptor (CD117), causing GC proliferation, 
inhibiting CC apoptosis and luteinization, and modulating CC metabolism. 
Pyruvate metabolism doubles along with a rise in oxygen (O2) utilization in mouse 
pre-ovulatory oocytes compared to primary oocytes (Harris et al., 2009).  Anti-
Müllerian hormone (AMH), another member of the TGF-β superfamily, is produced 
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by growing follicles and may inhibit primordial follicle activation but the mechanism 
by which it acts has not been elucidated.  
Three studies utilizing microarray have demonstrated that MGCs and CCs 
isolated from the follicles of women undergoing ART exhibit vastly diverse RNA 
expression patterns with thousands of genes being differentially expressed.  Many 
of these differences were confirmed by quantitative real-time polymerase chain 
reaction (qRT-PCR).  Koks and coworkers (Koks et al., 2010) found that the 
mRNAs for fibrinogen gamma chain (FGG), neurotensin (NTS), FosB proto-
oncogene, AP-1 transcription factor subunit  (FOSB), and dual specificity 
phosphatase 6  (DUSP6) showed a greater than 2-fold decrease in pooled CCs 
compared to pooled MGCs, while tenascin C (TNC), epidermal growth factor like 
repeats and discoidin domains 3 (EDIL3), UL16 binding protein 1 (ULBP1), and 
ryanodine receptor 2 (RYR2) transcripts showed more than a 2-fold increase in 
CCs compared to MGCs.  This study did not consider differences in oocyte 
maturational status when pooling cells and may have confounded the data as an 
oocyte’s maturity does affect gene expression.  A study by Grondahl and colleages 
(Grondahl et al., 2012) analyzed paired CCs and MGCs taken from a single large 
pre-ovulatory follicle containing a mature oocyte from each patient thereby 
controlling for oocyte maturational differences and oocyte yield.  When comparing 
CCs to MGCs, the mRNAs for growth hormone receptor (GHR), NTS, pepsinogen 
3, group I (pepsinogen A) (PGA3), pepsinogen 4, group I (pepsinogen A) (PGA4), 
pepsinogen 5, group I (pepsinogen A) (PGA5), progesterone receptor membrane 
component 1(PGRMC1), and cytochrome P450 family 11 subfamily A member 1 
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(CYP11A1) were significantly increased, while mRNAs for calcium channel, 
voltage-dependent, L type, alpha-1C subunit (CACNA1C), interleukin 7 receptor 
(IL7R), growth-associated protein 43 (GAP43), AMH, TNC, and RYR2 were 
significantly decreased.  A third study examined MGCs and CCs samples from 
mature oocytes (Burnik et al., 2015b).  These authors also conducted a meta-
analysis with the data generated from the previous two studies (Burnik et al., 
2015a, Grondahl et al., 2012) and collectively found 3156 genes differentially 
expressed.  The later study identified two unique genes that were not previously 
reported in human follicular cells:  prokineticin 2 (PROK2) and pregnancy 
upregulated nonubiquitous CaM kinase (PNCK). Further, validation of microarray 
results by qRT-PCR showed mRNA levels increased for angiotensin I converting 
enzyme 2 (ACE2), HtrA serine peptidase 1 (HTRA1), PNCK, and RYR2, while they 
decreased for DUSP6, FGG, interleukin 1 beta (IL1B), and PROK2 when 
comparing CCs to MGCs.  These three studies showed clear differences between 
the two distinct granulosa cell types however, the differential mRNA gene 
expression (DRGE) among the studies could be due to pooling or not pooling cells 
of different oocyte maturational status, different samples sizes in the number of 
oocytes per patient used and number of individual patients, stimulation types 
between studies, freezing and handling of cells, and varying infertility diagnoses.  
Regardless, these studies demonstrate that the different expression profiles of the 
MGC and CC populations should be taken into consideration when examining 
possible pregnancy and live birth biomarkers. 
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1.5 The Menstrual Cycle 
The reproductive cycle is a repetitive cyclical process. During the cycle, 
several events will occur, including follicular growth, oocyte development, 
ovulation, alterations of the endometrial lining of the uterus, and maintenance of 
pregnancy or menstruation.  This process is governed by modulations of the 
hormones of hypothalamic/pituitary/gonadal (HPG) axis (Figure 1.5) which include 
pituitary gonadotropins, follicle stimulating hormone and luteinizing hormone, and 
ovarian steroids, estradiol and progesterone.  The hormones of the HPG axis act 
upon a variety of tissues in a concerted manner through an elaborate feedback 
system. The actions of FSH are initiated by binding to specific membrane receptors 
which cause the GC population to proliferate, E2 production to increase, and also 
promote LH/chorionic gonadotropin receptor (LHR or LHCGR) expression. The 
actions of LH on the TCs serve to stimulate steroidogenesis by increasing the 
production of androgens which are used by GCs to produce E2.  LH is also 
responsible for ovulation of the mature oocyte and after the CL forms, LH 
stimulates luteal P4 production.  
Both FSH and LH are heterodimeric glycoproteins.  They both, along with 
chorionic gonadotropin (CG) and thyroid stimulating hormone share a common -
subunit while retaining their own unique -subunits (Richards et al., 2002).  Each 
receptor is a G-protein-coupled transmembrane receptor.  When the ligands bind 
to their respective receptors, they generate a second messenger in the form of 
cAMP via the PKA pathway.  The levels of cAMP are vital during folliculogenesis 
and oocyte maturation.   FSH sustains higher cAMP levels and modulates gap 
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junctions by enhancing permeability and altering the gap-junction alpha-1 gene 
(GJA1) within the oocyte (Burghardt et al., 1995).  It has also been demonstrated 
that GC signaling also involves other signaling pathways, including RAS and 
MAPKs (Fan et al., 2012).  
In primates, the reproductive cycle is termed the menstrual cycle (Figure 
1.6).  The HPG axis is a finely tuned feedback loop. The menstrual cycle begins 
with menstruation when the levels of E2 and P4 are low. Lack of circulating E2 
prompts the hypothalamus to commence pulsatile secretion of gonadotropin 
releasing hormone (GnRH).  Gonadotropin releasing hormone acts upon the 
anterior pituitary to release the pituitary hormones, FSH and LH.  Follicle 
stimulating hormone and LH are the principal drivers of female follicular and oocyte 
development (Richards, 1994).  Follicle stimulating hormone and LH, in turn, 
stimulate the ovaries.  As E2 increases, a negative feedback signal is received by 
the hypothalamus which will pause GnRH secretion until the E2 levels drop so the 
cycle can start again (Emanuele et al., 2002).  Additionally, GCs and TCs produce 
inhibins, which have also been shown to inhibit FSH secretion by the pituitary 
(Knight and Glister, 2006).   
The menstrual cycle consists of a follicular phase and a luteal phase.  The 
number of primary follicles that mature each cycle is related to a female’s age and 
to the number of oocytes within the ovary.  Cohort growth is initiated by stimulation 
from the hormones produced by the pituitary gland and paracrine factors 
generated by the ovary (Hsueh et al., 2000). During the follicular phase, secondary 
follicles grow and differentiate while the oocyte matures.  FSH levels are highest 
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on days 2-5 during the middle of the cycle.  During the follicular phase, GCs have 
FSH receptors (FSHRs) and the TCs have LHCGRs and produce androstenedione 
(Hillier, 2001).  FSHR mRNA levels are most abundant in human GCs in small 
antral (~6 mm) follicles in the early follicular phase and then decrease, whereas, 
LHCGR mRNA levels in human GCs increase starting during the mid-follicular 
phase and peak in preovulatory follicles (~15 mm) (Richards, 1994, Jeppesen et 
al., 2012). Granulosa cell E2 expression increases in response to androstenedione 
produced by the TCs, which is generated from cholesterol through the 
steroidogenic pathway as described below.  Androstenedione disseminates from 
the TCs via the basal lamina to the GCs. Follicle stimulating hormone then acts, 
by way of a cAMP signaling pathway,  to induce aromatase (CYP19A1) to convert 
androstenedione to E2 augmenting overall E2 production (Magoffin, 2005).    
As the follicular phase progresses and GC FSHRs decrease and LHCGRs 
increase, GCs are now able to respond to LH.  The LH surge causes the follicle to 
rupture, the oocyte to resume meiosis, and the CCs to radiate outward from the 
oocyte.  It also causes luteinization of GCs and TCs which form the CL.  The 
follicular phase culminates, and the luteal phase commences with the ovulation of 
the oocyte from the pre-ovulatory, or Graafian follicle, in response to the LH surge 
(Jeppesen et al., 2012).  Near mid-cycle, the negative feedback generated by E2 
switches to positive feedback causing the LH surge with E2 levels exceeded 150-
200 pg/mL for 36 hrs in humans.  Increased E2 levels suppress pituitary FSH 
secretion but promote LH secretion.  However, there is also a small surge of FSH 
at this time, which may signal a new set of follicles to begin recruitment for the next 
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cycle.  Luteinizing hormone is also necessary for completion of steroidogenesis as 
the surge stimulates the formation of the cells of the CL.  Amphiregulin (AREG), 
an epidermal growth factor-like growth factor found in CCs and MGCs, is induced 
by the LH surge and causes expansion of the CCs and mediates oocyte 
maturation.  Reduced AREG mRNA levels in CCs of oocytes have been shown to 
be associated with high-quality blastocysts derived from IVF (Feuerstein et al., 
2007).  Additionally, higher AREG mRNA levels in pooled human IVF derived CCs 
and MGCs have been shown to be associated with pregnancy (Huang and Wells, 
2010).   
The luteal phase is notable due to heightened P4 produced from the CL and 
modest E2 levels that prepare the uterine environment to be highly receptive to 
embryo implantation and the continuation of an ongoing pregnancy.  The LH surge 
causes TCs to proliferate, luteinize, and secrete increased amounts of 
androstenedione and promotes P4 secretion from the CL.  GCs transform into 
large luteal cells and TCs transform into small luteal cells of the CL (Devoto et al., 
2009, Niswender et al., 1994).  The gonadotropin surge has been shown to alter 
the gene expression in the CCs and MGCs in humans (Borgbo et al., 2013).   
When an embryo implants initiating a pregnancy, the menstrual cycle 
temporarily pauses until the pregnancy is complete.  In response to an embryo 
failing to implant, or when the pregnancy is concluding, GnRH secretion will 
increase as P4 levels decline.  In either case, the luteal cells of the CL will regress 
and develop into scar tissue known as the corpus albicans. 
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1.6 Steroidogenesis 
Granulosa cells and TCs produce androgens, estrogens, and/or progestins 
for use during the reproductive cycle. The collaborative relationship exhibited by 
the GCs and TCs is termed the two-cell, two-gonadotropin theory (Figure 1.7).   
The reproductive steroids are all derived from their common precursor, cholesterol.  
Cholesterol in the body originates from low- or high-density lipoproteins or 
hydrolysis of cholesterol esters.  Free cholesterol arrives at the mitochondria with 
the aid of the cytoskeletal system within the cell (Niswender et al., 2000).   
Steroidogenic acute regulatory protein (StAR) shuttles cholesterol into the 
mitochondria (Manna et al., 2001).  Cholesterol will be modified to pregnenolone 
by cytochrome P450 family 11 subfamily A member 1 (CYP11A1), also known as 
the cholesterol side-chain cleavage enzyme, irrespective of the final steroid 
generated.  CYP11A1, ferredoxin 1 (FDX1), and ferrodoxin reductase (FDXR) are 
all members of the cholesterol side-chain cleavage complex (CSCC) located on 
matrix portion of the inner mitochondrial membrane (Hanukoglu et al., 1990, Miller, 
2005). The components of the CSCC serve as an oxidation/reduction system as 
part of the process of steroidogenesis.  FDX1 and FDXR act as acceptors for 
electrons from nicotinamide adenine dinucleotide phosphate hydride (NADPH) 
(Hanukoglu and Jefcoate, 1980). They hydrolyze the cholesterol side-chain two 
times cleaving the bonds of carbons 20 and 22 forming pregnenolone and 
isocaproic acid. Next, cytochrome P450 family 17 subfamily A member 1 
(CYP17A1) transforms pregnenolone to dehydroepiandrosterone (DHEA) (Edson 
et al., 2009).  The final step before leaving the TCs, is the conversion of DHEA to 
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androstenedione by hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 (HSD3B1).  Androstenedione passes across the basement 
membrane to GCs.  Follicle stimulating hormone stimulates GC expression of 
CYP19A1 and 17-beta hydroxysteroid dehydrogenase (HSD17B) to convert 
androstenedione into E2.  Aromatase mRNA levels in human GCs increase 
starting during the mid-follicular phase and peak in preovulatory follicles (~15 mm) 
(Jeppesen et al., 2012).  DNA microarray studies in human CCs and GCs have 
shown that HSD3B1, CYP11A1, and StAR mRNA are upregulated in response to 
human chorionic gonadotropin (hCG) (Assou et al., 2006). 
In addition to the TCs and the MGCs, the COCs coordinate metabolic 
processes necessary for the energy requirements of the oocyte needed for 
fertilization and early development (Figure 1.8).  This means that mitochondrial 
functions within the CCs are intimately related to the overall developmental 
competence of the oocyte (Dumesic et al., 2016).  Therefore, mitochondria within 
the CCs and or MGCs may be a viable indirect biomarker to assess oocyte 
developmental competence.   
Mitochondria are abundant in the oocyte and GCs, with each mature human 
oocyte containing approximately 100,000-250,000 mtDNA copies.  Mitochondria 
are small double-membrane organelles transmitted to offspring through maternal 
inheritance, with infrequent rare exceptions (Cummins, 2000, Song et al., 2014).  
While spermatozoa do possess mitochondria, once an oocyte has been fertilized 
and the subsequent embryo progresses through development, animal and human  
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studies have shown that the paternal mitochondria are not present when the 
embryo surpasses the 4-cell stage (Cummins, 2000, Sutovsky et al., 2000). 
  Mitochondria are unique because they contain their own genome.  mtDNA 
contains 16.6 kb of circular double-stranded DNA with 37 genes encoding for 13 
proteins, two ribosomal RNAs, and 22  transfer RNAs (Benkhalifa et al., 2014).  
The proteins and RNAs are necessary for OXPHOS and constituents of the 
electron transport chain (ETC) with nuclear DNA (nDNA) providing the other 
components needed for proper mitochondrial function.   
Oxidative phosphorylation accounts for about 88% percent of a cell’s ATP 
production with the remainder of the ATP is produced via glycolysis and the 
tricarboxylic acid cycle (Seyfried and Shelton, 2010).  OXPHOS takes place across 
the inner membrane of the mitochondria and is the result of the transfer of electrons 
through the linked protein complexes of the ETC (Figure 1.9) which generate 
mitochondrial membrane potential by transporting protons across the membrane 
(Veatch et al., 2009). Electrons are transferred from electron donors, nicotinamide 
adenine dinucleotide hydride (NADH), NADPH, and flavin adenine dinucleotide 
hydride (FADH2) to electron acceptors (i.e. O2) during redox reactions.  The flow 
of electrons in turn transports protons across the inner mitochondrial membrane.  
Both the pH gradient and the electrical potential generated through this process 
generate potential energy, which converts adenosine diphosphate (ADP) to ATP, 
as protons flow through the ATP synthase enzyme.   
 Cumulus cells have high glycolytic activity and provide oocytes with 
pyruvate via gap junctions (Collado-Fernandez et al., 2012).  Oocytes exhibit 
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minimal glycolytic capacity due to low phosphofructokinase activity and rely upon 
pyruvate utilization for proper maturation (Barbehenn et al., 1974, Biggers et al., 
1967).  Oocytes overcome this energy deficiency due to low glycolytic activity by 
receiving ATP and other energy precursors including amino acids, pyruvate, 
nucleotides, and cholesterol from the highly glycolytic CCs through shared gap 
junctions (Figure 1.8) (Anderson and Albertini, 1976, Downs, 1995, Downs and 
Utecht, 1999, Johnson et al., 2007, Su et al., 2009).    The association of the oocyte 
and the CCs may be beneficial for better embryo development.  Human oocytes 
maintained within CCs in culture exhibit higher levels of ATP and improved embryo 
development (Van Blerkom et al., 1995). 
1.7 In Vitro Fertilization 
In vitro fertilization is a type of ART for humans where both the oocytes from 
the female and spermatozoa from the male are collected and combined in the 
laboratory as opposed to within the female’s body.  Once inseminated, the oocyte 
will fertilize and develop into a pre-embryo.  Fertilization is confirmed with the 
presence of both the male and female pronuclei and two polar bodies.  This first 
stage of development before syngamy, or fusion of the two pronuclei, is termed a 
pre-zygote (Braude and Rowell, 2003).  The fused pronuclei will undergo 
pronuclear breakdown before the first cleavage division.  The fertilized oocyte is 
called a zygote from the time immediately after syngamy until the first cell division.    
From that point forward through day 14, the conceptus is referred to as a pre-
embryo, although many use embryo and pre-embryo interchangeably.  
Somewhere between 72 to 96 hrs post insemination, the pre-embryo will undergo 
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compaction and progress from 16 cells to the blastocyst stage. The cells of the 
blastocyst will differentiate into an inner cell mass (ICM), which ultimately forms 
the fetus and the trophectoderm, which gives rise to the placenta.  When the 
primitive streak develops on day 14, the conceptus will be considered an embryo.  
From the end of the 8th-week post-ovulation until birth, the human conceptus is 
considered a fetus.  In the context of IVF, pre-embryos will be transferred to the 
uterus on day 3 (at the cleavage stage) or more commonly on day 5 or day 6 (at 
the blastocyst stage).  Untransferred supernumerary pre-embryos will be frozen 
for use in subsequent FET cycles.  Women undergo IVF for many different types 
of female infertility including but not limited to age, ovulation disorders, tubal 
disease, uterine factors, polycystic ovarian syndrome (PCOS), endometriosis, 
diminished ovarian reserve (DOR), and idiopathic or unexplained infertility.   
1.8 Patient Characteristics Influencing In Vitro Fertilization Biomarkers  
One of the main difficulties when evaluating microarray and qRT-PCR data 
in CCs and MGCs for biomarkers that relate to embryo quality and other 
reproductive endpoints used with IVF is the heterogeneous population of patients.  
Among the potentially complicating factors are the large variability in patient 
characteristics and the multiple stimulation types used during IVF procedures.  
Patient characteristics influencing IVF outcome and gene expression include age, 
body mass index (BMI), diagnosis, stimulation type, hormonal levels during 
stimulation, and oocyte yield (Adriaenssens et al., 2010a). To further complicate 
matters, uterine receptivity also influences the interpretation of transcriptomic data 
such that a non-receptive uterus will cause implantation failure regardless of the 
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quality of the transferred embryo.  This will affect the statistical sensitivity (# of true 
positives)/ (# of true positives + # of false negatives)) of studies. In light of this fact, 
for a small number of cases, ETs resulting in “not pregnant” or “no implantation” 
results will actually be false negatives due to poor uterine receptivity rather than 
embryo characteristics.  This section will review studies that demonstrate how 
these variables can impact the transcriptional profile of granulosa cells. 
In terms of heterogeneous patient populations, the mixture of multiple 
diagnoses and stimulation types will skew many analyses.  Andrianenssens and 
coworkers (Adriaenssens et al., 2010a) showed that mRNA gene expression 
profiles are influenced by a patient’s biological characteristics, type of stimulation 
used for the patient’s IVF cycle, and oocyte developmental features. In this study, 
CCs of 63 patients were evaluated by qRT-PCR for expression of 10 genes; gene 
expression was then related to 13 different IVF cycle characteristics.  Thirty-five 
patients were stimulated with gonadotropin releasing hormone agonist with high-
purity-human menopausal gonadotropin (HP-hMG) and 28 patients were 
stimulated with GnRH-agonist with recombinant follicle stimulating hormone 
(rFSH).   Patient characteristics, biological variables and embryo development 
were similar between the two treatment groups.  Most of the patients had male 
factor infertility (MFI) with subsets having female subfertility (<10%), idiopathic 
subfertility (<10%), and a combination of male and female subfertility combined 
(<15%).  These subgroupings may have influenced the outcome of the statistical 
analysis of the gene expression.  The analyses may have been stronger if only 
MFI patients were used, but on the other hand statistical power would be lost by 
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reducing sample size. Using a linear regression model, 5 of the 10 genes 
examined syndecan 4 (SDC4), versican (VCAN), gremlin 1, DAN family BMP 
antagonist (GREM1), sprouty RTK signaling antagonist 4 (SPRY4) and ribosomal 
protein S6 kinase A2 (RPS6KA2) showed differential expression based on the type 
of stimulation.  Patients stimulated with rFSH showed higher SPRY4 and lower 
SDC4 mRNA levels when compared with HP-hMG stimulated patients.  VCAN was 
negatively correlated with oocyte maturity in the rFSH group and RPS6KA2 was 
positively correlated with increasing age in the rFSH stimulated group.  GREM1 
showed a positive correlation with age and embryos having greater than seven 
cells and a negative correlation with serum progesterone on day of hCG 
administration in rFSH stimulated patients.  Interestingly, SDC4, GREM1, SPRY4, 
and RPS6KA2 are all involved in signaling TGF-β or epidermal growth factor (EGF) 
signaling pathways.  The above study provides evidence that the type of 
gonadotropin treatment can affect certain signaling pathways thereby altering 
gene expression. 
An individual patient’s diagnosis may also influence differential mRNA gene 
DRGE in CCs and MGCs.  PCOS compared to non-PCOS (Catteau-Jonard et al., 
2008, Wei et al., 2012, Schmidt et al., 2014, Chen et al., 2015b) endometriosis 
compared to non-endometriosis (Yanaihara et al., 2005, Allegra et al., 2014, 
Barcelos et al., 2015), and DOR compared to normal ovarian reserve (NOR) 
(Greenseid et al., 2011, Jindal et al., 2012, May-Panloup et al., 2012, Meng et al., 
2013) have all been shown to alter gene expression.  In fact, PCOS patients with 
or without insulin resistance were shown to have DRGE compared to non-PCOS 
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normal control patients (Kaur et al., 2012). Other pathologies may also alter gene 
expression but have not been examined.  Including any of these diagnoses in 
studies may also alter the actual transcriptional profiles and should be avoided if 
possible or analyzed separately. 
The major contributing factor to reduced fecundity is advanced maternal 
age (AMA), even among females who do not have other infertility problems.   
Advanced maternal age is becoming an increasing concern as more and more 
women are choosing to delay starting families past the ideal reproductive age.  
Reproduction in human females peaks around 25 years old, exhibits a moderate 
decline after the age of 30 and drops steeply following 37 years of age (O'Connor 
et al., 1998). This decrease in reproductive potential is due to reduced oocyte 
quality and production of more aneuploid embryos associated with aging (Hassold 
and Hunt, 2001, Hassold et al., 2007, Heffner, 2004). Comprehensive 
chromosomal screenings from trophectoderm biopsies of 15,169 human 
blastocysts showed the lowest aneuploidy rates of <30% occurred between the 
ages of 26 and 30 years of age, rates increased above 40% for patients younger 
than 26 and older than 36 years old, and peaked above 80% for patients over 42 
years old (Figure 1.10) (Franasiak et al., 2014).  Between 70-90% of aneuploidies 
occur within the oocytes due to chromosomal nondisjunction at meiosis I during 
oogenesis (Capalbo et al., 2017, Nagaoka et al., 2012). This increase in 
aneuploidy is partially due to the years human oocytes spend in a prolonged 
arrested state in meiosis I when they may incur physiological alterations. 
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It has been postulated that developmental abnormalities seen in oocytes 
with AMA are directly related the mitochondrial dysfunction owing to increased 
point mutations in mtDNA (Barritt et al., 2000, Bentov and Casper, 2013) and 
decreased mtDNA content (Chan et al., 2005, Duran et al., 2011, Murakoshi et al., 
2013).  mtDNA mutations are about 25-times higher than mutations in (nDNA) 
because mtDNA does not have associated histones or effective DNA repair 
processes to repair mutations caused from reactive oxygen species (ROS) and 
free radicals within the mitochondrial matrix (Lynch et al., 2006).  Since 
accumulation of abnormal mitochondria affects overall mitochondrial function, the 
investigation of mitochondrial metabolism may provide some insight into oocyte 
developmental competence and help to select the best oocyte and embryos for 
uterine transfer.   
The overall appearance of mitochondria is altered with increased age in 
humans as exhibited by cristae malformation, swelling, and vacuolization (Muller-
Hocker et al., 1996, Van Blerkom, 2011).  In addition to altered appearance, there 
are functional changes in the mitochondria of aging oocytes as well.  Mitochondrial 
membrane potential, which correlates to mitochondrial activity, is inversely related 
to age and reduced embryo development, which may be responsible for declining 
fertility with AMA (Wilding et al., 2001).  This decrease in mitochondrial membrane 
potential corresponds to other studies where ATP production and metabolic activity 
decreased with advancing age (Eichenlaub-Ritter et al., 2011, Van Blerkom, 2011).  
Oxidative damage due to ROS accumulation has also been implicated in reducing 
oocyte competence (Tatone et al., 2008).  It has been suggested that impaired 
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mitochondria, which typically begin resumption of biogenesis at the blastocyst 
stage (Figure 1.3), may begin replicating early to compensate for impaired function 
(May-Panloup et al., 2016).  This premature replication may account for increased 
mtDNA copy numbers seen by Fragouli and colleagues in trophectoderm biopsies 
from blastocysts from older patients (Fragouli et al., 2015). These observations, 
taken together, may indicate a disruption of the follicular environment 
compromising oocyte and GC communication, disruption of the cell cycle, and 
altered meiotic spindle assembly and chromosomal segregation (Eichenlaub-Ritter 
et al., 2004, Schon et al., 2000).  All these perturbations may contribute to 
decreased oocyte competence and result in reduced embryo development and 
account for the decline in fertility with AMA.   
Patient age has been shown to be associated with DRGE in CCs and MGCs 
(Al-Edani et al., 2014, Kedem et al., 2014, Hurwitz et al., 2010, Liu et al., 2010, 
McReynolds et al., 2012) as well as oocytes (Grondahl et al., 2010).  Patient BMI 
alters CC gene expression in both PCOS (Kenigsberg et al., 2009) and non-PCOS 
women (Robker et al., 2009).  Therefore, studies with a large range of ages or 
BMIs may show DRGE profiles that would not exist if the age ranges or BMI were 
controlled for in the studies. 
Lower mtDNA mRNA transcripts of genes associated with defending 
against ROS have been demonstrated to be associated with AMA in human MCGs 
(Tatone et al., 2006).   Another group demonstrated that mRNA of sirtuin 3 (SIRT3), 
which is a mitochondrial protein associated with metabolism and which alters 
mitochondrial function, was lower in MGCs from women with AMA and young 
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women with DOR compared to younger women with NOR and lower in CCs from 
women with AMA compared to younger women (Pacella-Ince 2014).  Additionally, 
a common mtDNA 4977 base pair deletion was observed at increased levels in 
GCs from women with AMA compared to younger women (Seifer et al., 2002).   
Furthermore, the 4977 base pair deletion in mtDNA was found to be higher in the 
CCs of non-pregnant women than pregnant women, with a higher incidence in 
women more than 34 years old (Tsai et al., 2010).    These studies suggest that 
women with AMA and DOR have altered mtDNA within their follicular cells, and 
this may affect oocyte developmental competence and ability to establish a 
pregnancy.   
1.9 Stimulation Protocols Influencing In Vitro Fertilization Biomarkers  
The goal of IVF is to harvest as many good quality oocytes as possible from 
the pool of oocytes ready to begin maturation at the start of the patient’s cycle in 
anticipation that one or more will lead to live birth.  This process is accomplished 
using controlled ovarian stimulation protocols.  The patient’s HPG axis is 
stimulated with medications in order to produce many oocytes from multiple 
follicles within a single reproductive cycle, as opposed to a single dominant follicle 
with a single oocyte typical of unstimulated cycles. The injectable medications 
used are called GnRH agonists or GnRH antagonists and are used in combination 
with gonadotropins to stimulate follicular growth.  The exact protocols used will 
vary between IVF clinics.  These protocols suppress the endogenous LH 
production from the pituitary and therefore a “trigger” medication, usually hCG or 
recombinant luteinizing hormone (rLH), is necessary to induce ovulation.   
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The impact of different gonadotropin treatments on gene expression profiles 
of GCs has been corroborated by other groups.  Grondahl and coworkers 
(Grondahl et al., 2009) published the first study to report DRGE profiles by 
microarray in MGCs with GnRH agonist protocols with either rFSH or HP-hMG. In 
their study, 85 genes showed DRGE of which LHCGR and genes involved in 
cholesterol and steroid synthesis had lower expression in the HP-hMG group 
compared to the rFSH group.  This DRGE seen between the agonist HP-hMG and 
rFSH treatments in MGC was also demonstrated in a subsequent study (Brannian 
et al., 2010).  Of the 1736 genes exhibiting a ≥ 2-fold expression difference 400 
were related to signal transduction.  This data was validated by qRT-PCR and 
insulin like growth factor binding protein 4 (IGFBP4), insulin like growth factor 
binding protein 5 (IGFBP5), and basigin (BSG) mRNA showed at least a 3-fold 
increase in mRNA levels when comparing the HP-hMG to rFSH group, whereas 
AKAP11: A-kinase anchoring protein 11 (AKAP11), hypoxia inducible factor 1 
alpha subunit (HIF1A), and bone morphogenetic protein receptor type 2 (BMPR2) 
were decreased. 
Gatta and coworkers (Gatta et al., 2013) evaluated different stimulation 
protocols comparing rFSH plus rLH or HP-hMG and found DRGE in CCs by 
stimulus type.  Two main clusters of genes varied with stimulation type with 61 
genes being upregulated with HP-hMG and downregulated with rFSH plus rLH, 
and 84 genes being upregulated with rFSH plus rLH and downregulated with HP-
hMG, compared to rFSH alone.  The genes identified mediated functions related 
to retinoic acid transport, phosphatase enzymes, DNA methylation and 
  
  34 
transcription, and oocyte/follicle development.  An additional 53 genes were 
upregulated in both groups compared to rFSH alone.   Assou and coworkers 
(Assou et al., 2013) retrospectively examined individual cumulus mass transcripts 
by microchip and embryo development using GnRH antagonist protocols with 
either HP-hMG or rFSH. In the HP-hMG group 45 genes were significantly 
upregulated including those related to cell-cell interaction and lipid metabolism 
whereas 49 genes were significantly upregulated in the rFSH group including 
extracellular matrix assembly and tumor necrosis factor family members.  No 
differences were observed between HP-hMG and rFSH treatments in CC mRNA 
levels of LHCGR, BMPR2, cytochrome P450 family 19 subfamily A member 1 
(CYP19A1), CYP11A1, steroidogenic acute regulatory protein (STARD1), 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 
(HSD3B2), activin A receptor type 1 (ACVR1), activin A receptor type 1B 
(ACVR1B), inhibin beta C subunit (INHBC), and inhibin beta B subunit (INHBB) or 
in fibroblast growth factor (FGF), insulin like growth factor (IGF), EGF, and platelet 
derived growth factor (PDGF) pathways. Not only does the type of GnRH-mediated 
stimulation alter the gene expression of CCs and MGCs but the “trigger” 
medication that induces the final maturation prior to oocyte retrieval modifies gene 
expression as well. After GnRH-antagonist priming, hCG and GnRH agonist 
“triggers” exhibit differing expression patterns related to steroidogenic pathways in 
CCs and angiogenic pathways in the MGCs (Borgbo et al., 2013). The GnRH 
agonist “trigger” also showed higher LHCGR mRNA in CCs than the hGC “trigger”.  
In another study, patient groups were given 0, 5,000 or 10,000 IUs of hCG (Coskun 
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et al., 2013). The gene expression profiles differed between the hCG groups and 
the non-hCG group with approximately 2000 genes up or downregulated in each 
hCG group, yet only 15 genes differed significantly between the two hGC doses.   
The GnRH “trigger” leads to an endogenous increase in LH, whereas hCG serves 
to mimic the LH surge.  hCG has a longer half-life and higher affinity than LH for 
the LHCGR (Choi and Smitz, 2014), yet LH is more potent at activating 
downstream signals such as cAMP accumulation, extracellular signal–regulated 
kinases  and protein kinase B activation. Another group examined the effects of a 
double “trigger” to produce final oocyte maturation using a GnRH agonist at 40 hrs 
before oocyte retrieval and hCG 34 hrs before oocyte retrieval.  They found that 
AREG, epiregulin (EREG), and serpin family f member (SERPINF1), also called 
pigment epithelium-derived factor (PEDF), mRNA levels were significantly higher 
while GJA1 mRNA levels were significantly lower in MGCs in the double trigger 
group (Haas et al., 2019).  Finally, a recent study small study examined the effects 
for hCG, GnRH agonist, or a double “trigger” using both medications on the CC 
transcriptome in a total of 30 poor, normal and high responder patients by next-
generation sequencing (NGS) (Fuchs Weizman et al., 2019).  The CC samples 
from patients with higher than average ovarian reserve tended to cluster together 
more closely than CC samples from the other groups.  mRNA levels differed 
between the 3 treatment groups and the 3 trigger types, including genes related to 
apoptosis, cell-cycle regulation, oocyte maturation, immune response, and 
inflammation.  These findings suggest that possible differences in activation of the 
LH receptor may account for trigger differences in CC gene profiles.  Moreover, 
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these studies indicate the type of gonadotropin stimulus should be considered 
when interpreting biomarker data, as different stimuli yield different gene 
expression profiles. 
1.10 Improving IVF Outcomes with Non-Invasive Biomarkers 
Even with improvements in ART over the past couple of decades, the 
success rates for procedures treating infertility and leading to live births is still less 
than optimal.  European data from 2011, as reported by the European IVF-
Monitoring Consortium and the European Society of Human Reproduction and 
Embryology showed the non-donor ET rate was 33% with the pregnancy rate per 
embryo thaw cycle being 21% (Kupka et al., 2016).  Recent national summary data 
from 2017, as reported by the Society for Assisted Reproductive Technology 
(SART) website (SART, 2019), indicate the cumulative live birth rate per oocyte 
retrieval including fresh and subsequent frozen transfers in the United States from 
IVF in patients less than 35 years old was approximately 54% and decreased with 
increasing maternal age.  There is a need to improve outcomes of IVF, which may 
require improved stimulation protocols to yield better oocytes/embryos or 
identifying new methods for assessing the most viable oocytes/embryos. Several 
approaches are being investigated to find reliable and reproducible surrogate 
biomarkers for oocyte competence and selection of the embryos with the best 
probability of producing live births.   
This suboptimal success rate of IVF may be due to the fact that most 
embryos selected for uterine transfer are chosen based on the morphological 
appearance of the embryos and their cleavage rates.  In fact, Munne and 
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coworkers  (Munne et al., 2007b) reported that most morphologically normal 
appearing embryos (based on shape, size, blastomere number, and 
fragmentation) may be aneuploid.  In an analysis of 6000 embryos produced from 
oocytes of women less than 35 years of age, approximately 56% of embryos with 
the best morphology and development rate were actually aneuploid (Munne et al., 
2007a).  Furthermore, morphologically good, aneuploid embryos increased to 
nearly 80% for the women age 41 and older.  These data indicate the need for 
better methodologies to reduce selection of aneuploid embryos. 
In a later study, Munne and coworkers (Munne et al., 2009) suggested that 
the best way to select euploid embryos for uterine transfer was to use a 
combination of both morphological appearance and PGT-A.  For PGT-A, 3-10 cells 
are biopsied from the trophectoderm of a day 5 or day 6 blastocyst for chromosome 
analysis.  This approach has been validated by several groups that have 
demonstrated  increased ongoing pregnancy, implantation, and delivery rates of 
nearly 20% with PGT-A screened versus non-PGT-A screened embryos 
(Schoolcraft et al., 2010, Yang et al., 2012, Scott et al., 2013, Forman et al., 2013). 
While PGT-A has been shown to increase positive IVF outcomes in several 
studies, it requires invasive manipulation which might harm the embryo potentially 
decreasing successful outcomes.  This idea is supported by a recent report which 
reviewed PGT-A embryo data in the United States for 2011 and 2012 and showed 
that utilizing PGT-A-screened embryos did not increase IVF success rates. In 
actuality, the success rate per uterine transfer was reduced from 46.2% to 39.3% 
when PGT-A was utilized (Kushnir et al., 2016).  The authors of this study 
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concluded that PGT-A decreases the chance of live birth, and that improvements 
previously reported with PGT-A in women over 37 years-old are due to selection 
bias.   
There are several non-invasive methods for embryo selection that have 
been used in conjunction with embryonic morphological appearance and 
development rate.  Numerous studies have evaluated the characteristics of GCs 
which surround the oocyte, follicular fluid contents or the secretions of the embryos 
while in culture.  Several non-invasive methods for embryo assessment have been 
reviewed elsewhere and include the study of epigenomics which consists of 
bisulfite sequencing to analyze DNA methylation of the GCs (Egea et al., 2014); 
proteomics, including electrophoresis, chromatography, and mass spectrometry of 
follicular fluid or oocyte culture media (Nel-Themaat and Nagy, 2011); 
metabolomics of spent human embryo culture media by gas chromatography,  high 
pressure liquid chromatography, or nuclear magnetic resonance (Uyar and Seli, 
2014); and time-lapse imaging of embryos (Kirkegaard et al., 2015).  A recent 
meta-analysis examining studies using time-lapse to select embryos for uterine 
transfers has shown improved pregnancy and live birth rates compared to embryo 
scoring methods alone (Pribenszky et al., 2017).    
The basis for using CCs and MGCs as biomarkers for oocyte health is the 
evidence that there is bi-directional signaling shared between the oocytes the 
somatic cells of the follicles providing the optimal environment for oocyte 
maturation, fertilization, and embryo development (Assou et al., 2008, Dumesic et 
al., 2015, Tsai et al., 2010).  These somatic cells are a great source of materials 
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for the studies of epigenomics (Egea et al., 2014), mitochondrial function and 
mtDNA content (Cecchino et al., 2018), and transcriptomics (Kordus and LaVoie, 
2017).  Epigenomics uses bisulfite sequencing to examine DNA methylation 
patterns.  Mitochondrial function examines both ATP production and OXPHOS.  
Transcriptomics uses RT-PCR or microarrays to observe differences in gene 
expressions patterns.   
1.11 mRNA in Cumulus Cells and Mural Granulosa Cells as Non-Invasive 
Biomarkers in IVF 
The ability of an embryo to develop appropriately and ultimately implant, 
grow, and result in a live birth is dependent upon the original oocyte’s 
developmental competence.  Therefore, any of the methods mentioned above that 
can reliably determine which oocytes are the most developmentally competent will 
be invaluable to help improve embryo selection before uterine transfer and 
increase IVF success.  One of the best sources for biomarkers for non-invasive 
study for oocyte development competence is the GCs for the reasons described 
above (Feuerstein et al., 2012). 
Early assessment of RNA transcripts in GCs addressed small numbers of 
genes and techniques utilized were less quantifiable.  Such reports included semi-
quantitative analyses of RT-PCR and northern blotting of a single or handful of 
expressed genes. The ability to analyze thousands of transcripts simultaneously 
was made possible with the availability gene microarrays.  Furthermore, the 
application of qRT-PCR allowed more accurate quantification and validation of 
transcript changes.  A single microarray can exhibit hundreds, if not thousands, of 
DRGE patterns. It is important to validate mRNA level changes by qRT-PCR as 
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microarray can produce false positive signals (Provenzano and Mocellin, 2007).  
Groundbreaking early microarray work, which evaluated the transcriptomes of 
human luteinized granulosa cells from IVF patients, showed differences in 
thousands of mRNA transcripts between women with NOR and DOR, however 
changes were not validated through qRT-PCR thereby limiting the data 
interpretation (Chin et al., 2002). RNA-seq is a more recent method that can 
replace microarrays; in this technique, RNA is converted to cDNA then undergoes 
deep-sequencing to identify transcripts.   
An important factor to consider when evaluating DRGE in transcriptomic 
studies in whether or not mature and immature oocyte granulosa cells have been 
mixed together.  Mature and immature oocyte CCs have differing mRNA 
expression patterns (Assou et al., 2006, Gasca et al., 2007, Kwon et al., 2010, 
Ouandaogo et al., 2011, Ouandaogo et al., 2012, Devjak et al., 2012, Huang et al., 
2013, Grondahl et al., 2013).  A more recent study using ovarian cortical tissue 
from patients undergoing oophorectomy before treatment for cancer showed 
DRGE between GCs from primordial follicles and primary follicles (Ernst et al., 
2018).  This knowledge may help in finding appropriate biomarkers to determine 
pregnancy potential as there may be visually mature oocytes that exhibit immature 
gene expression profiles.  If the mature oocyte expression pattern can be linked to 
live birth, the embryos resulting from those oocytes can be preferentially selected 
for uterine transfer. 
At this time there is no one single gene transcript that appears to be capable 
of predicting which embryos produced by IVF will implant and lead to a live birth.  
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The gene biomarker studies undertaken have varied among the chosen endpoints 
which include oocyte nuclear maturation, fertilization, day 2 and day 3 embryo 
morphologies, day 5 and day 6 blastocyst morphologies, implantation, ongoing 
pregnancy, and live birth.  Appendices A-C summarize the findings of studies that 
show genes positively associated with pregnancy or live birth (Appendix A), genes 
that have conflicting findings between different studies (Appendix B), and genes 
whose data do not support an association with pregnancy or live birth (Appendix 
C). While the most desirable endpoint for transcriptomics studies is live birth, 
several studies examined the gene expression of CCs in relation to embryo 
development (Anderson et al., 2009, Assou et al., 2013, Cillo et al., 2007, Dhali et 
al., 2017, Feuerstein et al., 2007, Hammond et al., 2015, Liu et al., 2018, 
Hasegawa et al., 2005, McKenzie et al., 2004, Nivet et al., 2016, Scarica et al., 
2019, Zhang et al., 2005). Since embryos with the best morphological appearance 
are usually selected for uterine transfer and have been shown to implant at a higher 
rate than morphologically low quality embryos (van Loendersloot et al., 2010), the 
gene expression profiles of these studies may serve as an indirect marker of 
embryo viability and be at least loosely related to live birth rates. 
The first retrospective study to look at CC transcripts and pregnancy as the 
end point was conducted by Assou and coworkers (Assou et al., 2008).  Thirty 
patients less than 35 years old with MFI were included in the study. The stimulation 
protocols were varied and included GnRH agonist or antagonist with rFSH or hMG.  
The data showed that there was DRGE between the pregnant and not pregnant 
groups.  Out of the 569 upregulated genes in the pregnant group, pathway analysis 
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showed enrichment in genes associated with oxidative stress and nuclear factor 
kappa-light-chain-enhancer of activated B cells signaling.  Of the 61 
downregulated genes associated with pregnancy, pathways included insulin-like 
growth factor 1 (IGF1) and Sonic hedgehog signaling.  Five CC masses each from 
pregnant patients and non-pregnant patients were used to further validate the 
microarray data.  BCL2 like 11 (BCL2L11) and phosphoenolpyruvate 
carboxykinase 1 (PCK1) were downregulated while nuclear factor I B (NFIB) was 
upregulated in pregnant versus non-pregnant samples.  There was no analysis 
performed for the mixed stimulation protocols, and thus it is difficult to determine 
the impact of stimulation type.  The qRT-PCR analyses were only performed on 5 
samples each, which does not provide much statistical power.  The upregulation 
of nearly 600 genes in the pregnant group may indicate that the genome of CC 
may need to become transcriptionally activated to achieve pregnancy. 
As a follow-up to their 2008 study, Assou and coworkers (Assou et al., 2010) 
identified 45 genes as CC biomarkers associated with pregnancy.  They conducted 
a prospective study with patients < 36 years old undergoing IVF with ICSI.  The 
study was split into two groups where the two day 3 embryos selected for transfer 
were chosen either based on the CC mRNA expression profile or embryo 
morphology.  In the first group, 267 individual CC from 30 patients were analyzed 
by qRT-PCR.  Ongoing pregnancy rates per retrieval were 70% in the group which 
used qRT-PCR versus 47% for the morphology group alone demonstrating the use 
of CC mRNA expression as a useful prognostic tool.  The authors note a large 
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cohort study would be the best way to confirm this data. Unfortunately, the genes 
examined in this study were not specified. 
A similar study was the first to look at the CC gene expression transcriptome 
based on single ET (Hamel et al., 2008).  Forty women undergoing IVF with tubal 
factor, endometriosis, or idiopathic infertility were part of the study.  MGCs and 
CCs were pooled into 2 groups for those that formed a positive pregnancy and 
embryos that arrested. From the hybridizations of the positive pregnancy and 
negative pregnancy MGC forward-subtracted PCR products were used as probes 
to hybridize a custom-made microarray.  Following microarray analyses 18 
candidate genes were validated by qRT-PCR with the pooled MGC samples.  Five 
genes showed DRGE in the positive versus negative pregnancy groups with 
CYP19A1, cell division cycle 42 (CDC42), serpin family E member 2 (SERPINE2), 
HSD3B1 and FDX1 showing a statistically significant increase in the positive 
pregnancy groups.  Drawbacks of the study are that the methods did not mention 
what type of stimulation protocols were used, and the study included endometriosis 
and idiopathic infertility patients and did not take these diagnoses into account or 
specify the number of each patient with each diagnosis. 
In a follow-up study, the MGCs of transferred embryos from 18 patients 
were pooled from embryos that formed an ongoing pregnancy at 6-8 weeks or 
embryos that failed to implant (Hamel et al., 2010b).  The patient population was 
mixed with tubal factor, idiopathic infertility, and endometriosis and the stimulation 
was unspecified.  Microarray analysis showed DRGE preferentially expressed for 
25 genes in the pregnancy group and 19 genes in the non-pregnant group.  
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Validation of 10 genes was performed using qRT-PCR and showed UDP-glucose 
pyrophosphorylase 2 (UGP2) and pleckstrin homology like domain family A 
member 1 (PHLDA1) gene expression was significantly higher in the pregnant 
group.  In addition, the same lab performed a slightly different study and performed 
logistical regression analysis to determine which genes would best predict 
pregnancy (Hamel et al., 2010a). Included in these analyses were 9 patients for 
intra-patient analysis with successful pregnancies versus arrested embryos, and 
38 patients for interpatient analysis which included a third group with unsuccessful 
pregnancies.  Successful pregnancies were those in which either the single 
transfer or one or both of two transferred embryos implanted.  With two transferred 
embryos resulting in a singleton pregnancy, determining which embryo implanted 
is difficult, so the study employed principal component analysis (PCA) to predict 
which embryo most likely implanted.  PCA is a statistical method whereby the 
correlated variables from the embryos known to implant were used to estimate 
which one of a pair of embryos implanted when two were transferred but only one 
implanted.  Phosphoglycerate kinase 1 (PGK1) and regulator of G-protein 
signaling 2 (RGS2) were determined to be the best predictors of pregnancy from 
the intrapatient analysis and PGK1 and CDC42 were the best predictors of 
pregnancy from the interpatient analysis. 
Two separate studies combined traditional embryo morphology and zona 
pellucida birefringence (refractive index) to examine gene expression (Assidi et al., 
2011, Assidi et al., 2015).  In the first study, CCs from 8 patients having the same 
stimulation protocol were divided into two groups base on positive or negative 
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pregnancy results.  Day 3 post-insemination embryos for transfer were selected 
based on good embryo morphology and high zona pellucida birefringence. 
Dipeptidyl peptidase 8 (DPP8), H4 clustered histone 3 (H4C3), ubiquilin 1 
(UBQLN1), calmodulin 1 (CALM1), neuropilin 1 (NRP1), and proteasome 26S 
subunit, non-ATPase 6 (PSMD6) mRNA levels were all shown to be related to a 
positive pregnancy while target of myb1 membrane trafficking protein (TOM1) was 
related to a negative pregnancy following ET. In the second study, seven patients 
with MFI were stimulated with GnRH agonist with hMG/FSH.  The embryos were 
divided into CCs with high zona pellucida birefringence and positive pregnancy 
and CCs with low zona pellucida birefringence and negative pregnancy and 
compared. By microarray analysis, 48 genes were overexpressed and 27 genes 
were under expressed. These genes included CALM1, NRP1, and PSMD6 as 
seen in the previous study.  DPP8 and UBQLN1, as well as the 3 genes listed 
previously showed DRGE by qRT-PCR between the two groups, however, no 
correlation was seen between oocyte competence and zona pellucida 
birefringence, thereby indicating DRGE is a viable option for embryo selection 
while refractive index may not be. 
Prostaglandin-endoperoxide synthase 2 (PTGS2) and VCAN mRNA 
expression were shown to be significantly higher in CCs from oocytes that led to a 
live birth, and GREM1 and phosphofructokinase, platelet (PFKP) mRNA 
expression was correlated with the baby’s birth weight (Gebhardt et al., 2011). 
These results came from a retrospective study evaluating pregnancy resulting from 
38 single ETs.  All patients had long down-regulation protocols with rFSH. 
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Feuerstein et al. (Feuerstein et al., 2012) performed 96 microarray hybridizations 
and qRT-PCR with 197 individual CC masses from oocytes of 106 IVF patients 
and compared the results with embryo development and pregnancy.  The samples 
were separated by oocyte nuclear maturation.  RGS2 was shown to be linked to 
pregnancy potential while pentraxin 3 (PTX3) showed a significant correlation with 
blastocyst development but only showed a positive correlation with pregnancy.  
Perilipin 2 (PLIN2) and angiogenin (ANG) were also associated with 
developmental competence.  Biomarkers related to LH signaling have also been 
examined in relation to IVF success.  Papamentzelopoulou and coworkers  
(Papamentzelopoulou et al., 2012b) showed that a more robust CC LHCGR mRNA 
expression was positively associated with pregnancy. Forty patients with GnRH-
agonist protocols with rFSH treatment were examined.  Medium to high LHCGR 
expression was exhibited in 6 out of 7 patients who became pregnant.  RUNX 
family3K transcription factor 2 (RUNX2) gene expression, which is induced by the 
preovulatory LH surge, was examined in CCs (Papamentzelopoulou et al., 2012a).  
This study examined 41 ICSI patients between 24 and 45 years old being treated 
for MFI and each had at least one prior unsuccessful IVF cycle.  All the patients 
were treated with a GnRH-agonist protocol.  The RUNX2 gene was detected in 12 
out of 41 women.  Of the 12 expressing RUNX2 in the cumulus mass only 1 
became pregnant, while 7 of the remaining 28 patients who did not express the 
gene did become pregnant.  The presence of RUNX2 in CCs may signify an oocyte 
that will likely not yield a pregnancy while the presence of LHCGR mRNA could 
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indicate embryos capable of forming a pregnancy and both could be potentially 
useful biomarkers for embryo selection. 
Increased levels of GDF9 and BMP15 expression have both been 
associated with positive pregnancy as well as mature oocytes, fertilization rate, 
and embryo quality (Li et al., 2014).  This study utilized one of the largest sample 
sizes to date, using 2426 CC masses from 196 patients with MFI, normal BMI, age 
27 to 37 years old, and stimulated with a GnRH protocols.  GDF9 and BMP15 
expression was analyzed by qRT-PCR.  Considering that downstream genes 
affected by GDF9 and BMP15 such as PTGS2 and GREM1 have been shown to 
be related to pregnancy it is not surprising that their own gene expression would 
serve as potential biomarkers for IVF success. 
In a small retrospective study assessing the CCs from 16 individual 
embryos transferred in 16 IVF patients, mRNA levels of 11 out of 92 mRNA 
transcripts associated with the phosphoinositol 1,3-kinase/serine/threonine kinase 
1 (PI3K/AKT) pathway were lower in CCs from oocytes resulting in implanted 
embryos (Artini et al., 2017).  The researchers also looked at 4 transcripts from 4 
pregnant patients and 4 non-pregnant patients by RT-PCR.  Estrogen repector 1 
(ESR1) showed lowered mRNA levels in the pregnant group while forkhead box 
O4 (FOXO4) showed higher mRNA levels.  Forkhead box O1 (FOXO1) and 
forkhead box O3 (FOXO3) did not show a difference.  Since this data only used 
eight patients total it is difficult to discern the accuracy of this data.    To validate 
their array results, the investigators selected three genes out of the 11 showing 
DRGE and collected CCs from CD-1 mice at various time points following hCG 
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injection.  Lower levels of AKT serine/threonine kinase 1 (Akt1), BCL2-like 2 
(Bcl2I2) and SHC adaptor protein 1 (Shc1) mRNAs were noted from oocytes that 
fell within the optimal maturation window of 12-15 hrs post-hCG whereas higher 
levels were seen in CCs immature and post-mature oocytes. These results indicate 
there may be an optimal maturation window which will have a distinct expression 
profile that may be able to identify the most competent embryos and the genes of 
the PI3K/AKT pathway may play an essential role in that determination.   
Another interesting study examined the role genes related to histone 
demethylation may have in contributing to oocytes competence.  It was noted that 
by immunohistochemical staining that lysine demethylase 4A (KDM4A) was 
present in oocytes, GCs, and CLs and that lysine demethylase 4B (KDM4B) was 
present in oocytes, GCs, TCs, and CLs (Krieg et al., 2018).  This observation 
prompted the investigators to determine the mRNA expression of the two genes in 
the GCs of IVF patients.  Examining both CCs and MGCs of 84 women, it was 
demonstrated that KDM4A and KDM4B mRNA levels were lower in the CCs and 
MGCs from oocytes resulting in embryos that resulted in pregnancies.  This data 
should be interpreted with caution as there were significant differences in age, 
AMH levels, E2 levels, FSH levels, numbers of oocytes retrieved, number of 
fertilized oocytes, and there were very diverse reasons for infertility which may 
confound the data.  However, this study may provide early evidence that 
epigenetics plays a role in modifying GC gene expression in relation to oocyte 
developmental competence.   
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Another group examined 10 individual CC samples from 10 idiopathic 
patients and looked at the differences in 10 microarray expression profiles between 
oocytes that resulted in pregnancies versus no-pregnancies and live births versus 
no-pregnancies (Demiray et al., 2019).  The authors found that in the pregnancy 
assessment group that the genes related to circadian entrainment exhibited the 
most DRGE while the genes of the apoptosis and the neurotrophin signaling 
showed the highest DRGE in the live birth assessment group.  They also identified 
20 genes presenting the highest DRGE in the two groups; however, they did not 
confirm any of the results by RT-PCR.  Also, this data should be viewed with 
caution as only three patients out of ten became pregnant, and only two patients 
gave birth, indicating the power of this study was low.    
In the most recent study to date, microarray analysis indicated that DRGE 
was present in 165 genes when comparing oocytes resulting in pregnancy and 
oocytes that did not implant (Fortin et al., 2019).  The study compared gene 
expression of MGCs from 16 patients with each group consisting of 4 pools of 4 
patients each.  The microarray analyses indicated higher levels of pro-
inflammatory cytokines and other inflammatory genes.  They validated their 
microarray data with six genes by RT-PCR using material from the 32 patients 
used in the microarray study, and they also performed a second validation adding 
12 more patient samples that were not pregnant and 53 patient samples from 
patients who became pregnant.  In the first analysis, C-X-C motif chemokine ligand 
2 (CXCL2) and docking protein 5 (DOK5) mRNA levels significantly decreased in 
the pregnant group.  In the second analysis, DOK5 and NTS mRNA levels 
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significantly decreased in the pregnant group.  The study may indicate that 
overexpression of genes related to inflammation may play a role in interfering with 
the ability of an oocyte to lead to a viable pregnancy.   
While several studies have shown DRGE between the CCs of embryos 
which form viable pregnancy and those that do not, several studies have also 
shown no significant DRGE between the groups.  For example, Anderson and 
coworkers (Anderson et al., 2009) examined the genes hyaluronan synthase 2 
(HAS2), brain derived neurotrophic factor (BDNF), GREM1, PTGS2, tumor 
necrosis factor alpha induced protein 6 (TNFAIP6) and PTX3 and showed no 
correlation between the gene expression and pregnancy. Only GREM1 showed a 
higher gene expression trend with pregnancy but it was not statistically significant.  
In two recent studies, evaluating CC and MGC gene profiles and implantation 
potential or fertilization, no gene differences were found to be significantly 
associated with these endpoints (Burnik et al., 2015a, Burnik et al., 2015c).  The 
authors selected 3 genes from the published literature that were proposed 
biomarkers in CCs for pregnancy in at least 2 studies and were validated with qRT-
PCR.  RGS2 and VCAN showed no DRGE between CCs of embryos that formed 
a pregnancy or did not, whereas ephrin B2 (EFNB2) showed a trend toward higher 
expression in the embryos that failed to form a pregnancy.  In contrast to a previous 
GC study (Fujino et al., 2008), CC expression of survival factor gene baculoviral 
inhibitor of apoptosis repeat containing 5 (BIRC5) showed no correlation with 
pregnancy when examined in Greek women (Varras et al., 2012).   
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In a study examining ten aquaporin (AQP) subtypes, LHCGR, and STARD1 
from GCs of 111 women, no statistical differences were noted between women 
who were pregnant and those that were not pregnant (Lee et al., 2016).  More 
recently a group engaged in a paired prospective study of 34 CCs from euploid 
sibling embryos using RNAseq and found no differences in the transcriptome of 
those oocytes resulting in embryos that resulted in a live birth and those that did 
not (Green et al., 2018).  This study differed from all the other studies reviewed so 
far because it controlled for the uterine environment.  By transferring two embryos 
into each patient, the CC transcripts between the two embryos could be assessed 
without the false-negative results due to uterine environments in other studies.  
Although there were no differences seen, it is important to note that the embryos 
transferred were most likely very similar as they had already been tested by PGT-
A meaning these were blastocysts of high enough quality to undergo biopsy and 
were genetically normal.  If the entire cohort of embryos was transferred back into 
a single patient over time, and many more patients were analyzed, DRGE may 
become apparent.  Variations in those studies showing DRGE differences and 
those with no differences may be due to the more restrictive inclusion criteria in 
studies with negative findings such as exclusion of patients with particular 
diagnoses such as endometriosis or sample size differences. 
To better identify abnormal embryos, Fragouli and coworkers (Fragouli et 
al., 2012) used first polar bodies to access oocyte ploidy.  Differential mRNA gene 
expression between euploid and aneuploid oocytes was evaluated in CCs.  
Women (n=28) ranging in age from 23 to 46 with varied ovarian stimulation 
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protocols which included GnRH agonist started in the mid-luteal phase of the 
previous cycle with rFSH, a combination of either GnRH agonist or an antagonist 
with rFSH, with or without hMG participated in the study.  Customized TaqMan 
low-density arrays (TLDAs) were utilized to evaluate CC transcriptomes and 
initially showed 729 potentially altered genes in CCs associated with aneuploid 
oocytes.  SplA/ryanodine receptor domain and SOCS box containing 2 (SPSB2) 
and putative quinone oxidoreductase (TP5313) were significantly downregulated 
in CCs of aneuploid oocytes.  SPSB2 showed a positive but non-significant 
correlation with live birth. If oocytes that lead to aneuploid embryos could be 
identified using CC gene profiles it would be an asset to the embryologist.  The 
combined use of morphological endpoints with gene expression profiles may lead 
to more precise prediction models. 
All the previously discussed studies have examined the transcriptomes of 
CCs or MGCs based on the various endpoints of interest.  However, none of the 
studies attempted to generate a predictive model for prospective embryo selection 
based upon the gene expression profiles until Wathlet and coworkers (Wathlet et 
al., 2011).  This study examined 25 patients stimulated with GnRH antagonist with 
rFSH and compared them to 20 patients stimulated with GnRH agonist with HP-
hMG.  The causes of infertility were mixed with 10% idiopathic, 55% male factor 
only, 19% combined male and female (3% PCOS, tubal 6%, endometriosis 10%), 
and 16% endometriosis.  Multivariable stepwise regression analysis was 
performed to develop several predictive models of embryo competence and 
pregnancy.  Better day 3 embryo quality prediction models included transient 
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receptor potential cation channel subfamily M member 7 (TRPM7) and inositol-
trisphosphate 3-kinase A (ITPKA), while pregnancy prediction models included 
VCAN and SDC4.  The best pregnancy prediction model had a sensitivity of 74% 
and a specificity of 91%.  It is worth noting that the strongest prediction models not 
only included the CC gene transcription profiles, but also included other 
parameters such as the number of COCs retrieved/gonadotropin dose and the 
number of cells in day 3 embryos. 
Wathlet and coworkers (Wathlet et al., 2012) performed a follow-up study 
using a different set of genes.  In this study, 11 genes in 99 CC masses from 33 
patients were examined.  The patient population was again mixed with 55% male 
factor only, 9% female factor (endometriosis, ovulation disorder, and myomatosis), 
male and female factor 12% (tubal and PCOS), and 24% idiopathic infertility.  All 
patients were stimulated with GnRH antagonist protocols with rFSH (Gonal-f or 
Puregon).  For all pregnancy and live birth analyzes only the transferred oocytes 
were considered.  The best live birth prediction model with gene expression utilized 
calcium/calmodulin dependent protein kinase ID (CAMK1D), EFNB2, and 
stanniocalcin 2(STC2).  The full predictive model for live birth contained the same 
genes as well as the days of stimulation.  While VCAN was again assessed in this 
study its gene expression did not differ between the pregnant and non-pregnant 
patients.  This may be due to the fact that the patient infertility diagnoses differed 
between the two studies with respect to the proportion of each type of infertility as 
PCOS and endometriosis have both been shown to alter the transcriptome as 
mentioned previously. 
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Building upon the two previous studies, a third study was conducted 
validating the CAMK1D, EFNB2, and STC2 model and evaluating 9 additional 
candidate genes (Wathlet et al., 2013).  Also, for the first time, an intra-patient 
model in relation to frozen/thawed embryos from the same patient was examined. 
CC from 47 patients undergoing single ET and stimulated with GnRH antagonist 
protocols were analyzed.  Using just CAMK1D, EFNB2, and STC2 in the model, 
an accuracy of 72% was obtained.  Five of the 12 genes gave the best predictive 
model and included EFNB2, glutathione peroxidase 3 (GPX3), glutathione S-
transferase alpha 3 (GSTA3), glutathione S-transferase alpha 4 (GSTA4), and 
progesterone receptor (PGR).  The model gave a positive predictive value of 78%, 
a negative predictive value of 83%, and an accuracy of 81%.  Adding the days of 
stimulation, relative serum estradiol, and age to the model increased all three 
model endpoints to 93%.  The receiver operating characteristic (ROC) curves for 
the two models were 0.93 and 0.95.  For intra-patient pregnancy prediction, the 5 
gene predictive model was used since the patient characteristics were the same 
in each patient.  The model was able to correctly rank the embryos in 6 of 7 
patients.  These three studies taken together represent, as the authors state, a 
“cascade” strategy for selecting candidate genes.  The genes yielding the best 
predictive model from one set of candidate genes are kept and the ones that do 
not show any predictive value are discarded, then a new set of genes are tested 
along with the predictive set and kept or discarded in the same way in order to 
yield the best model. 
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Iager and coworkers (Iager et al., 2013) conducted a retrospective study 
between 3 different clinical sites to compare a pregnancy prediction model 
accounting for patient and clinic variation.  The endpoints for this study were 
pregnancy and live birth.  The training set revealed 1,180 differentially expressed 
genes which were narrowed down to 227 genes in the validation set using 
weighted voting analysis with a 97% prediction accuracy on the training set and 
87% on the validation set.  From the 227 predictive genes a custom TLDA with 
196 genes was made.  This array was used to further narrow the predictive gene 
set down to 12 genes fibroblast growth factor 12 (FGF12), G protein-coupled 
receptor 137B (GPR137B), solute carrier family 2 member 9 (SLC2A9), AT-rich 
interaction domain 1B (ARID1B), nuclear receptor subfamily 2 group F member 6 
(NR2F6), zinc finger protein 132 (ZNF132), COX20, cytochrome c oxidase 
assembly factor (COX20), zinc finger protein 93 (ZNF93), rhomboid like 2 
(RHBDL2), DnaJ heat shock protein family (Hsp40) member C15 (DNAJC15), 
microtubule associated tumor suppressor 1 (MTUS1), and nucleoporin 133 
(NUP133).  This pregnancy prediction model resulted in an accuracy of 78% and 
a ROC curve of 0.76. 
By examining the previous published literature Ekart and coworkers (Ekart 
et al., 2013) developed a ranking system for selection of mature oocytes that would 
theoretically lead to pregnancy based on CC gene transcription.  In this 
retrospective study, they selected an 8 gene panel, HAS2, follicle stimulating 
hormone receptor (FSHR), solute carrier family 2 member 4 (SLC2A4), activated 
leukocyte cell adhesion molecule (ALCAM), secreted frizzled related protein 2 
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(SFRP2), VCAN, NRP1 and PGR based on prior published studies (McKenzie et 
al., 2004, Gebhardt et al., 2011, Wathlet et al., 2011, Fragouli et al., 2012, Iager et 
al., 2013) to predict the mature oocytes that would lead to live birth.  Based on their 
qRT-PCR results, it was determined that HAS2, FSHR, VCAN, and PGR would be 
the best genes to rank the oocytes.  If embryos had been chosen based on the 
model from the four gene transcript levels, a single good blastocyst capable of 
implantation for transfer would have been selected 76% of the time.  As the authors 
acknowledge, the method needs to be validated in a large unselected population 
to assess its validity on a larger scale.  This implies that an embryologist could 
choose which oocytes to inseminate based on the gene expression of the CCs. 
The difference in MGC and CC transcriptomes were analyzed to develop a 
statistical classification system using a support vector machine algorithm to predict 
live birth (Borup et al., 2016).  Samples were collected from 60 women stimulated 
with long GnRH agonist protocols.  Sixteen individual CCs and their paired MGCs 
which were associated with a live birth and embryo morphology-matched CCs and 
their paired MGCs which failed to form a pregnancy were analyzed.  In total 30 
genes found in CCs were predictive of live birth with an accuracy of 81%, a positive 
predictive value of 77%, a negative predictive value of 86%, and a ROC curve of 
0.86.  This model was further applied to three other data sets using blastocyst 
formation as the endpoint and had a prediction accuracy of 62%, 75%, and 88%, 
respectively.  The genes included in the model were related to apoptosis and 
extracellular matrix formation. 
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In a recent study, the creation of a newer model of CC predictive genes was 
prospectively analyzed in IVF patients (Adriaenssens et al., 2019).   Further 
refining the previous works of Wathlet and colleagues, the researchers used three 
genes in their model, EFNB2, CAMK1D, and SAM and SH3 domain containing 1 
(SASH1).  The researchers termed their model the “Corona Test”.  The results of 
the Corona Test were given to the embryologists 2 days following oocyte retrieval 
and before ET on day 3.   Patients with 2 or more high-quality embryos on day 3 
had the embryo with the highest Corona Test rank transferred.  This group (n=62) 
was compared to 2 control groups with a matched single embryo transferred on 
day 3 (n=62) and day 5 (n=44) without Corona Test results.  The Corona Test 
group had a clinical pregnancy rate of 63%, followed by day 5 at 43% and day 3 
at 27%.  Live birth rates were 55%, 39%, and 23% in each group, respectively.  
The ROC analysis had an area under the curve (AUC) of 0.8081, implying it had 
very good predictive accuracy.  Subsequently, 26 frozen ETs were also analyzed 
for those patients who did not get pregnant in the fresh Corona Test group.  In that 
analysis, the experimental group had a cumulative pregnancy rate (those who 
were pregnant following the fresh or subsequent frozen ETs) of 78% in the Corona 
Test group compared to 65% and 56% in the day 5 and day 3 controls, 
respectively.  The time to pregnancy from the first transfer until a successful 
pregnancy was established was significantly reduced in the Corona Test group.  
Corona Test scores were discordant compared to embryo morphology in 73% of 
all embryos, which means that either that best-looking embryo was not the one 
with the highest Corona Test score or that the Corona Test score differed between 
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at least 2 embryos that were morphologically the same.  This study demonstrates 
the proposed utility of using CCs as putative biomarkers to select the best embryos 
for transfer using non-invasive methods.   
These above studies show that the use of several genes can generate 
predictive models with good accuracy and ROC curves.  It is also apparent that 
the models are incomplete and need further testing. The addition of patient 
characteristics to the models seems to improve the specificity as well.  None of 
these models, with the exception of the (Iager et al., 2013) study, have been 
validated by an outside group to confirm the accuracy of the models across 
different labs. 
1.12 Mitochondria as Non-Invasive Biomarkers for IVF 
Mitochondrial function and its relationship to human reproductive potential 
is poorly understood, and further research needs to be conducted regarding oocyte 
developmental competence and embryonic development. Studies have shown that 
mature human oocytes contain more mtDNA than immature oocytes and more 
mitochondria than other cells types in general.  Mitochondria are abundant in GCs 
as well (Ramalho-Santos et al., 2009).  What differentiates high-quality oocytes 
which will form high-quality embryos and lead to a live birth is not well understood, 
and the molecular mechanisms remain to be elucidated.  One potential explanation 
includes deficient mitochondrial function (Bentov et al., 2011).  
Embryos require large amounts of energy throughout the cleavage divisions 
that occur during early embryogenesis; therefore, embryo viability may be related 
to energy production via the mitochondria (May-Panloup et al., 2005a, Reynier et 
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al., 2001, Zhao et al., 2010).  Van Blerkom and associates demonstrated increased 
ATP content in unfertilized oocytes was more likely to be associated with embryos 
that displayed good development in the same cohort (Van Blerkom et al., 1995).  
Mitochondrial content amplifies significantly within the oocyte during oogenesis 
until ovulation (Figure 1.3).  As the embryo undergoes cell division, each cell, also 
called blastomere, should receive half of the amount of the mitochondria from that 
starting pool.   This means the number of mitochondria per blastomere decreases 
as the amount of energy required by the embryo increases.  This inverse 
relationship indicates oocytes with higher ATP production, and by association 
higher mitochondrial content or better metabolism, will be more likely to develop 
appropriately to the blastocyst stage when the mtDNA starts to replicate again 
(May-Panloup et al., 2016, Chappel, 2013).  This observation shows that mtDNA 
copy number may be a good surrogate biomarker for embryo development (de Los 
Santos et al., 2018, Diez-Juan et al., 2015, Fragouli et al., 2017, Fragouli et al., 
2015, Ravichandran et al., 2017).  However, mtDNA copy number alone does not 
account for how efficiently the mitochondria function.   
Early mitochondrial studies in IVF examined mtDNA content in oocytes.  
The average mtDNA content between individual oocytes varies in humans even 
within the same patient (Reynier et al., 2001).   However, it appears there are some 
consistent observations, including lower mtDNA levels associated with oocytes 
that fail to fertilize, AMA, and aneuploidy.  Studies have demonstrated higher mean 
mtDNA levels in fertilized human oocytes compared to both unfertilized oocytes 
and degenerated oocytes (Reynier et al., 2001, Santos et al., 2006), although large 
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variations were seen between individual oocytes and no threshold had been 
established.  Higher mtDNA levels were again seen in unfertilized oocytes and 
embryos that failed to cleave in patients older than 40 years old (Murakoshi et al., 
2013).   
Recent mitochondrial research in IVF has focused mtDNA content in 
trophectoderm cells related to blastocyst development.  In an elegant study by 
Fragouli and colleagues, 379 trophectoderm biopsies from blastocysts were 
examined by array comparative genomic hybridization (aCGH), RT-PCR, and NGS 
(Fragouli et al., 2015).  Euploid blastocysts compared to aneuploid blastocysts, 
embryos from younger women compared to older women, and blastocysts that 
implanted compared to blastocysts that did not implant all exhibited lower mtDNA 
levels in trophectoderm cells. Additionally, the researchers established a predictive 
threshold value and found that 30% of the euploid embryos that did not implant 
were above the threshold value.  Blastocysts which failed to implant, having higher 
mtDNA levels in trophectoderm cells, were corroborated in a separate study (Diez-
Juan et al., 2015).  In another retrospective study examining 1641 trophectoderm 
biopsies from 402 patients, mtDNA levels in the trophectoderm biopsies were 
higher in aneuploid embryos, embryos from patients with higher BMIs, lower P4 
levels, and poor grade trophectoderm (de Los Santos et al., 2018).  In another 
blinded retrospective study 282 euploid blastocysts were transferred 
(Ravichandran et al., 2017). A total of 185 embryos with lower relative mtDNA 
levels in trophectoderm cells resulted in pregnancies while 0 out of 33 embryos 
with elevated mtDNA above the predicted threshold value failed to implant.  This 
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100% negative predictive value may indicate that mtDNA copy number in 
trophectoderm cells may be a possible method to improve the odds of selecting 
the most viable embryos.  Finally, in a prospective blinded non-selection study, 
199 euploid blastocysts were transferred, and mtDNA levels in trophectoderm cells 
were analyzed.  This study also showed a 100% negative predictive value with the 
nine embryos with mtDNA content above the threshold level failing to produce a 
pregnancy (Fragouli et al., 2017). 
Other groups have refuted these observations.  Victor and associates 
postulate the data of the above studies may be biased due to a lack of 
mathematical corrections necessary to appropriately determine mtDNA copy 
number in trophectoderm cells (Victor et al., 2017).  When they retrospectively 
analyzed 1396 trophectoderm biopsies, they found no difference in mtDNA 
trophectoderm copy numbers based on age, ploidy status, or implantation.  
Another retrospective study where PGT-A tested blastocysts were transferred in 
pairs, showed no predictive value of mtDNA trophectoderm copy number indicating 
the need for further analysis before being applied to make clinical decisions about 
which embryos to transfer (Treff et al., 2017).  In a retrospective study of 1510 
trophectoderm biopsies from patients between 31 and 38 years old, poor quality 
embryos exhibited higher mtDNA trophectoderm content overall, but when 
reanalyzed only assessing euploid embryos, this predictive trend was abolished.  
Additionally, mtDNA trophectoderm levels did not show differences in terms of 
pregnancy or implantation (Klimczak et al., 2018).  Most recently, a prospective 
study of 109 trophectoderm biopsies from 100 IVF patients showed no differences 
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in mtDNA levels between embryos that implanted and those that did not (Victor et 
al., 2019).      
It has been hypothesized that the mtDNA pool in CCs and MGCs are 
responsible for proper oocyte maturation and that the mtDNA originating in oocytes 
supports the early embryonic cleavage divisions making both key players in 
ultimate embryo viability.  Evidence for this hypothesis has been shown with 
correlations between oocyte and CC mtDNA content in IVF patients (Boucret et 
al., 2015).  Additionally, the presence of the mtDNA 4977 base pair deletion in 
human CCs is associated with lower pregnancy rate (Tsai et al., 2010).  
While lower mtDNA copy numbers were associated with better blastocyst 
development and implantation as described above, in three separate studies, 
increased mtDNA copy numbers in CCs have been shown to be associated with 
embryos that developed into high- versus low-quality embryos and embryos more 
likely to implant than those that did not implant.  Ogino and colleagues first 
proposed using mtDNA in CCs as a biomarker and were also the first to 
demonstrate increased mtDNA copy number in CCs using RT-PCR to determine 
copy number in humans.  In this prospective study, 60 individual COCs were 
collected from women undergoing IVF.  They used a mtDNA copy number 
threshold value of 86 to distinguish between good- and poor-quality embryos with 
a positive predictive value of 84.4 and a negative predictive value of 82.1.  The 
mean values of good- and poor-quality embryos were 140 (25–75% quartile, 97–
264) and 57 (25–75% quartile, 34–74), respectively.  In this study, there was no 
difference in good and poor embryo development based on maternal age (Ogino 
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et al., 2016).  A larger study examined the mtDNA content in CCs by RT-PCR from 
452 COCs from 62 patients undergoing IVF (Desquiret-Dumas et al., 2017).  
Increased mtDNA copy number in CCs was associated with good- and poor-quality 
embryos although there was a much larger interquartile range 738 (25-75% 
quartile, 250–1228) and 342 (25-75%, quartile, 159–818) between this study and 
the first study.  Additionally, the patient’s with lower BMIs and those that were 
smokers had higher CC mtDNA copy numbers.  The third study from the same 
group as the previous study, focused on mtDNA copy number in CCs relating to 
implantation and ongoing pregnancy.  84 COCs were analyzed with RT-PCR from 
71 patients undergoing IVF.  Those embryos that implanted showed a significantly 
higher mtDNA copy number in CCs than those that did not implant, independently 
of other patient variables with means of 215 [sd 375] and 59 [sd 72], respectively 
(Taugourdeau et al., 2019).   Interestingly, while increased mtDNA copy numbers 
in CCs have been associated with better embryo development and implantation 
the inverse was seen in trophectoderm cells.  It has been postulated that increased 
mitochondria within a blastocyst may serve to compensate for reduced 
mitochondrial energy dysfunction due to metabolic stress from ROS and free 
radicals (Diez-Juan et al., 2015, Fragouli et al., 2015, Grindler and Moley, 2013, 
May-Panloup et al., 2016). 
1.13 Specific Aims 
Infertility affected approximately 1 in 7 couples from 2015-2017 in the United 
States, according to the Centers for Disease Control National Survey of Family 
Growth (CDC, 2019).  Many of these couples turn to IVF to treat this disease. It 
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has been estimated that less than 10% of all oocytes harvested during an IVF cycle 
will produce a live a birth (Lemmen et al., 2016) and the odds of taking home a 
child in the United States following IVF is only 30% per oocyte retrieval based on 
data tracked by the SART (SART, 2019).  Additionally, as a woman ages the 
probability of taking home a baby from IVF drastically decreases.  These statistics 
indicate that current approaches of selecting embryos for uterine transfer are 
insufficient, and newer methods for embryo selection are required.  Since IVF 
procedures have high costs, there is a critical need to identify the embryos with the 
highest potential of leading to implantation and live birth as quickly as possible to 
reduce IVF costs and offset the effects of advancing age with subsequent 
procedures.   
Our long-term goal is to create a panel of biomarkers that can help 
embryologists quickly and easily select an embryo from a patient’s cohort 
of embryos that has the best chance of implanting, leading to live birth, and 
improving patients’ odds of success using IVF the first time.  We hypothesize 
that this can be accomplished using the cells which surround the oocytes during 
follicular maturation.  Cumulus cells and mural granulosa cells collectively 
comprise the granulosa cell pool.  Granulosa cells are by-products harvested 
during the oocyte retrieval in assisted reproduction procedures, and they closely 
reflect the oocyte’s maturational status and developmental potential (Dumesic et 
al., 2015).  
Our objectives are to determine a set of non-invasive biomarkers in GCs 
which identify the oocytes that will result in a live birth within a patient’s cohort of 
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oocytes.   In Aim 1, we will analyze several carefully selected mRNA biomarkers 
in individual CC masses to determine if a single or panel of biomarkers can be 
used to predict euploid embryos that will have the best odds of resulting in a live 
birth.  In Aim 2, we will examine the mitochondrial metabolic substrate utilization in 
pooled granulosa cells and compare between patients based on age, serum AMH 
levels, BMI, and number of mature oocytes retrieved per cohort, and embryo 
cohort development.  We will also examine selected mRNA biomarkers of interest 
from Aim 1 and compare them within the same Aim 2 groups.   
AIM1:  To test the hypothesis that out of the group of selected cumulus 
cell mRNA biomarkers there will be one or a panel that will allow selection of 
the embryo with the highest odds of implanting and leading to live birth.  
Levels of 19 mRNA biomarkers will be assessed via qRT-PCR and related to the 
development of their corresponding individually cultured oocytes and subsequent 
embryos, embryo ploidy status, and live birth outcomes.   
AIM2: (A) To determine if mitochondrial function differs between 
patients based on age, serum AMH levels, BMI, number of mature oocytes, 
and embryo cohort development and (B) to determine of individual 
substrates can be used as mitochondrial biomarkers for IVF.  The rates of 
mitochondrial metabolic substrate utilization by mitochondria in pooled CCs and 
MGCs will be assessed and related to patient demographics including age, serum 
AMH level, BMI, percent of mature oocytes, fertilization rate, day 3 embryo 
development, blastocyst development, mitochondrial content, and mRNA levels of 
selected genes. 
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Successful identification of non-invasive biomarkers to select the most 
competent oocytes will revolutionize the field of IVF.  Once a panel is created that 
faithfully identifies the oocytes with the best chance of success, an embryologist 
would select the embryos with the best probability of resulting in live birth from the 
cohort of embryos created.  This procedure would reduce the number of 
procedures needed to have a viable pregnancy resulting in a live birth, increasing 
the overall success IVF and reduce cost to the patient.  In theory, an embryologist 
may only need to inseminate a small number of oocytes from the cohort rather 
than all of them.  This change in procedure would prevent creation of excess 
embryos and the moral dilemma of what to do with any extra unused embryos.   
1.14 Innovation 
Few studies have examined the link between CC mRNA levels and 
oocyte/embryo ploidy status (Fragouli et al., 2010, Fragouli et al., 2012, Parks et 
al., 2016, Green et al., 2018). Our study will employ a focused set of CC mRNA 
biomarkers related to CC expansion and oocyte maturation, steroidogenesis, and 
hormone modulation and signaling to determine if specific mRNA levels correlate 
with oocyte maturity, abnormal embryo development, embryo ploidy status, and 
live birth outcomes.  Using data collected, we will create a model of specific CC 
mRNA biomarker levels to identify a mature oocyte’s ability to produce euploid 
embryos with best live birth potential.  
Most studies of GC, oocyte, and embryo mitochondria have exclusively 
evaluated mitochondrial copy numbers.  These proposed studies will evaluate 
GC mitochondrial activity in a novel way.  This will be the first examination of a 
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new mitochondrial function assay that has not previously been used to assess 
mitochondrial substrates in GCs.  It measures the rate of electron flow through 
the electron transport chain from varying metabolic substrates that produce 
NADH or FADH2.  The goal will be to see how substrate utilization differs 
between various patient groups. Additionally, we will examine fertilization rates, 
day three embryo development, blastocyst development, and mRNA levels of 
selected genes between the groups to see if one or more substrates can be used 









Figure 1.1. Midsagittal section of the female reproductive tract. Uterus-poster 3791876: freepik.com. This cover has 
been designed using resources form Freepik.com. 
  
 






Figure 1.2. The ovary exhibiting different stages of follicular development.  A random cross-sectional view as seen 
here would exhibit follicles and corpora lutea at various stages from development from primordial follicles through corpus 
albicans.  Typically Graafian follicles, developing corpus luteum, and corpus luteym are not present in the ovary 















Figure 1.3. Mitochondrial biogenesis during oogenesis, folliculogenesis (F = Follicle, I primary, II pre-antral, III 
antral) and early embryonic development in humans. During early maternal embryogenesis, the mtDNA content of 
each embryonic cell undergoes a drastic reduction. This is followed, during oogenesis, by a restriction and amplification of 
mtDNA content leading to a refreshed and purified mtDNA pool as illustrated in the bottleneck (green), quantitatively 
sufficient for allocation among the embryonic blastomeres. The close relationship between the oocyte and the surrounding 
cumulus cells appears to be important for the constitution of the oocyte mitochondrial pool (orange). Modified from (May-
















Figure 1.4. Follicular development.  The diagram summarizes the process of ovarian follicle development and growth, 
from oocyte nests present in the fetal ovary through follicle growth, ovulation and corpus luteum formation during 
adulthood.  Modified from (Hernandez-Ochoa et al., 2009). Reprinted with permission. 
  
 











Figure 1.5. The female hypothalamic–pituitary–gonadal axis. The hypothalamus produces and secretes gonadotropin 
releasing hormone (GnRH) into a system of blood vessels that link the hypothalamus and the pituitary gland. GnRH 
stimulates the pituitary gland by attaching to specific molecules (i.e., receptors). After the coupling of GnRH with these 
receptors, a cascade of biochemical events causes the pituitary gland to produce and secrete two hormones, luteinizing 
hormone (LH) and follicle–stimulating hormone (FSH). LH and FSH are two of a class of hormones commonly known as 
gonadotropins. They are secreted into the general circulation and attach to receptors on the ovary, where they trigger 
ovulation and stimulate ovarian production of the hormones estrogen and progesterone. These female hormones cause 
monthly menstrual cycling and have multiple effects throughout the body. In particular, estrogen has profound effects on 
the skeletal system and is crucial to maintaining normal bone health.  Modified from (Emanuele et al., 2002).  
  
 











Figure 1.6. The human menstrual cycle. A typical human menstrual cycle lasts 28 days, with ovulation occurring at 
midpoint, at day 14. The first day of vaginal bleeding is day 1. The first phase of the cycle is the follicular phase, during 
which progesterone levels are very low, and estrogen levels start low and slowly increase. At approximately day 12, 
estrogen levels peak, causing increased secretion of pituitary LH and FSH, with levels peaking on day 13-14. The LH 
surge results in ovulation, and a transient drop in estrogen, and a new increase in progesterone levels. During the post-
ovulation period, called the luteal phase, estrogen and progesterone levels first rise, then fall back to very low levels, at 
which point the next menses starts. The progesterone scale is 1000-fold higher than the estrogen scale.  Modified from 
(Emanuele et al., 2002).  
  
 











Figure 1.7.  The two-cell, two-gonadotropin theory of follicular conversion of cholesterol to steroid hormones.  
Free cholesterol is deposited into theca cells by low-density lipoprotein (LDL) receptor-mediated LDL endocytosis. The 
conversion of cholesterol to pregnenolone by CYP11A1 in the inner membrane of the mitochondria is initiated by the 
binding of luteinizing hormone (LH) to the luteinizing hormone receptor (LHR).  Pregnenolone is converted to 
dehydroepiandrosterone (DHEA) by CYP17A1 in the endoplasmic reticulum (ER).  DHEA is converted to androstenedione 
by HSD3B1.  Androstenedione diffuses across the basement membrane to the granulosa cells (GCs). Finally, 
androstenedione is converted to estradiol (E2) by aromatase (CYP19A1) which is initiated by the binding of follicle-
stimulating hormone (FSH) to the follicle-stimulating hormone receptor (FSHR). (Black solid line arrows: synthesis step; 
blue solid line arrow with + symbol: activation; dotted line arrows: transfer step). Modified from (Hebert-Schuster et al., 























Figure 1.8.  Metabolic cooperativity between oocytes and cumulus cells, and the role of oocyte-derived paracrine 
factors in promoting metabolism in cumulus cells. Oocytes are deficient in metabolizing glucose by glycolysis, 
synthesizing cholesterol from acetate and taking up alanine directly, as compared with cumulus cells. Oocytes obtain 
products of the glycolysis (e.g., pyruvate) and cholesterol biosynthesis (e.g., cholesterol) pathway, as well as alanine from 
cumulus cells. Oocytes, via secreting paracrine factors, promote these metabolic processes in cumulus cells by promoting 
the expression of transcripts encoding key enzymes in the corresponding pathways, as well as the expression Slc38a3 
encoding an amino acid transporter for L-alanine. GDF9 and BMP15 are involved in promoting cholesterol biosynthesis in 
cumulus cells, while cooperation between BMP15 and FGFs are required for promoting glycolysis. Which oocyte-derived 
paracrine factor(s) participate in the induction of Slc38a3 expression, as well as L-alanine uptake by cumulus cells are 
unknown.  (Su et al., 2009). Reprinted with permission. 
  
 











Figure 1.9.  Mitochondrial metabolism.  Glucose breakdown through glycolysis and the tricarboxylic acid cycle (dark 
blue) generates reduced NADH and FADH2. Fatty acid β-oxidation (FAO, light blue) of fatty acyl-CoA esters is performed 
in four enzymatic reactions that also generate NADH and FADH2, as well as acetyl-CoA. Electrons derived from NADH 
and FADH2 are utilized by the five OXPHOS complexes (green) to generate ATP. Complex I (CI, NADH: ubiquinone 
oxidoreductase), complex III (CIII, ubiquinol: ferricytochrome c oxidoreductase) and complex IV (CIV, cytochrome c 
oxidase) pump electrons out of the mitochondrial matrix to generate a membrane potential (Δψm) that drives the synthesis 
of ATP by complex V (CV, FoF1-ATP synthetase). CII, complex II (succinate: ubiquinone oxidoreductase).  (Nsiah-Sefaa 
















Figure 1.10.  Prevalence of aneuploidy in human women. The prevalence of aneuploidy relative to the age of the 
female partner demonstrates the lowest risk in women from their middle to late twenties, with significantly higher rates in 
embryos obtained from both younger and older women (P<1*10−6). The relationship between age and the rate of 
aneuploidy is a best fit at the 5th degree polynomial (regression line shown). Modified from (Franasiak et al., 2014).  





Materials and Methods 
2.1 Ethical Approval 
These studies were approved by the University of South Carolina Institutional 
Review Board (IRB registration number: 00000240) and Greenville Health System 
Institutional Review Board (IRB number: Pro00072006). 
2.2 Patient Controlled Ovarian Stimulation and Granulosa Cell Harvest 
Granulosa cells were harvested from patients undergoing infertility treatment 
at Advanced Fertility and Reproductive Endocrinology Institute (Columbia, SC, 
USA) and Fertility Center of the Carolinas (Greenville, SC, USA).  Patient 
demographics, cycle information, pregnancy, and live birth data were collected.  
Each patient’s ovaries were stimulated using either a long luteal protocol or an 
antagonist controlled ovarian stimulation protocol.  In the antagonist cycles, when 
one follicle reached at least 13 mm or the patient’s estradiol level reached 300 
IU/mL, a GnRH antagonist (Cetrotide, EMD-Serono, Rockland, MA, USA or 
Ganirelix, EMD-Serono, Rockland, MA, USA) was administered.  In both protocols, 
when 2-3 follicles reach >17 mm by ultrasound an ovulatory dose of hCG (Pregnyl, 
EMD-Serono, Rockland, MA, USA) or Lupron (Leuprolide Acetate, Sandoz, 
Princeton, NJ, USA) was delivered.  Thirty-six hrs later, the patient’s oocyte 
retrieval was performed by a physician.  Each CC mass was mechanically 




Scientific, Santa Ana, CA, USA), a medium containing 21 mM N-2-
Hydroxyethylpiperazine-N’-2- ethanesulfonic acid (HEPES) and 4 mM sodium 
bicarbonate buffered modified human tubal fluid (HTF) and 5 mg/ mL human serum 
albumin to remove debris.  For the PGT-A related studies, each CC mass and its 
associated oocyte/embryo were kept separate throughout the entire process.  
Cumulus cell masses were snap-frozen and maintained in liquid nitrogen (LN2) 
until they were transported from the clinics to the University of South Carolina 
School of Medicine where they were stored in a freezer at -70°C until use.  For the 
mitochondrial function assay associated RT-PCR, the CCs and MGCs were pooled 
together, and an aliquot of GCs were placed in RNAlater solution, (Life 
Technologies, Carlsbad, CA, USA) cooled for 24 hrs at 4°C, snap-frozen and 
handled as above. 
2.3 Embryo culture and ploidy assessment 
Mature oocytes were inseminated via ICSI.  Fertilization was confirmed by 
the presence of two pronuclei and two polar bodies 16-18 hrs after insemination.  
Embryos for the PGT-A studies were individually cultured in 20 µL LifeGlobal® 
global total media drops (Cooper Surgical, Trumbull, CT, USA) under oil (Ovoil, 
Vitrolife, Englewood, CO, USA) at 37°C, 6% CO2, 5% O2, 89% N2 in a humidified 
atmosphere until day 5 or day 6 post retrieval.  For PGT-A related studies, embryo 
morphologies were assessed using Gardner’s blastocyst grading (Gardner et al., 
2000), and 3-7 trophectoderm cells were biopsied and sent to Igenomix (Miami, 
FL, USA) for genetic testing using NGS.  Frozen embryo transfers were performed 




the patient’s obstetrician, including delivery dates, gender, and if there were any 
maternal or neonatal interventions or complications.  For mitochondrial related 
studies, embryos were group cultured in 50 µL LifeGlobal® global total media 
drops (Cooper Surgical) under oil (Vitrolife) at 37°C, 6% CO2, 5% O2, 89% N2 in a 
humidified atmosphere until day 5 or day 6 post retrieval.  Embryo morphologies 
were assessed using the American Society for Reproductive Medicine (ASRM) 
(Racowsky et al., 2010) criteria for day 3 embryos and day 5/6 blastocysts. 
2.4 RNA Isolation and cDNA synthesis 
RNA was isolated from each CC sample or pooled CC/MGC samples using 
the Direct-zol MiniPrep Kit with DNase treatment (Zymo Research, Irvine, CA, 
USA) following the manufacturer’s instructions.  Samples were removed from 
storage at -70°C and Ribozol (600-1000 μL) was added to each sample and 
incubated 5 min at room temperature (RT) to lyse cells.  Lysates were transferred 
to clean RNase/DNase free microcentrifuge tubes.  A 1:1 volume of 95-100% 
ethanol was added to tubes containing the Ribozol lysates and vortexed.   Samples 
were loaded into Directzol spin columns and centrifuged at 15,000xg for 1 min in 
a refrigerated microfuge (Eppendorf, Hauppauge, NY, USA).  Each spin was 
performed at 15,000xg in the same microfuge throughout this protocol.  The flow-
through was discarded.  Each spin column was placed into a clean RNase/DNase 
free tube and 400 μL of RNA wash buffer was added into each column and 
centrifuged for 1 min. The flow-through was discarded.  An 80 μL DNase mixture 
containing DNase, 1X DNase reaction buffer, and kit water was added into each 




for 30 seconds and 400 μL RNA pre-wash buffer was added to the columns and 
they were centrifuged for an additional 1 min. The flow-through was discarded. 
Another 400 μL RNA pre-wash buffer was added and then centrifuged again, and 
the flow-through was discarded.  A total of 700 μL RNA wash buffer was added to 
each column, centrifuged for 1 min, and the flow-through was discarded. Columns 
were centrifuged for another 2 min in order to dry the columns.  Each column was 
transferred to a new RNase/DNase-free tube.  50μL RNase/DNase-free kit water 
was added to the columns for the pooled samples and 30 μL were added for the 
individual samples, and incubated at RT for 5 min. The columns were centrifuged 
for 2 min to elute RNA, and then kept on ice for immediate use or stored at -70°C.  
The RNA concentration and purity of individual CC masses was assessed at the 
wavelengths of 260 and 280 nm using a spectrophotometer with a 2 mm lid 
(NanoDrop 2000C, Thermo Scientific, Waltham, MA, USA).  RNA concentration 
and purity for pooled samples were assessed at the wavelengths of 260 and 280 
nm using a Biophotometer 6131 spectrophotometer (Eppendorf).    
2.5 DNA Isolation 
DNA was isolated from pooled GCs using the Direct-zol MiniPrep Kit as 
described above but omitting the DNase treatment step (Zymo Research).  DNA 
concentration and purity were assessed at the wavelengths of 260 and 280 nm 
using a Biophotometer 6131 (Eppendorf). 
2.6 cDNA synthesis  
Each sample was reverse transcribed into cDNA using the iScript kit (Bio-




mix, and 1 μL of iScript Reverse Transcriptase enzyme were combined on ice, 
vortexed and pulsed down.  Samples were allowed to sit for 2 min at RT before 
starting the program.  The reverse transcription reaction was carried out in a 
thermocycler (Eppendorf), for 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C.  
After cDNA synthesis, each sample of the cDNA was diluted with DNase/RNase-
free water and stored at -20°C for subsequent qRT-PCR. 
2.7 Quantitative Real-Time PCR 
Synthesized primers were cartridge purified (Life Technologies).  Primers 
included:  AMH, AREG, CALM1, CYP11A1, CYP19A1, FSHR, GJA4, GREM1, 
HSD3B1, insulin-like growth factor 2 (IGF2), IGFBP5, inhibitor of growth protein 1 
(ING1), inhibin beta A subunit (INHBA), LHCGR, mitochondrially encoded ATP 
synthase 8 (MT-ATP8), pappalysin-1 (PAPPA), PGR, PGRMC1, PTGS2, 
steroidogenic acute regulatory protein (STARD1), and VCAN.  Primer sets may be 
found in Tables 3.2 and 4.3.  Real-time PCR reactions were run with 2 or more 
wells per sample for 40-45 cycles and threshold cycle (Ct) values were averaged.  
The reactions included between 5-27 ng starting cDNA, 300 nM of each upstream 
and downstream primer, and 10 µL 2X SsoAdvanced Universal SYBR Green 
Supermix (Bio-Rad Laboratories) and sterilized PCR-grade water to a final volume 
to 20 µL per well.  PCR-grade water was substituted for the cDNA as a negative 
control.  PCR amplification was performed using the iCycler iQ Real-Time PCR 
Detection System (Bio-Rad Laboratories).  TATA-box binding protein (TBP) mRNA 
was used as an internal control for cDNA samples (Nelson-Degrave et al., 2005) 




(nDNA) samples (Diez-Juan et al., 2015).  Primer efficiency curves were 
determined on all amplicons. Single amplicons of the correct size were verified 
using agarose gels and by the presence of single melt-curve peaks.  All primers 
not previously reported in the literature had their amplicons sequenced.  mRNA 
and nDNA quantities were derived from a standard curve for each transcript using 
serial dilutions of its purified amplicon.  TBP has extensively been tested as a 
control gene in our laboratory with human GCs under multiple conditions and 
treatments and has not been found to be regulated under any circumstances.  
Target mRNA values were expressed relative to values of the TBP mRNA control.   
2.8 Quantification of mtDNA 
Relative amounts of mtDNA and nDNA and were determined by qRT-PCR.  
The nuclear gene ACTB was selected as a reference gene to calculate mDNA 
content and the mtDNA gene MT-ATP-8 was used to quantify mitochondrial 
genome content.  The ratio of mtDNA:(2x nDNA) was used to determine mtDNA 
content.    
2.9 Analysis of Mitochondrial Metabolic Substrates 
Cumulus cells from each patient were rinsed in sperm washing medium 
(FUJIFILM Irvine Scientific) following oocyte retrieval and placed in a 5 mL tube.  
Follicular fluid containing MGCs from each patient was split between 50 mL tubes 
and centrifuged for 15 min at 300xg.  Each spin was performed at 300xg in the 
same centrifuge throughout this protocol.  Follicular fluid was decanted from the 
tubes and a filtered solution of hyaluronidase (50 mg/mL) from bovine testes 




incubated at 37°C for 10 min to remove cell clumps.  Calcium/magnesium-free 
phosphate-buffered saline (PBS) (Gibco, Gaithersburg, MD, USA) was added to 
bring the pellet to ≥4 mL.  Mural granulosa cells were layered on top of 35% over 
70% Percoll solutions in 15 mL tubes and centrifuged for 30 min.  A 30 µL assay 
mix containing 2x Biolog Mitochondrial Assay Solution (MAS) (Biolog, Hayward, 
CA, USA), 6x Redox Dye (Biolog), 24x saponin (90 µg/mL) for permeabilization 
(Alfa Aesar, Ward Hill, MA, USA), and sterile water was added to each well of the 
96-well MitoPlate S-1 plates (Biolog) to incubate for 1 hour.  Mural granulosa cells 
were partitioned into 1 or 2 bands with the blood pelleting to the bottom of the 
tubes.  The upper band containing purified MGCs was removed, 25 mL of 
calcium/magnesium-free PBS (Gibco) and the CCs were combined.  The mixture 
was poured through a 70-micron strainer.  Pooled GCs were centrifuged for 20 
min.  The supernatant was decanted, and the pellet was resuspended in 1x MAS 
buffer (Biolog) to 2 mL.  The GC/MAS mixture (0.5 mL) was removed and a 10 µL 
sample was counted on a hemocytometer.  The remaining aliquot was centrifuged 
for 5 min.  The supernatant was decanted and the pellet was placed in 0.5 mL 
RNAlater solution (Life Technologies), stored at 4°C for 24 hrs, and snap-frozen in 
LN2 until it was transported to the University of South Carolina School of Medicine 
for further processing.  The remaining 1.5 mL GC/MAS mixture was diluted to 3.0 
mL with 1x Biolog MAS and a 10 µL sample was counted with a hemocytometer 
and averaged with the first cell count to determine the total cells in each sample.   
After 1 hr incubation, 30 µL of the GC/MAS suspension was added to each well of 




mitochondrial activity using MitoPlate S-1 plates. The plates contained 31 
cytoplasmic and mitochondrial metabolic substrates. Metabolism of substrates 
was assessed by a colorimetric change of a terminal electron acceptor tetrazolium 
redox dye at a wavelength of 590 nm read every 2.5 min for 50 cycles on a kinetic 
plate reader.  Results were normalized to mtDNA copy number per sample and 
the negative control wells containing GC/MAS and assay mix without any 
additional substrates and positive control wells containing GC/MAS and assay mix 
with succinic acid.   Slope ratio = [Slope (sample) – Slope (negative control)] / 
[Slope (positive control) – Slope (negative control)].   
2.9 Statistics 
Real-time PCR reactions were run with 2 or more wells per sample for 40-45 cycles 
and threshold cycle (Ct) values were averaged.  The mRNAs were normalized 
against internal controls as described above. Statistical analysis of the results was 
performed using generalized linear mixed models (GLMMs) fitted by maximum 
likelihood using the R package lme4 (Bates et al., 2015).  Substrates on in the 
mitochondrial function assay were run in triplicate on the same plate along with a 
negative control and a positive control.  The slopes of the kinetic curves were 
averaged.  Multiple linear regression models were estimated to predict the 
normalized average rate of each substrate’s metabolism and mitochondrial 
metabolic score using Box-Cox transformation for normality (Box and Cox, 1964). 
Statistical analysis was performed using the statistical analysis environment R 
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3.1.1 Purpose: To determine whether a selected set of mRNA biomarkers 
expressed in individual cumulus granulosa cell (CC) masses show association with 
oocyte developmental competence, embryo ploidy status, and embryo outcomes. 
3.1.2 Methods: This prospective observational cohort pilot study assessed levels 
of mRNA biomarkers in 163 individual CC samples from 15 women stimulated in 
antagonist cycles. Nineteen mRNA biomarker levels were measured by real-time 
PCR and related to the development of their corresponding individually cultured 
oocytes and subsequent embryos, embryo ploidy status, and live birth outcomes. 
3.1.3 Results:  PAPPA mRNA levels were significantly higher in CC from oocytes 
that led to euploid embryos resulting in live births and aneuploid embryos 
compared to immature oocytes by ANOVA.  LHCGR mRNA levels were 
significantly higher in CC of oocytes resulting in embryos associated with live birth 
compared to immature oocytes and oocytes resulting in arrested embryos by 
ANOVA.  Using a General Linearized Mixed Model to assess ploidy status, CC 
HSD3B1 mRNA levels in oocytes producing euploid embryos were significantly 
lower than other oocyte outcomes, collectively.  When transferred euploid embryos 
outcomes were analyzed by ANOVA, AREG mRNA levels were significantly lower 
and PAPPA mRNA levels significantly higher in CC from oocytes that produced 
live births compared to transferred embryos that did not form a pregnancy. 
3.1.4 Conclusions:  Collectively, PAPPA, LHCGR, and AREG mRNA levels in CC 




HSD3B1 mRNA levels may be able to identify oocytes capable of producing 
euploid embryos. 
3.1.5 Key Words: cumulus cells, real-time PCR, mRNA levels, oocyte 
developmental competence, euploid embryo 
3.2 Introduction 
Successful in vitro fertilization (IVF) is highly dependent upon the quality of 
the oocytes harvested and the subsequent quality of embryos used for uterine 
transfer (Uyar et al., 2013).  Several studies have shown that use of 
preimplantation genetic testing for aneuploidy (PGT-A) to select euploid embryos 
for uterine transfer increases implantation, ongoing pregnancy, and delivery rates 
(Chen et al., 2015a, Yang et al., 2012, Scott et al., 2013), whereas other studies 
showed PGT-A decreased pregnancy rates (Kushnir et al., 2016, Chang et al., 
2016).  Conflicting PGT-A findings might indicate that other methods beyond 
genetic screening are needed to improve IVF pregnancy rates.  The differing PGT-
A study results may also reflect the invasive methodology of PGT-A, which 
requires the removal of 3-10 cells from the trophectoderm.  Increased numbers of 
trophectoderm cells per biopsy have been correlated with decreased implantation 
rates (Zhang et al., 2016).  Therefore, a method for identifying oocytes that will 
produce euploid embryos with the greatest chances of leading to a live birth that 
does not require embryo manipulation would be advantageous. 
Some non-invasive methods for assessing oocyte and embryo live birth 
potential include preimplantation embryo metabolomics and proteomics of 
secreted products (Uyar and Seli, 2014, Nel-Themaat and Nagy, 2011) and 




GC biomarkers is based on knowledge that cumulus granulosa cells (CCs) and 
mural granulosa cells (MGCs) interact with oocytes and can reflect the health and 
maturational status of the oocyte (Tanghe et al., 2002, Uyar et al., 2013).  GCs are 
obtained as a by-product of oocyte retrieval and can be rapidly assessed for mRNA 
levels by reverse transcription and quantitative polymerase chain reaction (PCR).  
Several studies suggest that CC biomarker mRNA levels from individual oocytes 
can be used to generate models capable of predicting pregnancy and live birth 
(Ekart et al., 2013, Iager et al., 2013, Wathlet et al., 2011). 
Approaches to evaluate differentially expressed genes in CCs have 
employed large-scale microarray, transcriptome deep sequencing, PCR arrays 
and quantitative PCR (Kordus and LaVoie, 2017).  In most cases the ploidy status 
of the embryos was not known, which could have altered the study outcomes.  Only 
a handful of studies have examined CC mRNA levels in conjunction with oocyte or 
embryo ploidy status (Fragouli et al., 2012, Parks et al., 2016, Green et al., 2018).  
Taken together, a focused quantitative PCR analysis of CC target genes selected 
from prior studies combined with the ploidy status of the embryos should yield 
valuable information regarding mRNA biomarker usefulness in predicting live birth. 
Many oocytes fail to fertilize, or when fertilized, arrest before reaching the 
blastocyst stage, or fail to develop into euploid blastocysts.  We hypothesize that 
while many mature oocytes appear morphologically normal, the actual 
developmental competence of those oocytes is variable, and will be reflected by 
varying mRNA levels of specific biomarkers in their associated CCs.  Furthermore, 




a mature oocyte, when fertilized, will result in a euploid embryo.  In addition, we 
hypothesize that certain CC mRNA biomarkers and their levels will associate with 
oocytes that are capable of producing viable embryos which result in live births. 
A comprehensive review of the human literature for potential CC candidate 
mRNA biomarkers was performed (Kordus and LaVoie, 2017), and genes were 
selected based on their functions.  In some cases, the genes selected were based 
on data in non-human animals (Christenson et al., 2013, Vigone et al., 2013, Assidi 
et al., 2008, Blaha et al., 2015, Nivet et al., 2013, Saini et al., 2015, Glister et al., 
2010).  Gene products associated with oocyte maturation included calmodulin 1 
(CALM1), gap junction alpha-4 protein (GJA4), gremlin (GREM1), and inhibitor of 
growth protein 1 (ING1).  Genes associated with cumulus mass expansion 
included amphiregulin (AREG), prostaglandin-endoperoxide synthase 2 (PTGS2), 
and versican (VCAN).  Genes encoding proteins mediating de novo 
steroidogenesis, estrogen, and progesterone production included aromatase 
(CYP19A1), cholesterol side-chain cleavage enzyme (CYP11A1), hydroxy-delta-
5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 (HSD3B1), and 
steroidogenic acute regulatory protein (STARD1).  Genes related to hormone 
modulation included insulin-like growth factor 2 (IGF2), insulin-like growth factor-
binding protein 5 (IGFBP5), and inhibin beta A subunit (INHBA), and pappalysin-1 
(PAPPA).  Gene encoding hormone receptors included follicle-stimulating 
hormone receptor (FSHR), luteinizing hormone/choriogonadotropin receptor 
(LHCGR), progesterone receptor (PGR), and progesterone receptor, membrane 




model of specific CC mRNA biomarker levels could identify a mature oocyte’s 
ability to produce euploid embryos.  The secondary goal of this study was to 
determine if specific CC mRNA biomarker levels could indicate oocytes capable of 
leading to euploid embryos with live birth outcomes. 
3.3 Materials and methods 
3.3.1 Study population, participants, and CC isolation 
This study is a prospective observational cohort pilot study.  In total, 164 
individual CC masses were harvested from their corresponding oocytes from 15 
patients undergoing infertility treatment with PGT-A at Advanced Fertility and 
Reproductive Endocrinology Institute (Columbia, SC, USA) from February 2015 
through June 2016.  Patient’s either electively desired PGT-A or it was 
recommended based on the patient’s diagnosis (Table 3.1).  Patients with 
endometriosis or diminished ovarian reserve (DOR) were not included as prior 
work indicates these conditions alter GC gene expression (Greenseid et al., 2011, 
May-Panloup et al., 2012, Allegra et al., 2014, Barcelos et al., 2015).  Patient 
demographics and cycle information (Table 3.1), blastocyst development, PGT-A 
results, and live birth data (Supplemental Table 3.1), as well as CC mRNA levels 
were collected.  Each patient’s ovaries were stimulated using an antagonist 
protocol until at least one follicle at 15 mm was present when a GnRH antagonist 
(Cetrotide, EMD-Serono, USA or Ganirelix, EMD-Serono, USA) was administered.  
When two follicles reached 18 mm or 50% of the follicles were ≥ 15 mm by 
ultrasound, an ovulatory dose of human chorionic gonadotropin (hCG) (Pregnyl, 




Thirty-six hrs later patients underwent oocyte retrieval.  Each CC mass was 
mechanically separated from its oocyte and rinsed in HTF-HEPES, medium (Irvine, 
USA) to remove debris.  Each CC mass and its associated oocyte/embryo were 
kept separate throughout the entire process.  A summary flowchart of the fate of 
the collected oocytes is shown in Figure 3.1.  CC masses were snap frozen and 
maintained in LN2 until they were transported to the University of South Carolina 
School of Medicine for further processing. 
3.3.2 Embryo culture and ploidy assessment 
Mature oocytes were inseminated via intracytoplasmic sperm injection.  
Fertilization was confirmed by the presence of two pronuclei and two polar bodies 
16-18 h after insemination. Oocytes and   embryos were individually cultured in 20 
µL media drops (Global total, Global, USA) under oil (Ovoil, Vitrolife, USA) at 37°C, 
6% CO2, 5% O2, 89% N2 in a humidified atmosphere until day 5 or day 6 post 
retrieval.  Blastocyst  morphologies were assessed using Gardner’s blastocyst 
grading scale (Gardner et al., 2000), and 3-7 trophectoderm cells were biopsied 
and sent to Igenomix (Miami, FL, USA) for PGT-A using NGS. Fifteen FETs were 
performed using the highest quality euploid embryos (19 embryos total) for each 
patient. Live birth outcomes were obtained from the patient’s obstetrician including 
delivery dates and if there were any maternal or neonatal interventions or 
complications. 
3.3.3 RNA Isolation and cDNA synthesis 
RNA was isolated from each CC mass using the Direct-zol MiniPrep Kit with 




purity were assessed at the wavelengths of 260 and 280 nm using a 
spectrophotometer with a 2 mm lid (NanoDrop 2000C, Thermo Scientific, USA).  
Sample amounts varied between 80 and 360 ng RNA per individual sample.  Each 
sample was reverse transcribed into cDNA using the Bio-Rad iScript kit (Hercules, 
CA, USA).  The reverse transcription reaction was carried out in an Eppendorf 
thermocycler, for 5 min at 25C, 30 min at 42C, and 5 min at 85C. 
3.3.4 Quantitative Real-Time PCR 
Gene primer sequences, annealing temperatures, and amplicon sizes can 
be found in Table 3.2.  Synthesized primers were cartridge purified (Life 
Technologies, Carlsbad, CA, USA).  PCR reactions were run with two or more 
wells per sample for 45 cycles and threshold cycle (Ct) values were averaged.  The 
reaction included 2 µL of cDNA (6-27 ng starting RNA), 300 nM of each upstream 
and downstream primer, and 10 µL 2X SsoAdvanced Universal SYBR Green 
Supermix (Bio-Rad Laboratories, Hercules, CA, USA) and sterilized PCR-grade 
water to a final volume to 20 L per well.  PCR-grade water was substituted for the 
cDNA as a negative control.  PCR amplification was performed using the iCycler 
iQ Real-Time PCR Detection System (Bio-Rad, USA).  TATA-box binding protein 
(TBP) mRNA was used as an internal control (Nelson-Degrave et al., 2005).  
Single amplicons of correct size were verified using agarose gels and by the 
presence of single melt-curve peaks.  mRNA quantities were derived from a 
standard curve for each mRNA made using serial dilutions of its purified amplicon.  
TBP has extensively been tested as a control gene in our laboratory with human 




be regulated under any circumstances.  Target mRNA values were expressed 
relative to values of the TBP mRNA control. 
3.3.5 Statistical analysis 
The mRNA levels were normalized using log2 transformation.  Principal 
Component Analysis (PCA) was conducted to explore the mRNA level correlation 
patterns between the CC samples.  CC mRNA levels were compared between 
different oocyte and subsequent embryo developmental outcomes using repeated 
measures analysis of variance (ANOVA) to accommodate for the variable number 
of oocytes per patient followed by Tukey’s post hoc tests for pairwise comparisons.  
The CC samples used for these studies were divided into the following categories:  
Immature oocytes, mature oocytes that failed fertilization, oocytes that produced 
embryos that arrested and were not appropriate for biopsy, oocytes that produced 
biopsied blastocysts that were aneuploid, and oocytes that produced biopsied 
blastocysts that were euploid.  Oocytes that produced euploid embryos were 
further subdivided into embryos that resulted in live birth, embryos that resulted in 
a negative pregnancy, and embryos that were vitrified and not transferred.  Each 
figure states which categories were used for the specific statistical analysis. 
3.3.6 Statistical models 
Models were estimated to predict multiple dichotomous oocyte 
developmental outcomes using generalized linear mixed models (GLMMs) fitted 
by maximum likelihood using the R package lme4 (Bates et al., 2015).  The 
GLMMs included the normalized gene expressions as variables and used patients’ 




for two ovulation induction or trigger medications).  Unstructured correlation 
patterns were used in fitted GLMMs to capture the correlation among the repeated 
observations from same individual.  The statistical models aimed to include as 
many patients as possible. However, some of the genes had high proportion of 
missing values for some patients because of limited RNA amounts that were 
obtained from CC masses. To ensure maximum utilization of the data we started 
the modeling by including all the genes and proceeded backward dropping the 
genes one-by-one with highest proportion of missing observations until the fitted 
mixed-effects model attained computational convergence successfully. Since 
different patients had missing observations on different genes, exclusion of the 
missing values eventually reduced the number of patients and number of 
observations in the sample used to fit the model.  The analysis sample size differed 
from model-to-model (for different response variables) as the maximum possible 
data points were used for a model to converge.  Statistical significance in all 
analyses was determined at a 0.05 significance level.  All the inference P-values 
were reported after adjusting for multiple comparisons (Hothorn et al., 2008).  The 
predictive performances of the fitted models were assessed using Receiver 
Operating Characteristics (ROC) curves and Area Under ROC Curves (AUC). The 
AUC values of the models used in this study ranged from 0.75 to 1.00 implying the 
models exhibited good/very good to excellent predictive accuracy.  Statistical 







In total, 164 CCs were harvested from 15 patients undergoing infertility 
treatment with PGT-A.  Fifteen FETs were performed after PGT-A results were 
obtained.  Eleven patients had single embryo transfers and four had double 
embryo transfers. In the four cases where two embryos were selected, one embryo 
of each gender was transferred.  Eight patients gave birth to nine healthy children 
with no complications.  163 of 164 CC samples (n=15 patients) analyzed contained 
a sufficient amount of RNA to detect the endogenous control house-keeping gene, 
TBP.  Due to limited starting sample RNA amounts, not all samples were able to 
be tested for each biomarker and the variations in sample size are noted in figures. 
PCA was utilized to test the hypothesis that several of the CC genes we 
examined would be correlated with one another.  The correlations of the CC mRNA 
levels of 151 observations from 14 patients were examined by creating a biplot 
within the multivariable dataset that contained the most biomarkers and individual 
patient observations that fit the model (Figure 3.2).  The biplot is based on the first 
and second principal components (PC1 and PC2) of the log2-transformed mRNA 
levels of each individual CC mass.  PC1 and PC2 explain 35.7% and 22.9% of the 
variability of the model, respectively.  All genes shown were positively correlated 
to PC1.  HSD3B1, IGFBP5, PAPPA, and PGR were all positively correlated with 
PC2 while CYP11A1, CYP19A1, and INHBA are negatively correlated with PC2.  
In addition, a significant (P < 0.001) strong positive correlation was observed 




positive correlations were observed for PGR and HSD3B (r = .59), CYP11A1 and 
INHBA (r = .50), PGR and IGFBP5 (r = .41), and PAPPA and INHBA (r = .41). 
We next wanted to test the hypothesis that the CC mRNA levels of the 
selected genes would vary by oocyte developmental competence and resulting 
embryo endpoint.  To test this hypothesis, we analyzed all the CC mRNA level 
data by the resulting developmental outcome for each group of oocytes by 
repeated measures ANOVA followed by Tukey’s post hoc test (adjusted P-values).  
PAPPA mRNA levels in CCs were higher in oocytes that resulted in euploid 
embryos that led to a live birth compared to immature oocytes and in oocytes that 
resulted in aneuploid embryos compared to immature oocytes, when comparing 
all groups (P < 0.05) (Figure 3.3).  LHCGR mRNA levels in CCs were higher for 
oocytes that resulted in embryos which led to a live birth compared to immature 
oocytes and oocytes that resulted in arrested embryos compared to immature 
oocytes, when comparing all groups (P < 0.05).  Other CC biomarkers showed no 
statistical differences between groups and their expression profiles are shown in 
Supplemental figure 3.1. 
We also wanted to test the hypothesis that certain CC biomarker mRNA 
levels associated with oocytes giving rise to euploid embryos would be distinct 
from those giving rise to aneuploid embryos and those oocytes that resulted in 
arrested embryos or those that failed fertilization.  Using a GLMM, the best fitting 
model examining whether CC biomarker mRNA expression associated with 
oocytes that became euploid embryos included 11 patients (n=78 CC masses) and 




LHCGR, and STARD1 (Figure 3.4).  CCs associated with oocytes that produced 
euploid embryos exhibited significantly (P < 0.05) lower CC HSD3B1 mRNA levels 
than those oocytes that led to mature oocytes resulting in aneuploid blastocysts, 
oocytes producing embryos that arrested and  did not reach the blastocyst stage, 
and mature oocytes that failed to fertilize, collectively (abnormal group).  CC ING1 
mRNA levels associated with oocytes that produced euploid embryos trended 
toward being lower than CCs from oocytes that gave rise to the abnormal 
outcomes, collectively (P = 0.061). 
A critical hypothesis we tested was that certain CC mRNA biomarker levels 
of oocytes giving rise to euploid embryos would be associated with live birth 
outcomes. CC mRNA levels from all 15 patients (n = 19 CC masses) were 
assessed for differences between oocytes yielding transferred embryos that 
resulted in a live birth and those that did not form a pregnancy, using repeated 
measures ANOVA followed by Tukey’s post hoc test (adjusted P-values). AREG 
mRNA levels were significantly lower in CCs from oocytes that resulted in live 
births (n = 8 from 8 patients) compared to the no pregnancy group (n = 7 from 5 
patients) (P < 0.05) (Figure 3.5).  PAPPA mRNA levels were higher in CCs from 
oocytes producing euploid embryos that resulted in live births (n = 9 from 8 
patients) compared to those that produced no pregnancy (n = 10 from 7 patients) 
(P < 0.05).  The other biomarkers showed no statistical differences between 
groups. 
Using a GLMM, we also compared the CC mRNA biomarkers associated 




oocyte outcomes not producing a live birth (non-viable group), collectively.  The 
non-viable group included immature oocytes, mature oocytes resulting in 
aneuploid blastocysts, oocytes producing embryos that did not reach the 
blastocyst stage, and mature oocytes that failed to fertilize.  The best fitting model 
for this comparison included 110 CC samples from 14 patients and included mRNA 
levels for CYP11A, CYP19A1, IGFBP5, PAPPA, PGRMC1, and STARD1 
(Supplemental Figure 3.2).  As revealed in the fitted model higher CC PAPPA 
mRNA levels (P < 0.05) significantly increased the odds of an oocyte producing an 
embryo that resulted in a live birth (OR = 4.591, 95% CI: 1.098 to 19.201).  The 
other five CC mRNA biomarkers did not significantly associate with live births. 
3.5 Discussion 
The key findings of this research were that higher PAPPA, higher LHCGR, 
and lower AREG mRNA levels in CCs were associated with oocytes that produced 
embryos capable of yielding live birth outcomes.  In addition, lower CC HSD3B1 
mRNA was associated with oocytes that resulted in euploid embryos compared to 
other outcomes.  Our premise was that although many retrieved oocytes in our 
study appeared mature, several oocytes would have mRNA expression profiles 
that were similar to those of immature oocytes. Aberrant mRNA levels would cause 
them to be incapable of forming euploid embryos and leading to live births. 
Therefore, an individual oocyte’s developmental competence would be reflected in 
specific mRNA levels of their CC masses.  For example, we predicted that an 
immature oocyte CC profile would differ from that of a mature oocyte CC profile 




This was partly the case for CC PAPPA and LHCGR mRNA levels which were 
higher in CCs surrounding mature oocytes that gave rise to embryos resulting in 
live birth than immature oocytes (by ANOVA).  However, by ANOVA the levels of 
CC PAPPA and LHCGR could not distinguish between oocytes giving rise to 
morphologically normal embryos that were aneuploid and transferred euploid 
embryos that resulted in live birth or no pregnancy.  When utilizing the best fit 
GLMM, higher CC PAPPA levels continued to associate with oocytes giving rise 
to embryos with live birth compared to transferred embryos that did not result in 
pregnancies as well as other oocyte outcomes, collectively.  In transferred 
embryos, lower CC AREG associated with oocytes giving rise to embryos with live 
birth outcomes by ANOVA analysis.  Combining these data with that for CC 
HSD3B1, where lower levels were associated with euploid embryos, one can 
envision using these findings to create a future practical model where the CC levels 
of all four mRNA biomarkers could be used to predict which of a patient’s cohort 
of oocytes and embryos will most likely be euploid and give rise to a live birth 
outcome.  Although four biomarkers of the selected group exhibited significant 
differences in statistical models, this was a small pilot study and the data is limited 
by the small sample numbers for FETs.  However, these results provide a starting 
point for a larger prospective future study. 
Several of our analyses indicated PAPPA may be a reliable novel biomarker 
in CCs for identifying oocytes capable of leading to a live birth.  PAPPA encodes 
a metalloproteinase that cleaves insulin like growth factor binding protein 4 




and protein in peri-ovulatory follicles may be necessary to increase intrafollicular 
free IGFs through enhanced cleavage of IGFBPs (Firth and Baxter, 2002).  IGFs 
are known to enhance gonadotropin signaling and FSH-induced LHCGR 
abundance (Wang and Chard, 1999).  We also found that immature oocytes 
possessed lower CC LHCGR mRNA levels compared to all the other groups 
except oocytes that resulted in arrested embryos. Similarly, others have shown 
that CC LHCGR mRNA levels were higher in mature compared to immature 
oocytes (Maman et al., 2012).  In addition, the ratio of CC LHCGR mRNA splice 
variants was previously reported to be higher in pregnant compared to non-
pregnant patients (Papamentzelopoulou et al., 2012b). 
Differential mRNA levels of steroidogenic genes in CCs may impact the fate 
of their associated oocytes.  A previous study utilizing GCs pooled from multiple 
patients and follicles showed increased CYP19A1 and HSD3B1 mRNA levels in 
GCs from oocytes producing embryos that resulted in pregnancies compared to 
oocytes resulting in embryos that failed to develop (Hamel et al., 2008).  In our 
study, lower CC HSD3B1 mRNA levels associated significantly with oocytes which 
yielded euploid embryos.  Additionally, HSD3B1 and PAPPA both positively 
correlated with principal component 1 and 2 in our biplot analysis.  The difference 
may have become apparent as we evaluated individual CC masses rather than 
pooling.  Before including the trigger in our best fitting model, lower CC CYP19A1 
mRNA level was associated with live birth (P = 0.048, not shown), but showed only 
a trend when trigger medication was added to the model (P = 0.052; Supplemental 




expression (Borgbo et al., 2013), caution must be used in interpreting HSD3B1 
and CYP19A1 mRNA data.  Like LHCGR, CYP19A1 is induced through FSH 
signaling, and CYP19A1 is higher in dominant follicles of monovulatory species 
(Hayashi et al., 2010, Sisco et al., 2003, Kristensen et al., 2017). 
Huang and colleagues found that higher AREG levels in CCs and MGCs 
were more likely to be associated with pregnancy (Huang et al., 2015).  This differs 
from our study as we saw lower AREG levels in CCs from oocytes associated with 
live birth.  As above, this discordant finding may be the result of pooling CCs and 
MGCs and/or the use four stimulation protocols in the Huang study.  Our results 
are consistent with Feuerstein and colleagues who showed reduced AREG mRNA 
levels for CCs of oocytes that resulted in high-quality blastocysts (Feuerstein et 
al., 2007). 
Two strengths of our study were that all patients received the same 
stimulation regimen, albeit with two differing trigger medications, and we excluded 
patients with endometriosis or DOR.  Differing stimulation protocols have been 
reported to alter mRNA expression and bias results (Adriaenssens et al., 2010a, 
Assou et al., 2013, Grondahl et al., 2009).  In previous studies, CCs and MGCs of 
patients with DOR (Greenseid et al., 2011, May-Panloup et al., 2012) or 
endometriosis (Allegra et al., 2014, Barcelos et al., 2015) exhibited altered mRNA 
expression relative to their control groups.  For these reasons we excluded patients 
with these conditions. 
As with any patient-driven clinical study, our study had limitations.  Patient 




(Hurwitz et al., 2010, Al-Edani et al., 2014) and differing trigger medications have 
been previously demonstrated to alter gene expression (Borgbo et al., 2013).  A 
study design including younger patients with only male factor infertility using the 
same trigger medication would be a more ideal group to examine.  Additionally, 
sample size may have influenced the findings.  While we were able to analyze 163 
samples, the samples were collected from 15 patients.  Additionally, we were not 
able to analyze all genes for each of the samples as RNA amounts were a limiting 
factor with individual cumulus masses.  With more patients, other mRNA 
expression level differences may have been apparent, and a larger prospective 
study is necessary to confirm the results we found and determine the predictive 
value of the CC mRNA levels for oocyte endpoints such as euploidy and live birth 
outcomes. Moreover, an argument can be made that looking at oocyte CC 
biomarkers and comparing the ploidy status of embryos disregards the potential 
that aneuploidy may have resulted from the paternal contribution to the embryos.  
We feel our study is still a valid assessment as aneuploidy is predominantly due to 
maternal origins (Rabinowitz et al., 2012).  Finally, we cannot overlook the impact 
of uterine receptivity.  Although we have no evidence of patient uterine receptivity 
issues, it is possible some non-implanting embryos were capable of leading to a 
live birth but were not able to implant due to a suboptimal uterine environment.  A 
way to account for this would be to perform double embryo transfers with euploid 
embryos and assess CC mRNA expression for those where one implants and one 




In conclusion, taken together the ideal oocyte developmental competence 
needed to produce live birth may be reflected by the interplay between AREG, 
HSD3B1, LHCGR, and PAPPA mRNA levels and likely their resulting proteins.  
The current data support that CC mRNA levels of these four biomarkers may be 
useful in assisted reproduction.  A larger prospective study will be needed in to 
order to corroborate the results and to determine numerical ranges for levels of 
these biomarkers that could potentially have clinical value in selecting oocytes to 
fertilize or embryos for uterine transfer that will have the highest odds of yielding 
live birth. 
3.6 Supplementary data 
Supplementary data are available at Journal of Assisted Reproduction and 
Genetics online. 
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Table 3.1 Patient demographics and cycle information  
 






















1 27.8 25.3 Sex selection 3 5.4 141.9 8 8 8 4 hCG 
2 36.4 26.4 Male factor 1 7.2 86.6 8 7 6 4 hCG 
3 39.7 25 AMA 1 12 100.4 7 4 3 3 hCG 
4 30 25.6 Donor 1 6 147.4 10 9 7 6 hCG 
5 32.6 26.4 Translocation 
w/PGT-A 
2 9.2 131.0 5 5 5 5 Lupron 
6 35.9 21 Idiopathic 1 8.3 163.3 4 4 4 2 Lupron 
7 39.7 38.8 AMA 1 11 145.5 9 9 6 5 Lupron 
8 40 32 AMA + male 
factor 
1 12 31.4 7 5 5 4 Lupron 
9 33 18.8 Male factor 1 10 194.7 11 10 10 4 Lupron 
10 42 20.3 AMA 1 6.6 108.2 5 5 5 3 hCG 
11 36.1 29.2 Tubal factor 1 5.2 179.5 23 23 18 12 Lupron 
12 37 20.7 AMA 1 11 142.2 16 15 14 8 Lupron 
13 33.9 35 Male factor 2 10 183.1 11 10 8 2 hCG 
14 28 28.4 PCO 1 5.9 184.2 24 6 5 4 hCG 
15 39.7 31 AMA 1 7.5 132.6 16 14 14 7 Lupron 
AMA = advanced maternal age, hCG = human chorionic gonadotropin, PGT-A = Pre-genetic testing for aneuploidy, PCO 














Table 3.2 Primer set information 
 












62° 251 (Feuerstein et al., 2007) 
 




231 (Assidi et al., 2011) 
 




269 (Tsutsumi et al., 2008) 
 




380 (Hamel et al., 2008) 
 




103 (Gonzalez-Fernandez et al., 2011) 
GJA4 For CATCTCCCACATCCGCTACT 
Rev GAAGCCTGCCTCTAGCACAC 
58 295 (Wang et al., 2009) 
 
GREM1 For CGCCGCACTGACAGTATGAG 
Rev ACCTTGGGACCCTTTCTTTTTC 
62 108 NG_013372.7 
HSD3B1 For TGTGCCAGTCTTCATCTACAC 
Rev TGTTTTCCAGAGGCTCTTCTTC 
60 101 (Hamel et al., 2008) 
IGF2 For TTCCGCAGCTGTGACCTGGC 
Rev CCTCGAGCTCCTTGGCGAGC 
62 229 NG_008849.1 
 
IGFBP5 For AAGAAGCTGACCCAGTCCAA 
Rev GAATCCTTTGCGGTCACAAT 
60 201 (Walker et al., 2007) 
ING1 For GCCTGGTGTGAGGAGGACAA 
Rev CCCTATGAAAGGAATGGTTCCTT 











Table 3.2 Continued 
 







Reference or NCBI no. 
INHBA For AAGTCGGGGAGAACGGGTATGTGG 
Rev TCTTCCTGGCTGTTCCTGACTCG 
62 123 (Seder et al., 2009) 
 
LHCGR For TGGAGAAGATGCACAATGGA 
Rev GGCAATTAGCCTCTGAATGG 
60 122 (Yung et al., 2014) 
PAPPA For GTCATCTTTGCCTGGAAGGGAGAA 
Rev AGGGCTGTTCAACATCAGGATGAC 
62 129 (Wagner et al., 2011) 
 
PGR For GTCATAGACCCCCGTTGCTA 
Rev GCTAAGCCAGCAAGAAATGG 
60 124 (Guzman et al., 2013) 
 
PGRMC1 For TCTGGACTGCACTGTTGTCCTTG 
Rev GCAAACACCTGTTCCTATTCTG 
60 290 (Zachariades et al., 2011) 
PTGS2 For GCTTTATGCTGAAGCCCTATGA 
Rev TCCAACTCTGCAGACATTTCC 
60 70 (Adriaenssens et al., 2010b) 
 
STARD1 For TACGTGGCTACTCAGCATCG 
Rev ACAGCAGGCTGGTCTTCAAC 
60 157 (Chen et al., 2009) 
 
TBP For CACGGCACTGATTTTCAGTTC 
Rev TCTTGCTGCCAGTCTGGACT 
62 79 (Nelson-Degrave et al., 2004) 
 
VCAN For GCACCTGTGTGCCAGGATA 
Rev CAGGGATTAGAGTGACATTCATCA 







Figure 3.1 Flow diagram summarizing the study population from oocyte 
retrieval to final outcome.  Oocytes (164) were retrieved from 15 patients and 
individually cultured.  Individual CC masses from each oocyte were collected and 
mRNA was harvested from each mass.  Of the 164 oocytes, 134 were mature and 
30 were immature.  All 134 were injected with sperm. Seventy-three of the fertilized 
oocytes became blastocysts and were biopsied for PGT-A testing and all were 
vitrified.  PGT-A results indicated that 39 embryos were euploid and 34 were 
aneuploid.  Nineteen of the euploid embryos were transferred and 20 remained in 
cryostorage.  Ten embryos from 7 patients failed to implant while 9 embryos from 
8 patients implanted and resulted in live births.  *The control TBP mRNA did not 
amplify in one CC sample from an oocyte yielding a euploid embryo and was not 

















Figure 3.2 Principal Component Analysis Biplot for CC mRNA expression.  Biplot of the log2-transformed mRNA levels 
for 7 genes from 14 patients along the first and second principal components (PC1 and PC2).  PC1 accounted for 35.7% of 
the observed variance while PC2 accounted for 22.9% of the variance.  Each data point represents an individual CC mass 
mRNA level associated with an individual oocyte (n=151 oocytes).  The biplot demonstrates the relationship between 
individual CC mRNA level patterns and the correlation between the different genes.  The closer the data points are to each 
other, the more similar the normalized CC gene expression patterns.  The closer the arrows are to each other, the higher 
the correlation between the normalized CC gene expressions.  Groups represent CC mRNA from oocytes with the following 
descriptions:  Aneuploid = mature oocytes resulting in aneuploid embryos; Arrested = mature oocytes resulting in embryos 
that did not reach the blastocyst stage; Euploid = mature oocytes resulting in euploid blastocysts that were not transferred; 
Failed Fert = mature oocytes that did not fertilize; Immature = immature oocytes that were not fertilized; Live Birth = oocytes 
that resulted in euploid embryos that resulted in live births; No Pregnancy = oocytes that resulted in euploid embryos that 
did not result in a pregnancy 
  
  














Figure 3.3 Biomarkers for CC mRNA expression associated with mature oocyte competence and embryo outcomes.  
To determine the differences in CC mRNA between groups where oocytes had different developmental and embryo 
outcomes, target mRNA levels were compared using repeated measures ANOVA followed by Tukey’s post hoc test 
(adjusted P-values) for pairwise comparisons.  Groups represent CC mRNA from oocytes with the following descriptions:  
Aneuploid = mature oocytes resulting in aneuploid embryos; Arrested = mature oocytes resulting in embryos that did not 
reach the blastocyst stage; Failed Fert = mature oocytes that did not fertilize; Immature = immature oocytes that were not 
fertilized; Live Birth = oocytes that resulted in transferred euploid embryos that resulted in live births; No Pregnancy = 
oocytes that resulted in transferred euploid embryos that did not result in a pregnancy.  Data are presented as the median 
copy number (line inside box), first and third quartile (bottom and top of box), and highest and lowest data points (top and 
bottom of whiskers).  Groups with different letters (a and b) exhibit significant differences (P < 0.05) 
  
  







Figure 3.3 Continued 
  
  














Figure 3.4  Biomarkers from the generalized linear mixed model associated with oocytes producing euploid 
embryos versus mature oocytes with other outcomes. To evaluate CC biomarker mRNA level association with oocytes 
capable of producing euploid embryos a model was fit with 78 CC samples from 11 patients and included the biomarkers: 
CYP11A1, CYP19A1, HSD3B, IGFBP5, PAPPA, PGR, PGRMC1, ING1, LHCGR, and STARD1.  Higher HSD3B mRNA 
level significantly decreased the odds of an oocyte resulting in a euploid embryo (OR = 0.408, 95% CI: 0.175 to 0.953).  
Higher ING1 mRNA levels marginally decreased the odds of an oocyte resulting in a euploid embryo (OR = 0.552, 95% CI: 
0.297 to 1.027).  Groups represent CC mRNA from oocytes with the following descriptions:  Abnormal = mature oocytes 
resulting in aneuploid blastocysts, oocytes producing embryos that did not reach the blastocyst stage, and mature oocytes 
that failed to fertilize; Euploid = mature oocytes that resulted in euploid embryos regardless of whether they were transferred 
or remained vitrified.  Data are presented as stated in figure 3.3 legend 
  
  






Figure 3.4 Continued 
  
  






Figure 3.4 Continued 
  
  















Figure 3.5 CC biomarkers associated with oocytes giving rise to euploid embryos with live birth or no pregnancy.  
Transferred embryos (n=19) from all 15 patients were assessed for mRNA level differences between those oocytes yielding 
embryos that resulted in a live birth and those that did not form a pregnancy using repeated measures ANOVA followed by 
Tukey’s post hoc test (adjusted P-values) for pairwise comparisons.  Of the transferred embryos, 9 resulted in live births.  
AREG mRNA levels were significantly lower in CCs from oocytes that resulted in live births (n = 8 from 8 patients) compared 
to the no pregnancy group (n = 7 from 5 patients) (P < 0.05).  PAPPA mRNA expression was significantly increased in CCs 
from oocytes producing embryos that resulted in live births (n = 9 from 8 patients) compared to no pregnancy (n = 10 from 
7 patients) (P < 0.05).  GREM1 mRNA levels (n = 3/group) were not significantly different and not shown.  Data are presented 
as in figure 3.3 legend 
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Table 3.3 Ploidy status and outcomes of biopsied embryos 
 
Pt # Embryo # Ploidy 
Status 
EXP ICM TROPH ET LB NI NT NU 
1 8 Euploid 5 A B X X      
1 10 Euploid 2 B B       X  
1 13 Euploid 5 B B       X  
1 14 Euploid 3 B B       X  
2 4 Euploid 6 A B X   X    
2 6 Monosomy  5 B B         X 
2 7 Monosomy  6 A B         X 
2 8 Monosomy  6 A B         X 
3 1 Euploid 5 A B       X  
3 3 Monosomy  2 B B         X 
3 5 Triple 
Trisomy 
5 A B         X 
3 7 Euploid 5 A B X X      
4 2 Euploid 2 B B X X      
4 4 Euploid 2 B B       X  
4 7 Monosomy  2 B B         X 
4 8 Trisomy 2 B B         X 
4 11 Complex 
Aneuploid 
2 B B         X 
4 12 Euploid 2 B B       X  
5 3 Euploid 5 A B X X      
5 4 Complex 
Aneuploid 
5 C C         X 
  
  






Table 3.3 Continued 
 
Pt # Embryo # Ploidy 
Status 
EXP ICM TROPH ET LB NI NT NU 
5 6 Monosomy  5 A B         X 
5 8 Complex 
Aneuploid 
3 B B         X 
5 9 XXX Super 
Female 
5 A A         X 
6 2 Trisomy 5 A B         X 
6 6 Euploid 6 A B X   X    
7 3 Euploid 3 B C X   X    
7 6 Euploid 5 B B       X  
7 7 Trisomy 5 B B         X 
7 8 Euploid 5 B C X   X    
7 11 Monosomy  2 B B         X 
8 2 Monosomy  5 A B         X 
8 3 Double 
Monosomy 
3 C C         X 
8 6 Monosomy  5 A A         X 
8 7 Euploid 5 A B X X      
9 1 Euploid 4 B A X   X    
9 2 Euploid 3 A A       X  
9 10 Complex 
Aneuploid 
2 B B         X 
9 15 Complex 
Aneuploid 
2 B B         X 
  
  





Table 3.3 Continued 
 
Pt # Embryo # Ploidy 
Status 
EXP ICM TROPH ET LB NI NT NU 
10 1 Complex 
Aneuploid 
4 B C         X 
10 4 Complex 
Aneuploid 
4 B C         X 
10 5 Euploid 4 B C X X      
11 3 Euploid 5 A A X X      
11 6 Euploid 5 A B       X  
11 7 Monosomy  5 B B         X 
11 8 Euploid 5 B C       X  
11 13 Trisomy/Mon
osomy 
5 B A         X 
11 14 Monosomy  5 A B         X 
11 15 Monosomy  5 A A         X 
11 17 Euploid 5 A B       X  
11 18 Euploid 5 A A       X  
11 19 Monosomy  3 A B         X 
11 20 Euploid 5 A A X X      
11 22 Euploid 5 B B       X  
12 5 Euploid 5 A B X X      
12 6 Euploid 5 A A       X  
12 7 Trisomy 5 A A         X 
12 8 Trisomy 5 B B         X 









Table 3.3 Continued 
 
Pt # Embryo # Ploidy 
Status 
EXP ICM TROPH ET LB NI NT NU 
12 14 Euploid 5 A A       X  
12 16 Trisomy 5 A A         X 
12 17 Monosomy  5 A B         X 
13 3 Euploid 4 B B       X  
13 7 Euploid 5 B B X   X    
14 2 Euploid 4 B B X   X    
14 4 Euploid 4 B A X   X    
14 5 Trisomy 4 A B         X 
14 14 Euploid 4 B C       X  
15 3 Trisomy 4 A A         X 
15 4 Euploid 3 B B X   X    
15 6 Euploid 3 B B       X  
15 8 Euploid 4 A A       X  
15 10 Euploid 4 B B       X  
15 11 Monosomy  4 A B       
 
X 
15 17 Euploid 4 B B X   X    
EXP = blastocyst expansion grade; ICM = inner cell mass grade; Troph = trophectoderm grade; ET = transferred embryo; 
LB = live birth; NI = no implantation; 




















Figure 3.6 Biomarkers for CC mRNA expression not associated with mature oocyte competence and embryo 
outcomes.  To determine the differences in CC mRNA between groups where oocytes had different developmental and 
embryo outcomes target mRNA levels were compared using repeated measures ANOVA followed by Tukey’s post hoc test 
(adjusted P-values) for pairwise comparisons.  Groups represent CC mRNA from oocytes with the following descriptions:  
Aneuploid = mature oocytes resulting in aneuploid embryos; Arrested = mature oocytes resulting in embryos that did not 
reach the blastocyst stage; Failed Fert = mature oocytes that did not fertilize; Immature = immature oocytes that were not 
fertilized; Live Birth = oocytes that resulted in transferred euploid embryos that resulted in live births; No Pregnancy = 
oocytes that resulted in transferred euploid embryos that did not result in a pregnancy.  No differences were seen in these 
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Figure 3.7 Generalized linear mixed model distinguishing CC from oocytes 
giving rise to live births and oocytes with outcomes not resulting in live birth, 
collectively.  To evaluate the potential of CC biomarker mRNA levels to identify 
oocytes capable of producing euploid embryos resulting in a live birth versus 
groups not producing live births, the best fitting model included 110 CC samples 
from 14 patients and included biomarkers: CYP11A1, CYP19A1, IGFBP5, PAPPA, 
PGRMC1, and STARD1.  Increased PAPPA mRNA expression (P < 0.05) 
significantly increased the odds of an oocytes producing an embryo resulting in a 
live birth (OR = 4.591, 95% CI: 1.098, to 19.201).  All previously stated categories 
were included in this model except oocytes yielding euploid embryos that were not 
transferred.  Groups represent CC mRNA from oocytes with the following 
descriptions:  Live Birth = mature oocytes that resulted in euploid embryos that 
lead to live births;  Non-Viable = immature oocytes, mature oocytes resulting in 
aneuploid blastocysts, oocytes producing embryos that did not reach the 
blastocyst stage, and mature oocytes that failed to fertilize, collectively. Data are 















Mitochondrial Metabolic Substrate Utilization in Granulosa Cells 
Reflects Body Mass Index and Total Follicle Stimulating Hormone 
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4.1 Abstract   
4.1.1 Purpose: To utilize a novel mitochondrial function assay with pooled 
granulosa cells to determine whether mitochondrial function would differ by 
patient demographics and embryo development.   
4.1.2 Methods: Prospective pilot study in a hospital based assisted reproductive 
program and public university.  The study assessed mitochondrial metabolic 
substrate utilization and mRNA levels in pooled granulosa cells from 40 women 
undergoing in vitro fertilization during 2018 and 2019. 
4.1.3 Results:  In pooled granulosa cells, mitochondrial utilization of citric acid (P 
< 0.01), L-malic acid (P < 0.05), and octanoyl-L-carnitine (P < 0.01) were 
significantly lower with lower body mass index.  Citric acid (P < 0.05), cis-acontic 
acid (P < 0.01), D-alpha-keto-glutaric acid (P < 0.05), L-glutamine (P < 0.05), and 
alanine-glycine (P < 0.05) were significantly lower with increasing FSH 
administered.  Utilization of glycogen (P < 0.05) was significantly lower with lower 
fertilization rates and D-alpha-keto-glutaric acid (P < 0.05) was significantly lower 
in good 8-cell embryos.  L-glutamine (P < 0.05) was significantly higher with 
lower blastocyst formation.  Mitochondrial metabolic scores, which reflect overall 
mitochondrial activity of granulosa, were significantly higher with increased 
numbers of zygotes formed (P < 0.05), higher BMI (P < 0.05), less FSH 
administered (P < 0.01), and with greater numbers of mature oocytes (P < 0.05).  
4.1.4 Conclusions:  Body mass index and FSH dose administered were 
associated with mitochondrial utilization of citric acid, L-malic acid, octanoyl-L-




glycine.  Glycogen, D-alpha-keto-glutaric acid, and L-glutamine may be possible 
biomarkers for embryo development.   
4.1.5 Key Words: granulosa cells, in vitro fertilization, mitochondrial function 
assay, mitochondrial metabolic score, mitochondrial utilization 
4.2 Introduction  
Mitochondria are double-membrane organelles, which are believed to 
have originated from a symbiotic relationship between bacteria and host cells 
(Margulis, 1996).  They are involved in apoptosis, calcium homeostasis, fatty acid 
oxidation, and metabolism.  Mitochondria, the key source of power within 
eukaryotic cells,  are responsible for generating 88% of a cell’s total energy in the 
form of adenosine triphosphate (ATP) created during oxidative phosphorylation 
via mitochondrial membrane potential (Seyfried and Shelton, 2010).  The 
remaining ATP required by the cell is produced from the processes of glycolysis 
and the tricarboxylic acid cycle through substrate-level phosphorylation.  
Oxidative phosphorylation is modulated by the cellular demand for ATP and the 
substrates available for processing within the cytoplasm.  Glucose is the main 
substrate that will produce ATP via the intermediates of glycolysis.  Pyruvate and 
other substrates of the glycolytic process will generate reducing equivalents, 
nicotinamide adenine dinucleotide hydride (NADH) and flavin adenine 
dinucleotide hydride (FADH2), which will transfer electrons to the electron 
transport chain (ETC).  The flow of electrons through the ETC will provide 
mitochondrial membrane potential ultimately producing ATP (Veatch et al., 




Successful embryo development relies upon energy metabolism 
generated by ATP processed through the mitochondria to drive the cleavage of 
blastomeres and other cellular processes during early embryo development.  
While human oocytes contain the most mitochondrial of all cell types within the 
body, it is problematic to relate mitochondrial DNA (mtDNA) copy number and 
function to oocyte developmental competence; since the oocytes, and 
subsequent embryos, are required for clinical use.  However, parallels between 
mtDNA content in human oocytes and granulosa cells (GCs), including both 
cumulus cells (CCs) and mural granulosa cells (MGCs), have been demonstrated 
(Boucret et al., 2015, Pawlak et al., 2016).   Additionally, the metabolism of CCs 
directly affects their enclosed oocytes by providing the proper energy substrates 
required to complete meiosis and fertilization.  Cumulus cells produce ATP and 
augment oocyte ATP supply during follicular growth.  The CCs also provide 
pyruvate, generated from glycolysis, to their enclosed oocytes via gap junctions 
(Su et al., 2009, Sutton-McDowall et al., 2010). Further, mitochondrial function, 
measured by ATP production in CCs, has been shown to relate to proper human 
oocyte maturation and in vitro fertilization (IVF) outcomes (Dalton et al., 2014, 
Huang and Wells, 2010, Tsai et al., 2010).   
Assessing mitochondrial substrate metabolism in GCs may allow for a 
non-invasive method for investigating oocyte competence and embryo 
development. Several studies have evaluated CCs, MGCs, and trophectoderm 
cells from blastocysts; and it appears there is a high correlation between the 




as a biomarker for oocyte competence (Desquiret-Dumas et al., 2017, Diez-Juan 
et al., 2015, Fragouli and Wells, 2015, Ogino et al., 2016, Boucret et al., 2015).  
Furthermore, increased mtDNA GC copy numbers are associated with good 
quality embryos (Ogino et al., 2016, Desquiret-Dumas et al., 2017).   Therefore, 
we hypothesized mitochondrial substrate utilization in pooled GCs, measured 
using a novel mitochondrial function assay, will also show correlations between 
various demographic and embryo endpoints.     
The goal of this study was to see how individual substrates and total 
substrate utilization differed between patients based on age, serum anti-Mullerian 
hormone (AMH) level, body mass index (BMI), and number of mature oocytes 
retrieved per cohort.   We also related individual and total substrate utilization to 
fertilization rates, day 3 embryo development, blastocyst development, and 
mRNA levels of selected genes to determine if one or more substrates can be 
used as a biomarker for IVF.  In a recent investigation by our laboratory, several 
candidate mRNA transcripts in individual cumulus masses showed associations 
with viable embryos capable of leading to live births (Kordus et al., 2019), and 
these mRNAs were also investigated in this study.  Genes of interest included, 
amphiregulin (AREG), which is associated with cumulus mass expansion;  
inhibitor of growth protein 1 (ING1), which is associated with oocyte maturation; 
aromatase (CYP19A1), cytochrome p450 family 11 subfamily A member 1 
(CYP11A1), and hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 (HSD3B1), which are associated with mediating de novo 




which is related to hormone modulation;  and  luteinizing 
hormone/choriogonadotropin receptor (LHCGR),  which encodes for it’s 
associated hormone receptor.  We also examined AMH mRNA due to the 
relationship of serum AMH with ovarian reserve.   
To our knowledge, this is the first study to examine a novel mitochondrial 
function assay to assess the metabolism of mitochondrial substrates in pooled 
GCs.  The assay measures the rate of electron flow through the electron 
transport chain from 31 metabolic substrates that, when metabolized by cell 
preparations, produce NADH or FADH2 using a tetrazolium dye (Bochner et al., 
2001).  The primary goal of this study was to determine if metabolic substrate 
utilization differed between patient groups and embryo cohorts.  We also wanted 
to determine if a mitochondrial metabolic score could be generated from the 
overall metabolic rate of the substrates combined, that would be related to 
patient groups and primary embryo developmental endpoints.   
4.3 Materials and methods 
4.3.1 Study Population, Participants, and GC isolation 
This study was a prospective cohort pilot study.  In total, 817 pooled CCs 
and MGCs from 40 patients undergoing infertility treatment at Fertility Center of 
the Carolinas (Greenville, SC, USA) were analyzed (Figure 4.1).  Of 58 starting 
patients, those with total GC numbers <650,000 per sample were excluded from 
the study (n=14), as well as patients with appropriate GC numbers where the 
positive assay control did not exhibit color change (n=4).  Patient demographics 




assay data were compared based on age, serum AMH levels, BMI, and number 
of mature oocytes retrieved per cohort.  Each patient’s ovaries were stimulated 
using a long luteal protocol or an antagonist protocol.  In the antagonist cycles, 
when one follicle reached 13 or 14 mm or the patient’s estradiol level reached 
300 IU/mL a GnRH antagonist (Cetrotide, EMD-Serono, USA or Ganirelix, EMD-
Serono, USA) was administered.  In both protocols, when 3 follicles reach >17 
mm by ultrasound an ovulatory dose of human chorionic gonadotropin (hCG) 
(Pregnyl, EMD-Serono, USA) was delivered.  Thirty-six hrs later patients 
underwent oocyte retrieval.  Each CC mass was mechanically separated from it’s 
oocyte and rinsed in medium (Sperm Wash Medium, Irvine, USA) to remove 
blood and debris and all CC masses per retrieval were combined in a single tube.  
The CCs and MGCs from each patient were taken to the research lab on ice for 
immediate processing.  
4.3.2 Embryo culture and ploidy assessment 
Mature oocytes were inseminated via intra-cytoplasmic sperm injection.  
Fertilization was confirmed by the presence of two pronuclei and two polar bodies 
16-18 hrs after insemination.  Embryos were group cultured in 50 µL LifeGlobal® 
global total media drops (Cooper Surgical, Trumbull, CT, USA) under oil (Ovoil, 
Vitrolife, Englewood, CO, USA) at 37°C, 6% CO2, 5% O2, 89% N2 in a humidified 
atmosphere until day 5 or day 6 post retrieval.  Embryo morphologies were 
assessed using the American Society for Reproductive Medicine (ASRM) 





4.3.3 Analysis of Mitochondrial Metabolic Substrates 
Follicular fluid, containing MGCs from each patient, was split between 2 or 
more 50 mL tubes and centrifuged for 15 min at 300xg.  A filtered solution of 
hyaluronidase (50 mg/mL) from bovine testes (Sigma, Raleigh, NC, USA) in media 
was added to each MGC pellet and the CC tube and incubated at 37°C for 10 min 
to dissociate cell clumps.  Calcium/magnesium-free phosphate-buffered saline 
(PBS) (Gibco, Gaithersburg, MD, USA) was added to bring the pellet to 
approximately 4 mL.  MGCs were purified by 35%-70% discontinuous Percoll 
gradient in 15 mL tubes and spun in a swinging bucket centrifuge for 30 min at 
300xg.  Assay mix (30 µL) containing 2x Biolog Mitochondrial Assay Solution 
(MAS) (Biolog, Hayward, CA, USA), 6x Redox Dye (Biolog), 24x saponin (90 
µg/mL) for permeabilization (Alfa Aesar, Ward Hill, MA, USA), and sterile water 
were added to each well of the 96-well MitoPlate S-1 plates (Biolog) and incubated 
for 1 hr per manufacturer’s instructions.  Mural granulosa cells (the uppermost 
band in the gradient) were removed and combined with CCs in 25 mL of 
calcium/magnesium-free PBS (Gibco).  The mixture was poured through a 70-
micron strainer to remove any remaining cell clumps.  Pooled GCs were 
centrifuged for 20 min, and the pellet was resuspended in 1x MAS (Biolog) to a 
volume of 2 mL.  A 0.5 mL aliquot of the GC/MAS mixture was removed and a 10 
µL sample was counted using a hemocytometer.  This remainder of the aliquot 
was centrifuged for 5 min, and the pellet was placed in 0.5 mL RNAlater solution 
(Life Technologies), stored at 4°C for 24 hrs, and snap-frozen in LN2 and stored 




stored at -70°C until processed.  The remaining 1.5 mL GC/MAS mixture was 
diluted to 3.0 mL with 1x Biolog MAS and a 10 µL sample was counted with a 
hemocytometer.   After 1 hr incubation at 37°C to allow all substrates to dissolve, 
30 µL of the GC/MAS suspension was added to each well of the MitoPlate S-1 
plate.  Permeabilized cells were assayed in triplicate for metabolism of individual 
substrates (Table 4.2) using MitoPlate S-1 plates. Metabolism of substrates was 
assessed by a colorimetric change of a terminal electron acceptor tetrazolium 
redox dye at an optical density of 590 nm read every 2.5 min for 50 cycles on a 
kinetic plate reader (Figure 4.2).  The slopes of the optical density absorbance 
readings were normalized to mtDNA copy number per sample (as described 
below) and the relative absorbance of the negative control wells containing 
GC/MAS without any additional substrates.   To quantitatively compare the 
metabolism of each patient we developed a scoring system based on the 
aggregate slope ratios of all substrates normalized to the negative control and 
positive control wells.  The mitochondrial metabolic score was the total of all the 
slope ratios of each substrate for each individual patient.   Slope ratio = [Slope 
(sample) – Slope (negative control)] / [Slope (positive control) – Slope (negative 
control)] (Vanderstichel et al., 2015).   
4.3.4 RNA Isolation and cDNA synthesis 
RNA was isolated from each pooled CC/MCG sample per patient using the 
Direct-zol MiniPrep Kit with DNase treatment (Zymo Research, Irvine, CA, USA) 
following the manufacturer’s instructions.  RNA concentration and purity for pooled 




biophotometer 6131 spectrophotometer (Eppendorf).   Each sample was reverse 
transcribed into cDNA using the iScript kit (Bio-Rad Laboratories, Hercules, CA, 
USA) following the manufacturer’s instructions.  The reverse transcription reaction 
was carried out in a thermocycler (Eppendorf), for 5 min at 25°C, 30 min at 42°C, 
and 5 min at 85°C.   
4.3.5 DNA Isolation and Quantification 
DNA was isolated from pooled GCs using the Direct-zol MiniPrep Kit (Zymo 
Research) as described above, omitting the DNase treatment step.  DNA 
concentration and purity were assessed at the wavelengths of 260 and 280 nm 
using a biophotometer 6131 (Eppendorf).  Relative amounts of mtDNA and nuclear 
DNA content (nDNA) and were determined by qRT-PCR (described below).  The 
ratio of mtDNA:(2x nDNA) was used to determine mtDNA content. 
4.3.6 Quantitative Real-Time PCR 
Synthesized primers were cartridge purified (Life Technologies).  Primers 
to amplify cDNA included:  AMH, AREG, CYP19A1, HSD3B1, ING1, LHCGR, 
PAPPA, and TATA-box binding protein (TBP) (Table 4.3).  The nuclear gene ACTB 
(beta-actin) was selected as a reference gene to calculate nDNA and the mtDNA 
gene mitochondrially encoded ATP synthase 8 (MT-ATP-8) was used to quantify 
mitochondrial genome content.  Real-time PCR reactions were run with 2 or more 
wells per sample for 40-45 cycles and threshold cycle (Ct) values were averaged.  
The reactions included 5 ng starting cDNA, 300 nM of each upstream and 
downstream primer, and 10 µL 2X SsoAdvanced Universal SYBR Green Supermix 




per well.  PCR-grade water was substituted for the cDNA as a negative control.  
PCR amplification was performed using the iCycler iQ Real-Time PCR Detection 
System (Bio-Rad Laboratories).  TBP mRNA was used as an internal control for 
cDNA samples (Kordus et al., 2019) and actin beta (ACTB) DNA was used as an 
internal control for nuclear DNA (nDNA) samples (Diez-Juan et al., 2015).  Target 
RNA and DNA quantities were derived from a standard curve made using serial 
dilutions of its purified amplicon.  TBP has extensively been tested as a control 
gene in our laboratory with human GCs under multiple conditions and treatments 
and has not been found to be regulated under any circumstances.  Target mRNA 
values were expressed relative to values of the TBP mRNA control.   
4.3.7 Statistical analysis  
Multiple linear regression models were estimated to predict the normalized 
average rate of each substrate’s metabolism and mitochondrial metabolic score 
using Box-Cox transformation for normality (Box and Cox, 1964). Each substrate 
was assessed separately, and a mitochondrial metabolic score was created based 
on the slopes of the normalized absorbance readings of all substrates combined.  
The mitochondrial metabolic scores were normalized against the mtDNA content 
in each sample.  The individual substrate rates and the mitochondrial metabolic 
scores were related to patient demographics. To determine the relationship 
between mitochondrial metabolic score and mRNA levels, Pearson’s correlation 
analysis was used with both variables being Box-Cox transformed.  We determined 




< P < 0.10 to be borderline significant. Statistical analysis was performed using the 
statistical analysis environment R 3.6.2 (R Core Team, 2019).
4.4 Results 
In total, 817 oocytes and associated GCs were harvested from 40 patients 
undergoing fertility treatment.  The CCs were combined with the MGCs from each 
patient.  Thirty-seven out of 40 patients had at least one fresh or frozen embryo 
transfer (FET) and currently 49% of patients who did receive an ET either have 
ongoing pregnancies or have delivered a child.    
We examined the mitochondrial metabolic profile of IVF patients using a 
novel mitochondrial function assay, Mitoplate S-1 which examined 31 different 
substrates.   In hypothesis one, we tested whether individual substrate utilization 
by pooled granulosa mitochondria would differ according to age, serum AMH 
levels, BMI, and total number of mature oocytes retrieved per patient cohort. 
Absorbance readings in the assay reflected metabolism of utilization of substrates. 
To test this hypothesis, we analyzed the averaged normalized absorbance 
readings of each metabolic substrate within the comparison groups using a 
multiple linear regression model using Box-Cox transformation examining the 
independent variables of age, BMI, serum AMH, mature oocytes per cohort, antral 
follicle count, stimulation type, amount a HMG given, and amount of FSH 
administered.  Age, BMI, serum AMH were divided into higher and lower groups 
as follows:  Older age ≥ 34 years old and younger age < 34 years old;  high BMI ≥ 
26 kg/m2 and low BMI < 26 kg/m2; and higher serum AMH ≥ 3.5 ng/mL and lower 




using observed data, patient mitochondrial utilization of citric acid (P < 0.01), L-
malic acid (P < 0.05), and octanoyl-L-carnitine (P < 0.01) were found to be 
significantly lower (Figure 4.3),  and mitochondrial utilization of cis-acontic acid (P 
< 0.10), D,L-beta-hydroxy-butyric acid (P < 0.10), and pyruvic acid/L-malic acid 
100 µM (P < 0.10) were found to be borderline lower in patients with lower BMI in 
pooled GCs, while no other substrates demonstrated utilization differences by BMI 
in the model, after adjusting for the other factors in the model (Figure 4.4).  
Individuals with a greater number of mature oocytes were found to have a 
significant increase for alpha-keto-isocaproic acid mitochondrial utilization by 
pooled granulosa (P < 0.01) (Figure 4.5).  No other substrates demonstrated 
utilization differences in the model (Figure 4.6).  Additionally, patient mitochondrial 
utilization for citric acid (P < 0.05), cis-acontic acid (P < 0.01),  D-alpha-keto-
glutaric acid (P < 0.05), L-glutamine (P < 0.05), and alanine-glycine (P < 0.05) were 
found to be significantly lower (Figure 4.7), and mitochondrial utilization of D,L-
isocitric acid (P < 0.10), D,L-beta-hydroxy-butyric acid (P < 0.10), L-glutamic acid 
(P < 0.10), acetyl-L-carnitine (P < 0.10), pyruvic acid/L-malic acid 100 µM (P < 
0.10)  were found to be borderline lower in pooled GCs of patients with higher 
administered FSH dosages, after adjusting for the other factors in the model while 
no other substrates demonstrated mitochondrial utilization differences for the 
number of mature oocytes in the model (Figure 4.8).   
The second hypothesis tested was that a mitochondrial metabolic score 
generated from the aggregate metabolism of the pooled GCs would differ 




retrieved per patient cohort.  To test this, we analyzed the mitochondrial metabolic 
scores using a multiple linear regression model using Box-Cox transformation 
examining the independent variables of age, BMI, serum AMH level, number of 
mature oocytes, zygote fertilization, good 8-cell embryo development, and overall 
blastocyst formation per patient cohort.  Based on the estimated multiple linear 
regression model using observed data, mitochondrial metabolic scores were found 
to be significantly higher in granulosa of patients with higher numbers of mature 
oocytes retrieved (P < 0.05), after adjusting for the other factors in the model 
(Figure 4.9).  In a backward selected best fit model using only the BMI and total 
FSH dosage administered, mitochondrial metabolic scores were found to be 
significantly lower in pooled GCs of patients with a lower BMI (P < 0.05) (Figure 
4.9), and significantly lower as the patient’s FSH dose administered increased (P 
< 0.01) (Figure 4.9). 
Our third hypothesis predicted that individual substrates metabolized by 
mitochondria in GCs of patients would differ by overall embryo cohort 
development. We created a multiple linear regression model using Box-Cox 
transformation looking at fertilization percentage, percentage good 8-cell embryo 
development on day 3, and percentage of blastocyst development by day 6. The 
3 groups were divided into higher and lower groups as follows:  higher fertilization 
percentage  ≥ 80%, and lower fertilization percentage < 80%;  higher good 8-cell 
development  > 55% and lower good 8-cell development ≤ 55%; and higher 
percentage of blastocyst formation > 55% and lower percentage of blastocyst 




she had an embryo transfer on day 3 with no additional embryos available for 
extended culture.   Based on the estimated multiple linear regression model using 
observed data, mitochondrial utilization of glycogen (P < 0.05) was found to be 
significantly lower in pooled GCs of patients with lower fertilization percentage 
(Figure 4.10). No other substrates demonstrated utilization differences for 
fertilization in the model (Figure 4.11).   In contrast, patient mitochondrial utilization 
of D-alpha-keto-glutaric acid (P < 0.05) was found to be significantly higher (Figure 
4.10),  and L-serine (P < 0.10) was found to be borderline higher in granulosa of 
patients with a lower percentage of good quality 8-cell embryos (Figure 4.12).  In 
addition, patient mitochondrial utilization of D-gluconate-6-phosphate (P < 0.10), 
and D,L-isocitric acid (P < 0.10) was found to be borderline higher in patients with 
a lower percentage of blastocyst formation in pooled GCs, after adjusting for the 
other factors in the model (Figure 4.13).  In a backward selected best fit model 
using only the percentage of good 8-cell embryos and percentage of blastocysts,  
GC mitochondrial utilization of L-glutamine (P < 0.05) was found to be significantly 
higher in patients with a lower percentage of blastocyst formation (Figure 4.10)  
and L-glutamine (P < 0.10) was found to be borderline higher in patients with a 
lower percentage of good quality 8-cell embryos in pooled GCs(Figure 4.12). 
A fourth critical hypothesis we wanted to test was that a mitochondrial 
metabolic score generated from the aggregate metabolism of the pooled GCs 
would be associated with better overall embryo development.  To test this 
hypothesis, we analyzed the patient mitochondrial metabolic score using a multiple 




variables of age, BMI, AMH level, mature oocytes per cohort, zygote fertilization, 
good 8-cell embryo development, and overall blastocyst formation.  Based on the 
estimated multiple linear regression model using observed data, mitochondrial 
metabolic scores were found to be significantly higher in granulosa cells of patients 
with higher overall number of fertilized zygotes (P < 0.05) in pooled GCs, after 
adjusting for the other factors in the model (Figure 4.14).   
Finally, we wanted to test the hypothesis that the mitochondrial metabolic 
score would be differ with mRNA levels of the genes:  AMH, AREG, CYP19A1, 
CYP11A1, HSD3B1, ING1, LHCGR, and PAPPA.  In order to test this hypothesis, 
we used Pearson’s correlation analysis with both variables being Box-Cox 
transformed, which demonstrated that HSD3B levels we borderline lower (P < 
0.10) as the mitochondrial metabolic score decreased (Figure 4.13).  No other 
mRNA levels varied. 
4.5 Discussion   
To our knowledge this is the first use of this mitochondrial function assay to 
investigate mitochondrial metabolic substrate utilization in the pooled GCs of IVF 
patients.  The mitochondrial function assay plates utilized in our study contained 
31 cytoplasmic and mitochondrial metabolic substrates to profile the metabolic 
capabilities of mitochondria in pooled GC from individual patients. Each well in the 
plate contained an individual chemical as the sole energy source.  The substrates 
were metabolized through different biochemical pathways by entering the 
mitochondria through different transporters and they were then modified by various 




Deviations in the mitochondrial metabolism of the substrates were detected by 
chemometric alterations in the energy-rich redox dye.  As the cells metabolized the 
energy source, tetrazolium dye in the media was reduced, generating a purple 
color according to the amount of NADH or FADH2 reducing equivalents generated 
and reflected the biochemical reactome of the substrates by the mitochondria 
(Bochner et al., 2001). 
Our main goal was to determine if mitochondrial metabolic substrates in 
pooled GCs of IVF patients were significantly associated with patient age, serum 
AMH levels, BMI, or the number of mature oocytes retrieved per cohort.  Secondly, 
we wanted to determine if mitochondrial substrate utilization was related to embryo 
cohort development.  We hypothesized that mitochondria would metabolize the 
individual substrates at differing rates based on patient demographics and embryo 
cohort development.  We also hypothesized that the overall mitochondrial 
metabolic utilization of all the substrates in the plate, combined, would allow us to 
score each patient’s overall GC mitochondrial function and perhaps be used as a 
prediction tool for embryo development.  
The key findings of our research were that GC mitochondrial utilization of 
the assay’s metabolic substrates citric acid, L-malic acid, and octanoyl-L-carnitine 
were found to be significantly lower in patients with lower BMI indicating a potential 
increase in oxidative phosphorylation and perhaps reactive oxygen species 
production in overweight patients.  Citric acid and L-malic acid are both 
components of the tricarboxylic acid cycle.  The conversion of L-malic acid to 




through the ETC.  Octanoyl-L-carnitine is a medium chain fatty acid that 
catabolizes to several acetyl-CoA molecules and feeds into the tricarboxylic acid 
cycle.  Granulosa cell utilization of citric acid, cis-acontic acid, D-alpha-keto-
glutaric acid, L-glutamine, and alanine-glycine in the assay were found to be 
significantly lower in patients with higher administered FSH dosages using a 
multiple linear regression model.  This indicates that the total FSH dose required 
to produce follicle maturation is associated with suppressed mitochondrial activity 
by the pool of granulosa.   Cis-acontic acid and D-alpha-keto-glutaric acid are both 
components of the tricarboxylic acid cycle.  The conversion of D-alpha-keto-
glutaric acid by alpha-ketoglutarate dehydrogenase produces NADH which is 
processed through the ETC.  L-glutamine, converted to alpha-ketoglutarate 
through glutamate dehydrogenase, enters the tricarboxylic acid cycle at that 
juncture.  Alanine-gflycine will be converted into pyruvic acid and enters the 
tricarboxylic acid cycle after pyruvic acid is converted to acetyl-CoA.   Four out the 
7 substrates altered by either BMI and/or FSH were substrates directly involved in 
the citric acid cycle.  Octanoyl-L-carnitine, modified by BMI, is involved in fatty acid 
metabolism.  There is a commonality between the BMI and FSH dose-altered 
substrates.  Both citric and cis-aconitic acid are modified by the enzyme aconitase 
in a reversible isomerization reaction.  L-malic acid and alpha-keto-glutaric acid 
are both modified by dehydrogenases and undergo oxidation.  The changes 
observed in the mitochondrial substrate utilization by GCs may indicate that 
dehydrogenase activity and oxidation reactions are altered by BMI and total FSH 




Patients who fall within the obese range (>30 kg/m2) of BMI have been 
shown to have almost 70% lower odds of becoming pregnant in their first IVF cycle 
compared to women who have lower BMI (Moragianni et al., 2012).  Furthermore, 
high BMI and diabetes have both been shown to be related to alteration of 
mitochondrial function in mouse oocytes (Igosheva et al., 2010, Ou et al., 2012). 
In human GCs, mitochondrial membrane potential is decreased with higher BMI 
levels (Gorshinova et al., 2017), and gene expression  has also been shown to be 
modified by BMI (Adriaenssens et al., 2010a, Kenigsberg et al., 2009, Robker et 
al., 2009).  In our study BMI and FSH both altered the utilization of several 
mitochondrial metabolic substrates related to the tricarboxylic acid cycle.  The 
findings that BMI and the total FSH dose administered alter mitochondrial 
metabolism in granulosa may be explained by the tendency of patients with higher 
BMI to receive higher doses of FSH during an IVF stimulation cycle (Fedorcsak et 
al., 2004).  Interestingly, total FSH dosage was previously shown to have no impact 
on mitochondrial  expression of a polycistronic RNA transcript in GCs of IVF 
patients (Saito et al., 2013),  Citric acid and ATP levels have been shown to be 
reduced in diabetic mice suggesting reduced mitochondrial function due to 
increasing BMI (Wang et al., 2010).  We found that the mitochondrial metabolic 
scores were significantly reduced when BMI was lower and total FSH dose 
administered was higher, when only BMI and FSH were in the backward selected 
models.  Our results may indicate that increasing BMI causes an increase in 
oxidative phosphorylation and reactive oxygen species.  This may or may not 




colleagues demonstrated that fibroblasts from infants born to overweight mothers 
(compared to lean mothers) had significantly higher mitochondrial oxygen 
consumption rates and increased ATP production indicating mitochondrial 
inefficiency;  cells also exhibited elevated ROS and oxidative stress  (Abraham et 
al., 2018). One may expect that higher doses of FSH administered would show a 
similar increase in metabolic utilization since higher doses of FSH are associated 
with higher BMIs, however, we found the opposite effect in this study.  This may 
indicate that GC from patients receiving higher FSH dose indeed suppress 
mitochondrial substrate utilization.  Unfortunately, we did not assess ATP 
production in this study, but a future study may be able to assess the effect of BMI 
and FSH dose administered on substrate utilization and ATP production to see if 
BMI and FSH affect mitochondrial function independent of ATP production.   
One of the key pathways for energy production is fatty acid oxidation.  
Lipotoxicity caused by excessive lipid accumulation and increased intracellular 
free fatty acid content leads to mitochondrial dysfunction which can compromise 
mitochondrial function through free fatty acid beta-oxidation and oxidative stress 
(Hauck and Bernlohr, 2016).  Gorshinova and colleagues demonstrated reduced 
mitochondrial membrane potential in CCs with increasing BMI (Gorshinova et al., 
2017).  Surprisingly, octanoyl-L-carnitine is an interesting metabolite whose usage 
was altered in our experiments.  Pyruvate, derived from the CCs surround the 
oocyte, and free fatty acid oxidization are the major sources of ATP production by 
oocyte mitochondria (Simerman et al., 2015).  Octanoyl-L-carnitine has been 




(Toleikis et al., 2001).  The modulation of octanoyl-L-carnitine may indicate that 
patients with high BMI suffer from compromised mitochondrial function, due to 
lipotoxicity, causing the mitochondria to work harder in order to produce the same 
amount of ATP as a person with lower BMI.  
We additionally hypothesized that oocyte maturity would be associated with 
altered mitochondrial metabolic function in granulosa cells as the amount of 
mtDNA in an oocyte has been previously shown to be important for oocyte maturity 
and fertilization (Reynier et al., 2001).  Since mtDNA content in the oocytes has 
been shown to be associated with mtDNA content in the GCs (Boucret et al., 2015, 
Desquiret-Dumas et al., 2017, Ogino et al., 2016) we hypothesized that the 
mitochondrial metabolism of the GCs should reflect the mitochondrial metabolism 
of the oocyte and relate to an oocyte’s overall developmental competence.   The 
amount of mtDNA in oocytes has previously been demonstrated to be reduced in 
older patients and those with diminished ovarian reserve and mitochondrial 
membrane potential has been shown to decrease with advancing age (de Boer, 
1999, Diez-Juan et al., 2015, May-Panloup et al., 2005b).    However, mtDNA copy 
number alone does not account for how efficiently the mitochondria function.  We 
observed a significant increase for alpha-keto-isocaproic acid metabolism by GCs 
in the assay as the number of mature oocytes increased.  Alpha-keto-isocaproic 
acid is converted to leucine by way of a transamination reaction.  Leucine then is 
converted to acetyl-CoA where it enters the tricarboxylic acid cycle. In our study, 
the calculated mitochondrial metabolic scores were significantly increased in a 




production and mitochondrial membrane potential in CCs have both been shown 
to correlate with the number of mature oocytes retrieved (Dumesic et al., 2016).   
Our observations may indicate there is a component of leucine metabolism that is 
related to final oocyte maturation.    
We did not find any significant differences in mitochondrial metabolism 
related to age or serum AMH (Figure 4.17 and 4.18).  AMH levels and advanced 
maternal age are closely related.  Both AMH gene and protein expression are 
increased in GCs with advancing age (Kedem et al., 2014) while serum AMH levels 
in the blood decrease as the supply of oocytes dwindles with age (Knight and 
Glister, 2006).  We performed correlation analysis between mtDNA copy number 
and patient age, BMI, serum AMH levels, and oocyte maturity and found no 
differences (Figure 4.19).   The reason we may not have seen differences in these 
groups is because were we unable to look at patients with low oocyte yield, which 
normally fall in the low AMH and older patient groups.  The minimum number of 
GCs needed to utilize the mitochondrial function assay required pooled CCs and 
MGCs from at least 10 oocytes.  Therefore, older women and those with lower 
AMH levels in our study were still within a better prognostic group than patients 
with low oocyte yield due to age or diminished ovarian reserve.  If we had been 
able to use fewer GCs for the assay and could have included patients with lower 
oocyte yield, we may have observed different results.   
A secondary goal of this study was to determine if mitochondrial substrates 
in pooled GCs would relate to a patient’s overall cohort development and yield 




pregnancy/live birth in future studies.  The premise of this hypothesis was that one 
potential explanation for compromised oocyte, and subsequent embryo quality, 
has been postulated to be deficient mitochondrial function (Bentov et al., 2011).  
Embryo viability is related to the amount of energy produced by the mitochondria 
in the oocyte and surrounding GCs as early embryogenesis demands substantial 
amounts of energy produced by the mitochondria to drive the cleavage divisions 
(May-Panloup et al., 2005a, Reynier et al., 2001, Zhao et al., 2010).  In fact, 
mitochondria with metabolic dysfunction may impair oocyte quality, overall embryo 
development, and live birth rates (Dumesic et al., 2016).   
Glycogen is a cytoplasmic substrate which is converted through several 
steps to acetyl-CoA where it enters the tricarboxylic acid cycle.  Mitochondrial 
utilization of glycogen was found to be significantly lower in patients with lower 
fertilization percentage.  Mitochondrial metabolic scores significantly increased as 
the number of mature oocytes retrieved increased, while the scores decreased as 
the number of fertilized oocytes increased.  This inverse relationship is likely due 
to the fact that GCs surrounding immature oocytes may exhibit increased 
mitochondrial activity which drops off as the oocyte matures and prepares for 
fertilization.  Prior studies have demonstrated higher mean mtDNA levels in 
fertilized human oocytes compared to both unfertilized oocytes and degenerated 
oocytes (Reynier et al., 2001, Santos et al., 2006, Murakoshi et al., 2013).  Our 
data appear to indicate that mitochondria in granulosa of oocytes that are better 
positioned to fertilize can utilize glycogen more efficiently to produce ATP than 




is needed in order to complete fertilization.  This data indicates that the 
mitochondrial metabolic score may be able to predict fertilization potential of a 
cohort of oocytes. 
Mitochondrial utilization significantly increased for D-alpha-keto-glutaric 
acid in GCs from patients with lower good quality 8-cell embryos compared to 
those with high good quality 8-cell embryos.  In addition, mitochondrial utilization 
of L-glutamine was found to be significantly higher in pooled GCs in patients with 
a lower percentage of blastocyst formation when using a backward selected model 
looking only at 8-cell embryos and blastocysts.  L-glutamine was likely converted 
to alpha-keto-glutaric acid and used the same biochemical pathway in the assay.  
Increased mtDNA copy numbers in CCs have been shown to be associated with 
embryos that developed into high quality versus low-quality embryos and embryos 
more likely to implant than those that did not implant.  It has been postulated that 
increased mitochondria within a blastocyst may serve to compensate for reduced 
mitochondrial energy production due to metabolic stress from reactive oxygen 
species and free radicals (Diez-Juan et al., 2015, Fragouli et al., 2015, Grindler 
and Moley, 2013, May-Panloup et al., 2016).  In future studies use of a single 
substrate that showed significant differences based on embryo development could 
conceivably be optimized to test individual CC masses to examine the endpoints 
of individual embryo development, pregnancy, and live birth.   
Finally, we wanted to test the hypothesis that the mitochondrial metabolic 
score, which reflects overall mitochondrial activity in the granulosa pool would be 




based on our original hypothesis that serum AMH levels would alter substrate 
utilization.  We selected AREG, CYP19A1, CYP11A1, HSD3B1, ING1, LHCGR, 
and PAPPA as genes of interest based on a prior study our lab conducted with 
individual cumulus masses (Kordus et al., 2019).  HSD3B levels were borderline 
lower (P < 0.10) as the mitochondrial metabolic score decreased, but none of these 
mRNAs showed significant regulation.  In our prior study we examined individual 
CC masses from oocytes and their individual embryos.  We believe we did not see 
any significant differences due to the use of pooled GCs in this study.   
A strength of this study was that we were able to compare multiple 
substrates at once over a specified time course using the mitochondrial function 
assay.  Another strength of this study was that we were able to assess 
mitochondrial function and not just mtDNA content.  This study was limited by the 
number of GCs needed to analyze each substrate in triplicate in the mitochondrial 
function assay.  We found that the threshold concentration of cells needed was 
approximately 7000 cells per well or just above 650,000 cells per plate in order to 
yield absorbance readings above the negative control values.  Therefore, this 
necessitated pooling of the MGCs and the CCs to achieve the required number of 
cells per patient for the assay plate.  Since we pooled the GCs, this caused us to 
have to examine at the embryo cohort as a whole, rather than individual embryos, 
which reduces the clinical utility of using this particular test to assess embryo 
development.  Since this was a pilot study, our goal was to narrow the cohort of 
substrates down to a few which could be optimized in the future to analyze 




resulting embryos in future studies.  Specialized assay plates could be made with 
only the substrates of interest in the wells.  Another limitation was the use of two 
stimulation protocols.  A more ideal study would include patients undergoing a 
single stimulation protocol, either long luteal stimulation or antagonist stimulation.  
Mitochondrial function and its relationship to human reproductive potential 
is poorly understood, and further research needs to be conducted regarding oocyte 
developmental competence and embryonic development.  In this study we found 
mitochondrial metabolic function was altered with BMI and FSH dosage.  We also 
found that there was a subset of mitochondrial metabolic substrates utilized by 
GCs that can potentially be used as novel biomarkers related to embryo 
development in future studies.  
4.6 Supplementary data 
Supplementary data are available at Journal of Assisted Reproduction and 
Genetics online. 
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Figure 4.1 Flow diagram summarizing the study population from oocyte 
retrieval to final outcome.  Oocytes, CC masses, and MGCs were collected from 
58 patients (pts).  Individual CC masses from each oocyte collected (n=817) were 
combined with the MGCs from each patient. Fourteen samples collected had an 
insufficient number of cells to visualize an appropriate color change in the wells of 
the assay plate and were excluded from the analysis.  Four patients did exceed 
the minimum number of cells required to run the plate but no color changes were 
observed with the control wells and thus were excluded from the analysis, so the 








Table 4.1 Patient demographics and cycle information  
 















1 34 23.1 MF 5.65 15 LL 300 825 22 77% 71% 47% 0.001184 
2 24 19.4 MF 2.25 27 LL 600 1125 9 89% 25% 50% 0.001294 
3 40 19.9 MF 3.86 20 LL 450 1488 20 90% 61% 61% 0.001562 
4 26 21.6 PCO 4.34 30 LL 750 1425 9 67% 33% 33% 0.001663 
5 32 19.1 RPL 1.98 11 AN 750 1700 14 86% 58% 50% 0.000311 
6 38 21 AMA 1.52 11 AN 675 1575 11 82% 55% 66% 0.001355 
7 36 29.7 RPL 2.48 26 AN 750 1800 25 92% 78% 73% 0.000824 
8 36 27.9 DOR 0.55 7 AN 1200 3300 9 67% 83% 100% 0.000778 




PCO 1.17 11 AN 675 2025 6 67% 0% 50% 0.000621 




PCO 3.02 25 LL 525 1050 14 36% 0% 0% 0.000592 
13 30 19 OD 2.5 22 LL 675 1425 13 85% 55% 54% 0.000927 
14 29 26.2 MF 1.85 13 LL 750 1500 10 60% 67% 50% 0.001091 
15 33 30.3 DOR 0.78 13 AN 600 1800 11 82% 67% 33% 0.001265 




AMA 1.14 12 AN 675 2250 7 86% 50% 50% 0.006901 




OD 1.75 11 AN 825 3150 15 73% 55% 55% 0.001608 
20 28 23 MF 6.8 18 LL 600 1050 11 46% 60% 20% 0.000809 










Table 4.1 Patient demographics and cycle information continued 
 
22 32 21.5 ENDO 4.73 20 LL  600 1275 24 58% 21% 57% 0.000362 
23 31 29.7 OD 5.06 23 LL 750 1500 19 84% 38% 62% 0.001179 
24 36 17.9 MF 1.26 23 LL 825 2475 12 58% 57% 43% 0.001328 
25 
31 29 PCO 11.5 27 LL 525 1050 10 90% 100% 78% 0.00098 
26 35 31.3 OD 0.85 7 AN 750 2250 11 100% 55% 55% 0.000769 
27 36 38.3 OD 1.92 9 LL 825 3000 12 92% 27% 9% 0.001229 





TRAN 1.61 9 AN 1050 3000 6 100% 83% 67% 0.000570 
30 34 25.8 MF 5.65 15 LL 300 775 25 84% 67% 52% 0.000354 
31 27 25.8 AMEN 9.66 30 LL 600 938 16 88% 79% 57% 0.000201 
32 33 23 RPL 5.13 30 LL 600 1050 22 68% 73% 73% 0.001147 
33 34 29.3 UT 6.19 27 LL 675 1175 15 73% 64% 55% 0.00108 
34 33 28.5 RPL 1.66 19 LL 675 1450 9 89% 50% 75% 0.000680 
35 31 34.4 OD 4.68 27 LL 600 1100 26 42% 36% 55% 0.000739 
36 28 29.8 OD 9.39 30 LL 750 1125 17 100% 88% 47% 0.000571 
37 31 20.2 OD 5.47 19 LL 750 1950 10 70% 86% 71% 0.001878 
38 38 33.1 AMA 3.15 30 AN 825 2625 22 82% 56% 72% 0.000675 
39 31 18.9 OD 6.55 30 LL 675 1525 26 100% 62% 81% 0.000837 
40 38 23.1 OD 9.97 30 LL 675 1350 11 73% 25% 0% 0.000944 











































Table 4.1 Patient demographics and cycle information continued 
_______________________________________________________________________________________________ 
8-C = 8-cell embryo, AFC = antral follicle count, AMEN = amenorrhea, AMA = advance maternal age, AMH = anti-
Mullerian hormone, AN = antagonist stimulation, BAL-TRAN = balanced translocation, Blast = blastocyst, BMI = body 
mass index, Diag = diagnosis, DOR = diminished ovarian reserve, ENDO = endometriosis, FERT = fertilization, FSH = 
follicle stimulating hormone, HMG = human menopausal gonadotropin, IDIO = idiopathic, IUs = international units, LL = 
long luteal stimulation, MAT = mature, MF = male factor, mtDNA = mitochondrial DNA, PCO = polycystic ovaries, Pt = 
patient, OD = ovulatory dysfunction, RPL = recurrent pregnancy loss, STIM = stimulation type, TUBAL = tubal factor, UT = 
uterine anomaly 






















Table 4.2 List of Substrates on the Mitoplate-S-1 Mitochondrial Function Assay 
Cytoplasmic substrates 
No substrate control  alpha-D-glucose   glycogen  D-glucose-1-phosphate          
D-glucose-6-phosphate  D-gluconate-6-phosphate  L-lactic acid  D,L-alpha-glycerol-phosphate 
Tricarboxylic acid cycle substrates 
pyruvic acid    citric acid    D,L-isocitric acid cis-aconitic acid 
D-alpha-keto-glutaric acid  succinic acid    fumaric acid  L-malic acid 
Other mitochondrial substrates 
alpha-keto-butyric acid  D,L-beta-hydroxy-butyric acid L-glutamic acid L-glutamine 
alanine-glycine   L-serine    L-ornithine  tryptamine 
Other mitochondrial substrates with malic acid 100uM  
malic acid 100uM   octanoyl-L-carnitine   acetyl-l-carnitine  palmitoyl-D,L-carnitine 













Table 4.3 Primer set information 
 









Reference or NCBI no. 
AMH For GTGCTGCTGCTGAAGATG 
Rev CTCCGACAGGCTGATGAG 





62 251 (Feuerstein et al., 
2007) 
ACTB For AGCGGGAAATCGTGCGTGAC 
Rev AGGCAGCTCGTAGCTCTTCTC 
60 116 (Diez-Juan et al., 
2015) 




380  (Hamel et al., 2008) 
 
HSD3B1 For TGTGCCAGTCTTCATCTACAC 
Rev TGTTTTCCAGAGGCTCTTCTTC 
60 101  (Hamel et al., 2008) 
ING1 For GCCTGGTGTGAGGAGGACAA 
Rev CCCTATGAAAGGAATGGTTCCTT 
62 124  (He et al., 2004) 
LHCGR For TGGAGAAGATGCACAATGGA 
Rev GGCAATTAGCCTCTGAATGG 
60 122  (Yung et al., 2014) 
MT-ATP8 For CTAAAATATTAAACACAAACTACCACCTACCTC 
Rev GTTCATTTTGGTTCTCAGGGTTTGTT TAA 
60 92 (Diez-Juan et al., 
2015) 
PAPPA For GTCATCTTTGCCTGGAAGGGAGAA 
Rev AGGGCTGTTCAACATCAGGATGAC 
62 129  (Wagner et al., 2011) 
 
TBP For CACGGCACTGATTTTCAGTTC 
Rev TCTTGCTGCCAGTCTGGACT 







Figure 4.2 Sample mitochondrial functional assay Mitoplate-S-1.  The 
mitochondrial function assay plates contained 31 cytoplasmic and mitochondrial 
metabolic substrates repeated in triplicate.  Each well in the plate contained an 
individual chemical as the sole energy source.  As the cells metabolized the energy 
source, tetrazolium dye in the media was reduced, generating a purple color 
according to the amount of NADH or FADH2 reducing equivalents generated over 











Figure 4.3 Substrates demonstrating significant mitochondrial utilization differences based on body mass index.  
To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear regression model 
using Box-Cox transformation.  BMI was divided into 2 groups with the higher group being patients with a BMI of ≥ to 26 
kg/m2 (n = 20) and the lower group being patients with a BMI of < 26 kg/m2 (n = 20).  Mitochondrial utilization of citric acid 
(P < 0.01), L-malic acid (P < 0.05), and octanoyl-L-carnitine (P < 0.01) were found to be significantly lower in pooled GCs 
of patients with lower BMI, after adjusting for the other factors in the model.   Data are presented as the median (line inside 
box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range beyond the 
















Figure 4.4 Substrates demonstrating no significant mitochondrial utilization differences based on body mass 
index.  To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear 
regression model using Box-Cox transformation between BMI groups.  BMI was divided into 2 groups with the higher group 
being patients with a BMI of ≥ to 26 kg/m2 (n = 20) and the lower group being patients with a BMI of < 26 kg/m2 (n = 20).  
Mitochondrial utilization of cis-acontic acid (P < 0.10), D,L-beta-hydroxy-butyric acid (P < 0.10), and pyruvic acid/L-malic 
acid 100 µM (P < 0.10) were found to be borderline lower in pooled GCs of patients with lower BMI, after adjusting for the 
other factors in the model.  No other substrates showed any mitochondrial utilization differences.   Data are presented as 
the median (line inside box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the 





























Figure 4.5 Substrates demonstrating significant mitochondrial utilization 
differences based on number of mature oocytes retrieved.  To determine the 
differences in mitochondrial utilization, substrates were modeled using multiple 
linear regression after Box-Cox transformation for normality.  Individuals with  
greater numbers of mature oocytes retrieved were found to have a significant 
increase in alpha-keto-isocaproic acid mitochondrial utilization (P < 0.01) in pooled 
GCs of patients, after adjusting for the other factors in the model. Data are 
presented as a scatter plot of the individual patient Box-Cox transformed values 

















Figure 4.6 Substrates demonstrating no significant mitochondrial utilization differences based on number of 
mature oocytes retrieved.  To determine the differences in mitochondrial utilization, substrates were modeled using 
multiple linear regression after Box-Cox transformation for normality.  No substrates in pooled GCs of patients demonstrated 
any significant mitochondrial utilization differences, after adjusting for the other factors in the model.  Data are presented as 



























































Figure 4.7 Substrates demonstrating significant mitochondrial utilization differences based on total FSH dose 
administered.  To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear 
regression after Box Cox transformation for normality.  Mitochondrial utilization for citric acid (P < 0.05), cis-acontic acid (P 
< 0.01),  D-alpha-keto-glutaric acid (P < 0.05), L-glutamine (P < 0.05), and alanine-glycine (P < 0.05) in pooled GCs of 
patients were found to be significantly lower as total FSH dose administered increased, after adjusting for the other factors 
in the model. Data are presented as a scatter plot of the individual patient Box-Cox transformed values showing the trend 



































Figure 4.8 Substrates demonstrating no significant mitochondrial utilization differences based on total FSH dose 
administered.  To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear 
regression after Box-Cox transformation for normality.  Mitochondrial utilization of D,L-isocitric acid (P < 0.10), D,L-beta-
hydroxy-butyric acid (P < 0.10), L-glutamic acid (P < 0.10), acetyl-L-carnitine (P < 0.10), pyruvic acid/L-malic acid 100 µM 
(P < 0.10)  were found to be borderline lower in pooled GCs of patients with higher administered FSH dosages, after 
adjusting for the other factors in the model.  No other substrates showed any mitochondrial utilization differences.   Data 























































Figure 4.9 Mitochondrial metabolic scores demonstrating significant utilization differences based on BMI, total FSH 
dose, and number of mature oocytes retrieved.   Mitochondrial metabolic scores were Box-Cox transformed for normality 
and modeled using multiple linear regression.  A) Mitochondrial metabolic scores were found to be significantly higher in 
GCs of patients with higher numbers of mature oocytes retrieved (P < 0.05), after adjusting for the other factors in the model.  
In a backward selected best fit model using only the BMI and total FSH dosage administered, B) mitochondrial metabolic 
scores were found to be significantly lower in pooled GCs of patients with a lower BMI (P < 0.05). BMI was divided into 2 
groups with the higher group being patients with a BMI of ≥ to 26 kg/m2 (n = 20) and the lower group being patients with a 
BMI of < 26 kg/m2 (n = 20).  C)  Mitochondrial metabolic scores were found to be significantly lower as the patient’s FSH 
dose administered increased (P < 0.01). For BMI, transformed mitochondrial metabolic scores are presented as the median 
(line inside box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range 
beyond the first and third quartile. For mature oocytes retrieved and FSH dose administered, the transformed scores are 










Figure 4.10 Substrates demonstrating significant mitochondrial utilization differences based on embryo cohort 
development.  To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear 
regression after Box-Cox transformation for normality. Cohorts were grouped as follows, higher fertilization percentage  ≥ 
80% (n = 22), and lower fertilization percentage < 80% (n = 18);  Higher good 8-cell development  > 55% (n = 22) and lower 
good 8-cell development ≤ 55% (n = 18); and higher percentage of blastocyst formation > 55% (n = 17) and lower percentage 
of blastocyst formation ≤ 55% (n = 22). One patient was excluded from the blastocyst formation data as she had an embryo 
transfer on day 3 with no additional embryos available for extended culture.  A) Mitochondrial utilization of glycogen (P < 
0.05) was found to be significantly lower in GCs of patients with lower fertilization percentage,  B) mitochondrial utilization 
of D-alpha-keto-glutaric acid (P < 0.05) was found to be significantly higher in GCs from patients with a lower percentage 
of good quality 8-cell embryos, after adjusting for the other factors in the model. C)  In a backward selected best fit model 
using only the percentage of good 8-cell embryos and percentage of blastocysts, mitochondrial utilization of L-glutamine (P 
< 0.05) was found to be significantly higher in GCs from patients with a lower percentage of blastocyst formation. Data are 
presented as the median (line inside box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 
















Figure 4.11 Substrates demonstrating no significant mitochondrial utilization differences based on fertilization 
percentage.  To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear 
regression model using Box-Cox transformation. The 2 groups were delineated by higher fertilization percentage ≥ 80% (n 
= 22), and lower fertilization percentage < 80% (n = 18).  Data are presented as the median (line inside box), first and third 







































Figure 4.12 Substrates demonstrating no significant mitochondrial utilization differences based on good 8-cell 
embryo development. To determine the differences in mitochondrial utilization, substrates were compared using a multiple 
linear regression model using Box-Cox transformation. The 2 groups were delineated by higher good 8-cell development   
> 55% (n = 22) and lower good 8-cell development ≤ 55% (n = 18).  Mitochondrial utilization of L-serine (P < 0.10) was 
found to be borderline higher in GCs of patients with a lower percentage of good quality 8-cell embryos. In a backward 
selected best fit model using only the percentage of good 8-cell embryos and percentage of blastocysts, L-glutamine (P < 
0.10) was found to be borderline higher in in pooled GCs from patients with a lower percentage of good quality 8-cell 
embryos. No other substrates showed significant differences.  Data are presented as the median (line inside box), first and 






































Figure 4.13 Substrates demonstrating no significant mitochondrial utilization differences based on blastocyst 
formation.  To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear 
regression model using Box-Cox transformation. The 2 groups were delineated by higher percentage of blastocyst formation 
> 55% (n = 17) and lower percentage of blastocyst formation ≤ 55% (n = 22).  Mitochondrial utilization of D-Gluconate-6-
phosphate (P < 0.10), and D,L-isocitric acid (P < 0.10) were found to be borderline higher in patients with a lower percentage 
of blastocyst formation in pooled GCs, after adjusting for the other factors in the model. No other substrates demonstrated 
significant differences.  Data are presented as the median (line inside box), first and third quartile (bottom and top of box), 





























Figure 4.14 Mitochondrial metabolic scores demonstrating significant 
utilization differences based the total number of fertilized oocytes.   Based 
on the estimated multiple linear regression model using observed data after Box-
Cox transformation for normality, mitochondrial metabolic scores were found to be 
significantly higher in granulosa cells of patients with higher overall number of 
fertilized oocytes (P < 0.05) in pooled GCs, after adjusting for the other factors in 
the model,  Data are presented as a scatter plot of the individual patient Box-Cox 










Figure 4.15 Mitochondrial metabolic scores based on mRNA levels.  Based on Pearson’s correlation analysis using 
data after Box-Cox transformation for normality, HSD3B mRNA levels were borderline significantly lower (P < 0.10) as the 
mitochondrial metabolic score decreased,  Data are presented as a scatter plot of the individual patient Box-Cox transformed 
















Figure 4.16 Tricarboxylic acid cycle diagram showing where the substrates of the mitochondrial function assay 
enter the cycle. This pathway diagram illustrates the various points where the substrates are converted and enter the 
tricarboxylic cycle.  The substrates were metabolized through different biochemical pathways by entering the mitochondria 
through different transporters and they were then modified by various enzymes and dehydrogenases to produce NADH or 
FADH2.  Blue = tricarboxylic acid constituents that are not substrates in the assay, Blue boxes = enzymes, Black = 
tricarboxylic acid cycle substrates, ETC = electron transport chain, FADH2 = flavin adenine dinucleotide hydride, Green = 









































Figure 4.17 Substrates demonstrating no significant mitochondrial utilization differences based on age.  To 
determine the differences in mitochondrial utilization, substrates were modeled using multiple linear regression after Box-
Cox transformation for normality.  Age was divided into 2 groups with the older age being ≥ 34 years old (n = 19) and 
younger age being < 34 years old (n = 21).  No substrates showed any statistically significant difference in mitochondrial 
utilization.  Box-Cox transformed data are presented as the median (line inside box), first and third quartile (bottom and top 

























































Figure 4.18 Substrates demonstrating no significant mitochondrial utilization differences based on serum AMH 
levels.  To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear regression 
after Box-Cox transformation for normality.  Serum AMH was divided into 2 groups with higher serum AMH being ≥ 3.5 
ng/mL (n = 20) and lower serum AMH being < 3.5 ng/ml (n = 20).  No substrates showed any statistically significant 
difference in mitochondrial utilization. Box-Cox transformed data are presented as the median (line inside box), first and 



























































Figure 4.19 Pooled granulosa cell mtDNA content had no significant association with patient demographics nor 
oocyte outcomes.  For categorical groups, Box-Cox transformed mtDNA values are presented as the median (line inside 
box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range beyond 
the first and third quartile. Averages were compared using independent samples t-tests. For continuous variables, data 
are presented as a scatter plot of the individual patient Box-Cox transformed values showing the trend line and the 95% 
confidence region. Pearson’s correlation coefficients were estimated and tested for statistical significance.  8-cells = 8-cell 
embryos, AFC = antral follicle count, AMH = anti-Mullerian hormone, ANT = antagonist stimulation, BMI = body mass 
index, FSH = follicle stimulating hormone, HMG = human menopausal gonadotropin, LL = long luteal stimulation, mtDNA 
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Granulosa cells within each follicle are composed of both the CCs and the 
MCGs that surround the individual oocytes.  The fact that granulosa are easily 
collected as a by-product of the IVF process, and the fact that GCs are intimately 
related to oocyte maturation and developmental potential (Dumesic et al., 2015), 
make them ideal non-invasive materials to investigate various biomarkers to 
improve IVF outcomes. Multiple oocytes and their corresponding cumulus and 
mural granulosa cells are retrieved during assisted reproduction.  As it is possible 
to isolate the CCs and MGCs associated with an individual oocyte from each 
retrieval, analyses of these cells may be valuable for screening biomarkers 
identifying embryos capable of producing a live birth.  Appendices A-C summarize 
biomarker studies and indicate that CCs more often than MGCs exhibit biomarkers 
associated pregnancy and live birth outcomes (Kordus and LaVoie, 2017).  Greater 
reliability of biomarkers being present in CCs seems logical as they are in direct 
contact with the oocyte at the time of retrieval from the ovary. Data from these 
studies suggest that the likelihood of a single expressed gene as a predictor of 
pregnancy is low, and that multiple genes and cycle characteristics are needed to 
create the best predictive models. Patient diagnoses, age, BMI, and IVF 
stimulation protocols; among other factors, can alter study outcomes.  A 
homogeneous patient study population is critical in identifying GC biomarkers for 
predictive models.  In addition, the paternal contributions to fertilization, embryo 
quality, and live birth outcomes is rarely addressed in studies, but should be 
considered.  Stepwise multivariate analysis where multiple variables include levels 
of several of the most predictive mRNA biomarkers corrected for variations in 
  
224 
specific patient characteristics, may yield a reliable approach for selecting the best 
embryos with potential for live birth (Adriaenssens et al., 2010a).  Predictive 
models that can be tested in multiple clinics will allow large scale validation of 
biomarkers and possibly transform procedures used for the selection of embryos 
for uterine transfer and improve assisted reproduction success rates. 
Our long-term goal is to create a panel of granulosa biomarkers that can 
help improve a patient’s odds of success using IVF on their first attempt.  
Ultimately, our objective is to obtain a biomarker panel that can help embryologists 
quickly and easily select an embryo, from a patient’s cohort of embryos, which has 
the best chance of implanting in the uterus and leading to a heathy child.   In our 
first set of aims, we prospectively examined mRNA transcripts in individual CC 
masses and related those biomarkers to individual oocyte, and subsequent 
embryo genetic status, oocyte developmental competence, and live birth 
outcomes.  In this series of experiments, we contributed several important and 
original contributions to the field of IVF: 
• We revealed for the first time that higher mRNA levels of a novel biomarker, 
PAPPA, may be a trustworthy biomarker in individual CCs associated with 
identifying oocytes capable of leading to a live birth.   
• We confirmed that higher mRNA levels LHCGR and lower mRNA levels of 
AREG in CCs were associated with oocytes that formed embryos capable 
of leading to live birth. 
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• We concluded that collectively, CC PAPPA, LHCGR, and AREG mRNA 
may be able to be employed as a biomarker panel to identify oocytes with 
the best odds of resulting in a live birth.   
• We indicated that lower CC mRNA levels of HSD3B1 were associated with 
oocytes that developed into euploid embryos.   
Since several studies previously investigated mRNA transcript biomarkers, we 
carefully selected transcripts that were potential biomarkers from several previous 
studies to validate and we also examined some novel transcripts.  Our study was 
slightly different than other prior studies as we chose to examine mRNA transcripts 
levels in relation to oocyte maturity, abnormal embryo development, embryo ploidy 
status, and live birth outcomes.  Relatively few studies have examined mRNA 
levels as related to ploidy status and IVF outcomes (Fragouli et al., 2010, Fragouli 
et al., 2012, Parks et al., 2016, Green et al., 2018).   
We hypothesized that certain mRNA transcripts in individual CCs could be used 
to select individual oocytes, and their subsequent embryos, with the highest 
probability of leading to viable pregnancies and resulting in live births.  We found 
that increased PAPPA and LHCGR mRNA levels were associated CCs 
surrounding mature oocytes that resulted in live births.  Differences were also 
observed between immature oocytes compared to aneuploid embryos and 
immature oocytes compared to arrested embryos, respectively.  This data 
indicates that embryos with increased CC mRNA levels of PAPPA and LHCGR 
should be preferentially selected first for uterine transfer, using these models, as 
they have been shown to be more likely to yield a live birth.  This differential mRNA 
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expression between immature oocytes and mature oocytes leading live birth 
provides evidence for a potential optimal maturation window.   
When comparing only transferred embryos within the entire biomarker 
panel, oocytes with decreased AREG and increased PAPPA mRNA levels in their 
CCs were more likely to produce a live birth.  When applied to the best fitting live 
birth prediction model, which included a smaller subset of the biomarker panel, 
PAPPA and CYP19A1 mRNA predicted live birth.  This could indicate that PAPPA 
mRNA may be a reliable biomarker for identifying oocytes capable of leading to a 
live birth.  PAPPA mRNA encodes a metalloproteinase that cleaves insulin-like 
growth factor binding protein 4 (IGFBP4) and IGFBP5 proteins and is found in 
follicular fluid (Conover et al., 1999, Laursen et al., 2001, Mazerbourg et al., 2001).  
It is a novel biomarker we chose to examine.  PAPPA mRNA is present in antral 
follicles >5 mm through the pre-ovulatory stage and corpora lutea, but absent in 
pre-antral, small antral (1-2 mm), and atretic follicles (Hourvitz et al., 2000).  
Furthermore, PAPPA mRNA is present in cultured GCs from human follicles >8 
mm (Conover et al., 2001) which coincides temporally with selection of the 
dominant follicle during the reproductive cycle (Baerwald et al., 2012).  Increased 
levels of PAPPA mRNA and its resulting protein in GCs of peri-ovulatory follicles 
may be necessary to increase intrafollicular IGF availability.  Cleavage of IGFBPs 
by PAPPA protein would release IGFs and result in an increase in free IGF 
available for signaling (Firth and Baxter, 2002).  IGFs are known to enhance FSH 
and LH signaling and increase LHCGR abundance (Wang and Chard, 1999).  
Increased free IGF could potentially augment FSH and LH action on follicular cells 
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during oocyte maturation leading to an optimized follicular environment, and thus 
enhance the chances of falling within the optimal maturation window at the time of 
oocyte retrieval.  Oocytes at optimal maturity would more likely yield euploid 
embryos and ultimately improve the chances of live birth.   
FSHR and LHCGR are both G-coupled protein receptors.  FSHR mRNA 
has previously been linked to good quality blastocyst development (Ekart et al., 
2013).  Papamentzelopoulou and colleagues demonstrated a relationship between 
LHCGR mRNA and pregnancy with the ratio of LH splice variants being higher in 
pregnant patients compared to non-pregnant patients (Papamentzelopoulou et al., 
2012b).  Webb and Campbell hypothesized that individual follicles have different 
sensitivities to FSH (Webb and Campbell, 2007); therefore, because FSH is known 
to induce the expression of LH receptors in GCs with follicular maturation, one 
might postulate that LHCGR expression is variable between individual follicles.  
Interestingly, others have shown that LHCGR mRNA expression in CCs was 
higher in mature, as opposed to immature oocytes, yet higher LHCGR mRNA 
expression resulted in lower fertilization rates (Maman et al., 2012).  Consistent 
with these prior studies, we also found that immature oocytes had lower CC 
LHCGR mRNA levels compared to all the other groups, with the exception of 
arrested embryos.  Haouzi and colleagues demonstrated that CC LHCGR mRNA 
expression varied between and within individual patient cohorts of mature oocytes 
(Haouzi et al., 2009).  Measuring individual CCs LHCGR mRNA levels may also 
have allowed us to show a difference between oocytes that led to a live birth and 
those that did not.   
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Genes related to CC expansion and oocyte maturation may show altered 
mRNA levels when comparing mature and immature oocytes.  AREG is an 
epidermal growth factor (EGF)-like family member previously shown to positively 
correlate with embryo quality as well as oocyte maturation and CC expansion in 
response to the LH surge (Freimann et al., 2004, Park et al., 2004, Zhang et al., 
2005).  AREG protein has shown correlations with good oocyte quality with in vitro 
matured porcine embryos (Sugimura et al., 2015) and human IVF derived good 
quality oocytes (Zamah et al., 2010).  Huang and colleagues showed that 
increased AREG mRNA levels in CCs and MGCs were more likely to be associated 
with pregnancy (Huang et al., 2015).  This differs from our study, as we saw 
decreased AREG mRNA levels in CCs from oocytes resulting in live birth.  This 
discordant finding may be due to multiple reasons.  In the Huang et al. study CCs 
and MGCs were pooled together.  In addition, the participants were more diverse 
in terms of diagnoses than our study, and four different stimulation protocols were 
used.  While the overall AREG mRNA levels per patient may have been increased, 
it is possible that the individual CC level for each oocyte leading to live birth was 
decreased.  Our results are consistent with a study by Feuerstein and colleagues 
who showed reduced AREG mRNA levels for CCs of oocytes that resulted in high-
quality blastocysts (Feuerstein et al., 2007).  
Steroidogenesis is a major function of developing follicles.  Granulosa cells 
and theca cells collectively produce androgens, estrogens, and progestins.  
Differential mRNA levels of steroidogenic genes in CCs may impact the fate of 
their associated oocytes.  Previously both CYP19A1 and HSD3B1 showed 
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increased mRNA levels between pooled GCs from embryos that resulted in 
pregnancies compared to embryos that failed to develop (Hamel et al., 2008).  In 
our study, decreased CC HSD3B1 levels significantly increased the odds of an 
oocyte resulting in a euploid embryo.  Additionally, CYP19A1 mRNA was one of 
the biomarkers that borderline predicted live birth in our best fitting model.  
CYP19A1 mRNA encodes aromatase, which converts androstenedione to estrone 
and testosterone to estradiol (Conley and Hinshelwood, 2001).  HSD3B1 protein 
converts pregnenolone to progesterone (Simard et al., 2005).  Like LHCGR, 
CYP19A1 mRNA is induced through FSH signaling, and CYP19A1 mRNA is more 
prevalent in dominant follicles of monovulatory species (Hayashi et al., 2010, 
Kristensen et al., 2017, Sisco et al., 2003).  The optimal maturation window needed 
to produce live birth may be reflected by the interplay between these genes as 
seen in our study.   
We also found decreased ING1 levels showed a borderline increase in the 
odds of an oocyte resulting in a euploid embryo.  ING1 mRNA is a novel biomarker 
we examined.  It encodes a tumor suppressor nuclear protein involved in both cell 
growth and apoptosis and is a member of the p53 signaling pathway (Garkavtsev 
et al., 1998).  ING1 protein is known to modulate androgen receptor (AR) signaling 
(Esmaeili et al., 2016b, Esmaeili et al., 2016a, Tallen et al., 2009) and suppress 
angiogenesis (Tallen et al., 2009).  We did not examine the mRNA expression of 
AR as Assidi and colleagues found no difference between AR mRNA expression 
of oocytes that formed a pregnancy and those that did not (Assidi et al., 2011). 
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There are multiple oocytes retrieved during an IVF cycle that would normally 
regress in a natural reproductive cycle and not ovulate.   Although many of these 
supernumerary oocytes will reach the MII stage of development morphologically, 
the reason IVF cycles may yield lower percentages of oocytes leading to live birth 
is because they fall outside the optimal maturation window.  We hypothesize that 
many mature appearing oocytes actually exhibit underlying pre- or post-mature 
biomarker expression patterns in their CCs and MGCs indicating those oocytes 
are incapable of producing high quality embryos that ultimately lead to live births.  
Our study only evaluated what we believe to be immature versus mature 
oocyte mRNA expression.  Evaluation of post-maturity may be more difficult in a 
clinical IVF setting.  However, in vitro maturation studies in humans or in vivo 
studies in lower mammals may help examine the post-mature aspect of oocyte 
development.  This concept has been recently demonstrated in CCs of CD-1 mice 
examined at various time points following hCG injection.  Artini and colleagues 
demonstrated how the concept of the optimal maturation widow could be 
investigated (Artini et al., 2017).  Oocytes that fell within the optimal maturation 
window exhibited lower levels of AKT serine/threonine kinase 1 (Akt1), BCL2-like 
2 (Bcl2I2) and SHC adaptor protein 1 (Shc1) mRNAs (Figure 5.1).  
Our second series of aims focused on identifying metabolic substrates 
utilized by mitochondria in pooled GCs to determine if any of the substrates were 
modulated in relation to patient age, serum AMH levels, BMI, percentage of mature 
oocytes within a patient cohort, and embryo developmental endpoints.  Since the 
literature on mitochondria related to IVF outcomes is sparse and has focused 
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mainly on mtDNA content, we wanted to quantify mitochondrial activity and see if 
we could identify a group of metabolic substrates differentially utilized by 
mitochondria that could be used as biomarkers for IVF.  In this series of 
experiments, we contributed several important and original contributions to the 
field of IVF: 
• We were the first to demonstrate that a novel mitochondrial function assay 
using tetrazolium dye measuring NADH or FADH2 reducing equivalents of 
individual substrates could be used to as a tool to investigate granulosa cell 
mitochondrial function.   
• We showed that BMI, FSH dosage administered, and the number of mature 
oocytes retrieved per cohort associate with how mitochondria utilize certain 
substrates in pooled GCs including citric acid, L-malic acid, octanoyl-L-
carnitine, cis-acontic acid, D-alpha-keto-glutaric acid, L-glutamine, and 
alanine-glycine.   
• We established that there were individual mitochondrial substrates 
including, glycogen, D-alpha-keto-glutaric acid, and L-glutamine that were 
altered in relation to oocyte fertilization, embryo development on day 3, and 
embryo development to the blastocyst stage. 
• We presented a mitochondrial metabolic scoring system, based on the 
mitochondrial function assay results, to interrogate different patient 
demographic groups and differences between embryo cohorts. 
We discovered that citric acid, L-malic acid, and octanoyl-L-carnitine utillzation by 
mitochondria were significantly lower in patients with lower BMI.  We expected to 
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find some differences in this patient demographic because impaired mitochondrial 
function including decreased mitochondrial membrane potential, lower ATP levels, 
and lower citric acid levels have been demonstrated to be associated with 
increasing BMI in mice (Wang et al., 2010, Igosheva et al., 2010, Ou et al., 2012).  
Further, obese patients have been shown to have reduced pregnancy and live birth 
rates (Koning et al., 2012, Petersen et al., 2013, Pinborg et al., 2013, Rittenberg 
et al., 2011).  Additionally, we found increasing dosages of FSH lowered 
mitochondrial utilization of citric acid, cis-acontic acid, D-alpha-keto-glutaric acid, 
L-glutamine, and alanine-glycine.  FSH dosage administered was previously 
shown to have no impact mitochondrial mRNA expression in GCs of IVF patients 
(Saito et al., 2013).  However, our data may indicate there is a physiological 
metabolic effect in the mitochondria related to FSH dosage.  We found that the 
mitochondrial metabolic scores were significantly reduced when BMI was lower 
and total FSH administered was higher.  FSH and BMI are linked during IVF 
stimulation as patients with lower BMI tend to require lower doses of FSH than 
patients with higher BMI (Fedorcsak et al., 2004).  These results seem to indicate 
that higher BMI increases, while increased dosages of FSH suppress, 
mitochondrial utilization of substrates related to dehydrogenase activity and 
oxidation reactions of the tricarboxylic acid cycle.   
Alpha-keto-isocaproic acid mitochondrial utilization significantly increased 
as the number of mature oocytes increased.  A prior study by Duran and 
colleagues demonstrated that ATP levels increase as oocytes mature from GVs to 
MII oocytes indicating an increase in mitochondrial metabolism as oocytes mature 
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(Duran et al., 2011).   We calculated that the mitochondrial metabolic scores were 
significantly increased in a linear relationship with the total number of oocytes 
retrieved.  Mitochondrial ATP production and mitochondrial membrane potential in 
CCs have both been shown to correlate with the number of mature oocytes 
retrieved (Dumesic et al., 2016).  The data from all these studies seem to coincide 
as overall metabolism appears to increase with larger numbers of mature oocytes 
harvested, potentially indicating a need for higher ATP requirements as GCs help 
prepare the oocytes for fertilization.   
The secondary goal of this study was more intimately related to our overall 
long-term goal.  One hypothesis for poor oocyte quality and compromised embryo 
development is deficient mitochondrial function (Bentov et al., 2011). We wanted 
to determine if mitochondrial substrates in pooled GCs would relate to a patient’s 
overall cohort development.  Mitochondrial utilization of products of glycogen 
degradation were found to be significantly lower in patients with lower fertilization 
percentage.  Mitochondrial metabolism significantly increased for D-alpha-keto-
glutaric acid from patients with lower good quality 8-cell embryos and utilization of 
L-glutamine was found to be significantly higher in patients with a lower percentage 
of blastocyst formation, when using a backward selected model looking only at 8- 
cell embryos and blastocysts.  Mitochondrial metabolic scores decreased as the 
number of fertilized zygotes increased.  This data indicates that the mitochondrial 
metabolic score may be able to predict fertilization potential of a cohort of oocytes.  
Focusing on the substrates which yielded differential metabolic function, one could 
potentially analyze individual CC masses and then relate those results to individual 
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oocytes and resulting embryos in future studies.  Specialized assay plates could 
be made with only the substrates of interest in the wells and optimized for fewer 
cells than the current commercial assay used.   
Proper meiotic spindle formation and function are essential for proper 
oocyte fertilization and embryo development.  Mitochondrial dysfunction has been 
associated with reduced ATP generation and meiotic spindle abnormalities 
(Sutton-McDowall et al., 2010) that may lead to compromised embryo 
development including fertilization failure (Reynier et al., 2001), aneuploidy (Schon 
et al., 2000), and abnormal cytokinesis and arrested development (Van Blerkom, 
2004, Shoubridge and Wai, 2007, Ramalho-Santos et al., 2009).  Reduction in 
ATP content generated by mitochondria may be a symptom of how substrate 
utilization is altered by the mitochondria, as seen in our research.    
Finally, we wanted to investigate whether there was a relationship between 
the mRNA levels with individual CCs observed in our first aim and the mRNAs of 
the pooled GCs from the mitochondrial function assay experiments in our second 
aim.  Examining the subset of genes from the first study which included AREG, 
CYP19A1, CYP11A1, HSD3B1, ING1, LHCGR, and PAPPA, lower HSD3B mRNA 
levels approached significance (P < 0.10) as the mitochondrial metabolic score 
decreased.  A prior study demonstrated HSD3B1 mRNA levels increased between 
pooled GCs from embryos that resulted in pregnancies compared to embryos that 
failed to develop (Hamel et al., 2008).  In our first mRNA biomarker study lower 
CC HSD3B1 mRNA levels significantly increased the odds of an oocyte resulting 
in a euploid embryo.  Perhaps there is a link between HSD3B mRNA levels and 
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mitochondrial function relating to euploid embryo development that needs to be 
further evaluated.    
We hypothesized mitochondrial substrate utilization may be altered based 
on studies that had previously shown mtDNA content differed in oocytes based on 
oocyte fertilization percentage (Santos et al., 2006, Reynier et al., 2001), mtDNA 
content in normal compared to diminished ovarian reserve in oocytes (May-
Panloup et al., 2005b), and mtDNA content in trophectoderm biopsies of high 
quality embryos and embryos that formed pregnancies (Murakoshi et al., 2013, 
Diez-Juan et al., 2015, de Los Santos et al., 2018, Fragouli et al., 2017, Fragouli 
et al., 2015, Ravichandran et al., 2017).  These prior studies did not look at CC 
mtDNA content, however, CC mtDNA content and oocyte mtDNA content have 
been shown to be positively correlated and increasing mtDNA content was 
demonstrated to be associated with better embryo development (Boucret et al., 
2015, Ogino et al., 2016, Desquiret-Dumas et al., 2017).  Specific mitochondrial 
substrate utilization may also indicate oocytes within the optimal maturation 
window.  Oocytes with proper mitochondrial function capable of leading to 
pregnancy and live birth would be reflected in the metabolic utilization of the 
substrate biomarkers.   In the same way we examined immature versus mature 
oocyte CC mRNA levels in study 1, one could examine mitochondrial function the 
same way.  Cumulus cells from immature and mature oocytes could be collected 
and pooled by maturity.  The assays could be performed when there are enough 
cells of each type to run a single replicate of the assay with a control in each assay 
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as a reference.  The individual assays could then be combined and used to 
compare the mature and immature mitochondrial function.  
Our studies have added valuable knowledge to the search for non-invasive 
biomarkers to help select the most viable embryos for uterine transfer.  One could 
imagine combining embryo morphology, PGT-A testing, mRNA levels of select 
genes, and mitochondrial substrates to create a robust prediction model and 
ranking system to select the best embryos for transfer.     Future studies will require 
prospective analysis of the models described above to determine the specificity 
and sensitivity of the biomarkers and the models and include larger samples sizes.  
Ideally, the models will be able to yield a method of ranking embryos from the most 
to least likely to lead to live birth.   Examination of protein levels in CCs related to 
the biomarkers of interest by flow cytometry, enzyme-linked immunosorbent 
assay, or radioimmunoassay may be valuable to determine if protein content 
corroborates with mRNA levels. Biomarker studies for embryo selection are far 
from complete and further studies need to be conducted in order to reach the goal 












Figure 5.1.  Example of an optimal maturation window in mice.  The curve draws an oocyte maturation profile.  Hours 
0-9 represents immature oocytes, hrs 12-15 represent the optimal maturation window, and hrs 15-24 represent a post-
mature maturation oocyte. Mouse oocytes that fell within the optimal maturation window exhibited lower levels of AKT 
serine/threonine kinase 1 (Akt1), BCL2-like 2 (Bcl2I2) and SHC adaptor protein 1 (Shc1) mRNAs (Artini et al., 2017).  
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Human pregnancy or live birth candidate biomarkers  
shown to have differential mRNA expression 
_________________________________________________________________________________________________________________________________ 
Gene name   Symbol  Function  Study Population Samples Reference____________________    
 
Down-regulated biomarkers 
Estrogen receptor 1  ESR1  Transcription factor 4 CC, 4 preg pts  Pooled  Artini et al. 2017  
         4 CC, 4 not preg pts  
 
Nuclear factor I B          NFIB  Transcription factor 5 CC, preg pts        Individual Assou et al. 2008 
         5 CC, not preg pts 
 
Docking protein 5   DOK5 *  Signal transduction MGC, 16 & 28 preg pts Pooled  Fortin et al. 2019 
         MGC, 16 & 69 not preg  
 
DnaJ heat shock   DNAJC15 Heat shock protein 101 CC, 58 pts,  Individual Iager et al. 2013  
  protein family (Hsp40)       multicenter        
  member C15       
 
Microtubule associated  MTUS1  Tumor suppressor 
  tumor suppressor 1 
 
Nucleoporin 133   NUP133  Nucleoporin 
 








APPENDIX A continued. 
_________________________________________________________________________________________________________________________________ 
Gene name   Symbol  Function  Study Population Samples Reference____________________ 
Zinc finger protein 93  ZNF93  Zinc finger protein  
 
Lysine demethylase 4A  KDM4A  Demethylase  31 CC, 31 MGC preg pts Pooled  Krieg et al. 2018  
         53 CC, 51 MGC not preg  
Lysine demethylase 4B  KDM4B  Demethylase       
 
Runt related                     RUNX2  Transcription factor 5 CC each, 41 pts Pooled  Papamentzelopoulou et al. 2012a 
  transcription factor 2 
 
Up-regulated biomarkers 
Forkhead box O4   FOXO4  Transcription factor 4 CC, 4 preg pts  Pooled  Artini et al. 2017  
         4 CC, 4 not preg pts  
 
Chromodomain helicase   CHD9  Chromatin remodeling 14 CC, 8 pts  Individual Assidi et al., 2011 
  DNA binding protein 9 
 
Proteasome 26S subunit,  PSMD6  Proteasome subunit 
  non-ATPase 6 
 
Ubiquilin 1   UBQLN1 Ubiquilin  
 
Dipeptidyl peptidase 8  DPP8  Peptidase  11 CC, 7 pts  Individual Assidi et al., 2015 
 
Proteasome 26S subunit,  PSMD6  Proteasome subunit 
  non-ATPase 6 
 
Ubiquilin 1   UBQLN1 Ubiquilin    
 
BCL2 like 11   BCL2L11 Apoptosis regulator 5 CC, preg               Individual Assou et al. 2008 
         5 CC, not preg 
Phosphoenolpyruvate   PCK1  Gluconeogenic enzyme  








APPENDIX A continued. 
_________________________________________________________________________________________________________________________________ 
Gene name   Symbol  Function  Study Population Samples Reference____________________    
Pleckstrin homology like  PHLDA1  Apoptosis regulator MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
  Domain family A member 1  
 
UDP-glucose   UGP2  Glucogenic enzyme  
  pyrophosphorylase 2 
 
AT-rich interaction  ARID1B  Chromatin remodeling 101 CC, 58 pts,  Individual Iager et al. 2013 
  domain 1B        multicenter        
 
COX20, cytochrome c  COX20  Electron transport chain 
  oxidase assembly factor      
 
Fibroblast growth factor 12  FGF12  Growth factor  
 
G protein-coupled receptor 137B  GPR137B G protein-coupled receptor 
          
Nuclear receptor subfamily 2 NR2F6  Transcription factor 101 CC, 58 pts,  Individual Iager et al. 2013  
  group F         multicenter  
  member 6      
 
Solute carrier family 2  SLC2A9  Glucose transport 
  member 9 
 
Zinc finger protein 132  ZNF132  Zinc finger protein 
 
Bone morphogenetic  BMP15  Paracrine signaling 2426 CC, 196 pts  Pooled  Li Y et al., 2014 
  protein 15      
 
Growth differentiation factor 9 GDF9  Paracrine signaling                   
_____________________________________________________________________________________________________________________________ 
* Two separate analyses were performed in the same study      










Human pregnancy or live birth candidate biomarkers  
with conflicting differential mRNA expression by qRT-PCR * 
_________________________________________________________________________________________________________________________________________________ 
Gene   Symbol  Function  mRNA expression  Study Population   Samples  Reference_______________ 
Activated leukocyte  ALCAM  Cell adhesion Live birth = not preg/loss 270 CC, 25 pts  Individual  Ekart et al. 2013 
  cell adhesion      Preg > not preg  42 CC, 42 pts  Individual  Wathlet et al. 2011 
  molecule 
 
Baculoviral IAP repeat BIRC5  Apoptosis  Preg = not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
  containing 5    regulator  Preg > not preg  MGC, 28 pts  Pooled  Fujino et al.2008 
       Preg = not preg  CC, 29 pts  Pooled  Varras et al. 2012  
 
Calmodulin 1  CALM1  Calcium binding Preg > not preg  14 CC, 8 pts  Individual  Assidi et al. 2011 
       Preg > not preg  11 CC, 7 pts  Individual  Assidi et al. 2015 
       Preg = not preg  39 CC, 39 pts  Individual  Burnik et al. 2015a 
 
Calcium/calmodulin  CAMK1D  Serine/threonine Preg > not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
  dependent      Preg > not preg ns trend  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
  protein kinase 
  kinase ID   
      
Cell division cycle 42DC42   Cell cycle control Preg > not preg  30 MGC, CC, 18 pts ea Pooled  Hamel et al. 2008  
       Preg > not preg ns trend  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
 
C-X-C motif ligand 2 CXCL2^  Inflammation Preg < not preg  16 MGC, 16 pts ea  Pooled  Fortin et al. 2019 
       Preg = not preg  28 MGC preg pts  Pooled  Fortin et al. 2019 










APPENDIX B continued. 
_________________________________________________________________________________________________________________________________________________ 
Gene   Symbol  Function  mRNA expression  Study Population   Samples  Reference_______________ 
Cytochrome P450   CYP19A1  Steroidogenic Preg > not preg  30 MGC, CC, 18 pts ea  Pooled   Hamel et al. 2008  
  family 19     enzyme  Preg = not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
  subfamily A        
  member 1 
 
Ephrin B2   EFNB2  Ephrin  Preg < not preg  43 CC, 43 pts  Individual  Burnik et al. 2015c 
Preg > not Preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
Preg > not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
 
Ferredoxin 1  FDX1  Steroidogenic Preg > not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 2008  
     enzyme  Preg = not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
 
Gremlin 1, DAN  GREM1  BMP antagonist Live birth = not preg** 38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
  family BMP                 Predicts pregnancy  108 CC, 8 ICSI pts  Pooled  Mckenzie et al.  2004               
  antagonist      Preg > not preg  42 CC, 42 pts  Individual  Wathlet et al. 201 
 
Hyaluronan synthase 2 HAS2  Glycosyl-  Live birth = not preg/loss 270 CC, 25 pts  Individual  Ekart et al. 2013 
transferase  Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
   Predicts pregnancy  108 CC, 8 ICSI pts  Pooled  Mckenzie et al.  2004 
 
H4 clustered histone 3 H4C3  Histone  Preg > not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
         Preg = not preg  11 CC, 7 pts  Individual  Assidi et al., 2015 
  
 
Hydroxy-delta-5-   HSD3B1  Steroidogenic Preg > not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 2008 
  steroid     enzyme  Preg = not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
  dehydrogenase, 
  3 beta-and steroid  
  delta-isomerase 1       
 
Inositol-trisphosphate ITPKA  Kinase  Preg = not preg  39 CC, 41 pts  Individual  Burnik et al. 2015a 
  3-kinase A      Preg > not preg  42 CC, 42 pts  Individual  Wathlet et al. 2011 
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_________________________________________________________________________________________________________________________________________________ 
Gene   Symbol  Function  mRNA expression  Study Population   Samples  Reference_______________ 
Luteinizing hormone/                LHCGR  G protein-coupled  See note **  CC, 40 pts  Pooled  Papamentzelopoulou  
choriogonadotropin receptor   receptor            et al. 2012b 
       Preg = not preg  MGC, CC, 111 pts  Pooled  Lee et al. 2016 
Preg = not preg  30 MGC, CC, 18 pts ea Pooled  Hamel et al. 2008 
 
Neuropilin 1  NRP1  Growth factor  Preg > not preg  14 CC, 8 pts  Individual  Assidi et al. 2011 
  receptor       Preg > not preg  11 CC, 7 pts  Individual  Assidi et al., 2015 
Live birth = not preg/loss 270 CC, 25 pts  Individual  Ekart et al. 2013 
Preg = not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
 
Neurotensin  NTS^  Neurotransmitter Preg < not preg  28 MGC preg pts  Pooled  Fortin et al. 2019 
          69 MGC not preg pts 
Preg = not preg  16 MGC, 16 pts ea  Pooled  Fortin et al. 2019  
   
Phosphoglycerate  PGK1  Kinase  Preg = not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 200 
kinase 1       Preg > not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a  
         
Prostaglandin-  PTGS2   Prostaglandin Preg = not preg  39 CC, 41 pts  Individual  Burnik et al. 2015a 
  endoperoxide    synthesis   Live birth > not preg  38 CC, 38 pts SET  Individual  Gebhardt et al. 2011 
  synthase 2               Predicts pregnancy  108 CC, 8 ICSI pts  Pooled  Mckenzie et al. 2004 
       Preg > not preg  42 CC, 42 pts  Individual  Wathlet et al. 2011 
 
Pentraxin 3  PTX3  Immune  Preg = not preg  90 CC, 45 pts  Individual  Cillo et al. 2007 
response  Preg > not preg  38 CC, 22 pts  Individual  Feuerstein et al.  2012 
Live birth > not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
ns trend 
 
Regulator of  RGS2  G protein  Preg = not preg  43 CC, 43 pts  Individual  Burnik et al. 2015c 
G-protein signaling 2   signaling  Preg > not preg  38 CC, 22 pts   Individual  Feuerstein et al.  2012 
       Preg = not preg  30 MGC, CC, 18 pts Pooled   Hamel et al. 2008 
Preg > not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
     
Syndecan 4  SDC4  Intracellular Preg > not preg  42 CC, 42 pts  Individual  Wathlet et al. 2011 
     signaling  Preg = not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
Serpin family E  SERPINE2 Peptidase Preg > not preg  30 MGC, CC, 18 pts  Pooled  Hamel et al. 2008 
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_________________________________________________________________________________________________________________________________________________ 
Gene   Symbol  Function  mRNA expression  Study Population   Samples  Reference_______________ 
Target of myb1  TOM1  Intracellular Preg > not preg  14 CC, 8 pts  Individual  Assidi et al. 2011 
  membrane    trafficking  Preg = not preg  11 CC, 7 pts  Individual  Assidi et al. 2015 
  trafficking protein 
 
Transient receptor  TRPM7  Ion channel Preg > not preg  42 CC, 42 pts  Individual  Wathlet et al. 2011 
  potential cation      Preg = not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
  channel subfamily  
  M member 7 
 
Taurine up-regulated 1 TUG1  Long non- Preg = not preg  14 CC, 8 pts  Individual  Assidi et al. 2011 
  (non-protein coding)   coding RNA Preg > not preg  11 CC, 7 pts  Individual  Assidi et al. 2015 
 
Versican   VCAN  Cell adhesion Preg = not preg  43 CC, 43 pts  Individual  Burnik et al. 2015c 
Live birth > not preg/loss 270 CC, 25 pts  Individual  Ekart et al. 2013 
Live birth > not preg^^ 38 CC, 38 pts SET  Individual  Gebhardt et al. 2011 
Preg > not preg  42 CC, 42 pts  Individual  Wathlet et al. 2011 
Preg = not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
_________________________________________________________________________________________________________________________________ 
* observed in two or more studies;  
**Splice variants were present in greater quantities in pregnant vs not pregnant patients 
^ Two separate analyses were performed in the same study   
^^positive correlation with birth weight      
CC = cumulus cells; MGC = mural granulosa cells; ICSI = intra-cytoplasmic sperm injection   
SET = single embryo transfer; pts = patients; ea = each group; preg = pregnant, ns = not significant  













Human pregnancy or live birth candidate biomarkers 
shown not to have differential mRNA expression by qRT-PCR 
_________________________________________________________________________________________________________________________________________________ 
Genes  Symbol  Function   mRNA expression  Study Population  Samples  Reference_______________ 
Aryl hydrocarbon AHR  Transcription factor  Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
      receptor 
 
Aldolase, fructose- ALDOA  Gluconeogenic   Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
  bisphosphate A    enzyme  
 
Aquaporin 1 AQP1  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
  (Colton blood  
   group) 
 
Aquaporin 2 AQP2  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
 
Aquaporin 3 AQP3  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
  (Gill blood group)  
 
Aquaporin 4 AQP4  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
 
Aquaporin 5 AQP5  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
 
Aquaporin 6 AQP6  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016
 
Aquaporin 7 AQP7  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
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Genes  Symbol  Function   mRNA expression  Study Population  Samples  Reference_______________ 
Aquaporin 11 AQP11  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016
 
Aquaporin 12A AQP12A  Passive H2O transport Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
 
Androgen receptor AR   Nuclear hormone  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
receptor 
BTB domain and BACH2  Transcription factor  Preg = not preg  30 MGC, CC, 18 pts ea Pooled  Hamel et al. 2008 
  CNC homolog 2            
 
Calmodulin 2 CALM2  Calcium binding  Preg = not preg  42 CC, 42 pts  Individual  Wathlet et al. 2011 
 
Calumenin CALU  Calcium binding  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
 
Chromogranin B CHGB  Secretory protein  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
 
C-X-C motif  CXCL8^  Inflammation  Preg = not preg  MGC, 16 & 28 preg pts Pooled  Fortin et al. 2019 
  chemokine          MGC, 16 & 69 not preg 
  ligand 8 
 
Cytochrome P450 CYP11A1  Steroidogenic enzyme Preg = not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
  family 11 
  subfamily A  
  member 1 
 
Dihydro-  DPYSL3  Enzyme   Preg = not preg  30 MGC, CC, 18 pts ea  Pooled   Hamel et al. 2008 
  pyrimidinase      Preg = not preg  MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
  like 3  
             
Early growth  EGR1  Transcription factor  Preg = not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 2008  
  response 1      Preg = not preg  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a  
 
Epiregulin EREG  EGF ligand  Preg = not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 2008  
Preg = not preg  MGC, CC, 18 pts   Pooled  Hamel et al. 2010b 
 
Follicle stimulating FSHR  G protein-coupled   Live birth = not preg/loss 270 CC, 25 pts  Individual  Ekart et al. 2013 
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Genes  Symbol  Function   mRNA expression  Study Population  Samples  Reference_______________ 
Forkhead box O1 FOXO1  Transcription factor  Preg = not preg  8 CC, 8 pts  Pooled  Artini et al. 2017  
 
Forkhead box O3 FOXO3  Transcription factor  Preg = not preg  8 CC, 8 pts  Pooled  Artini et al. 2017  
 
GA binding protein GABPB1  Transcription factor  Preg = not preg  MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
  transcription factor         
  beta subunit 1 
 
Glutathione GPX3  Glutathione  Preg = not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
  peroxidase 3     peroxidase 
 
Glutathione- GSR  Enzyme   Preg > not preg ns trend 47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
  disulfide reductase 
 
Glutathione GSTA3  Glutathione  Preg = not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
  S-transferase     peroxidase 
  alpha 3 
 
Glutathione GSTA4  Glutathione  Preg > not preg ns trend 47 CC, 47 ICSI pts  Individua l Wathlet et al. 2013 
  S-transferase     peroxidase 
  alpha 4 
 
Homeodomain HIPK1  Serine/threonine  Preg = not preg  39 CC, 41 pts  Individual  Burnik et al. 2015a 
  interacting protein      kinase 
  kinase 1 
 
Homer scaffolding HOMER1  Scaffold protein  Preg = not preg  MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
 protein 1            
 
Interleukin 1 beta IL1B^  Cytokine   Preg = not preg  MGC, 16 & 28 preg pts Pooled  Fortin et al. 2019 
          MGC, 16 & 69 not preg 
 
Interleukin 6 signal  IL6ST  Signal transduction  Preg = not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 2008 
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Genes  Symbol  Function   mRNA expression  Study Population  Samples  Reference_______________ 
Inhibin beta A INHBA  FSH secretion  Preg = not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 2008 
  subunit      inhibitor 
 
Integral membrane ITM2A  Membrane protein  Preg = not preg  39 CC, 39 pts  Individual  Burnik et al. 2015a 
 protein 2A 
 
Inositol 1,4,5- ITPR1  IP3 receptor  Preg = not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
  trisphosphate     
  receptor type 1 
 
KH RNA binding KHDRBS3 Signal transduction  Preg = not preg  39 CC, 39 pts  Individual  Burnik et al. 2015a 
  domain containing,  
  signal transduction  
  associated 3 
 
Keratin 6A KRT6A  Filament protein  Preg = not preg  39 CC, 39 pts  Individua l Burnik et al. 2015a 
 
Lactate  LDHA  Lactate   Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
  dehydrogenase A     dehydrogenase 
 
LDL receptor LRP8  Apolipoprotein E  Preg = not preg  MGC, CC, 18 pts   Pooled  Hamel et al. 2010b 
  related protein 8     and reelin receptor           
 
Myristoylated MARCKS  Actin binding  Preg = not preg  MGC, CC, 18 pts   Pooled  Hamel et al. 2010b 
  alanine  rich          
  protein kinase C 
  substrate 
 
Nudix hydrolase 10 NUDT10  Hydrolase  Preg = not preg  39 CC, 39 pts  Individual  Burnik et al. 2015a 
 
Parathyroid PTHLH  Hormone   Preg = not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
  Hormone 
  like hormone 
 
Phospho-, PFKP*  Glycolytic enzyme  Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
  fructokinase  
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Genes  Symbol  Function   mRNA expression  Study Population  Samples  Reference_______________ 
Progesterone PGR  Nuclear hormone  Preg = not preg  MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
  receptor      receptor   Preg = not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
Live birth = not preg/loss 270 CC, 25 pts  Individual  Ekart et al. 2013 
 
Pirin  PIR  Iron-binding protein  Preg = not preg  MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
 
Pyruvate kinase, PKM  Glycolytic enzyme  Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
  muscle 
 
Protein kinase N2 PKN2  Serine/Threonine  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
      kinase 
 
Prothymosin alpha PTMA^  Immune response  Preg = not preg  MGC, 16 & 28 preg pts Pooled  Fortin et al. 2019 
          MGC, 16 & 69 not preg 
 
Regulator of RGS3  G protein signaling  Preg > not preg ns trend  MGC, CC, 38 pts  Pooled  Hamel et al. 2010a 
  G-protein           
  signaling 3 
 
Ribosomal RPL9  Ribosomal protein  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
  protein L9 
 
Scavenger SCARB1  Lipoprotein receptor  Preg = not preg  30 MGC, CC, 18 pts ea Pooled   Hamel et al. 2008 
  receptor class          
  B member 1 
 
Semaphorin 3A SEMA3A  Secretion   Preg = not preg  MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
  membrane protein           
 
Serpin family A SERPINA3 Peptidase inhibitor  Preg = not preg  30 MGC, CC, 18 pts ea Pooled  Hamel et al. 2008 
  member 3      Preg = not preg  MGC and CC  Pooled  Hamel et al. 2010a 
     
Secreted frizzled SFRP1  Wnt signaling  Preg = not preg  MGC, CC, 18 pts   Pooled  Hamel et al. 2010b 
  related protein 1  
 
Secreted frizzled SFRP2  Wnt signaling  Preg = not preg  270 CC from 25 pts  Individual  Ekart et al. 2013 
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Genes  Symbol  Function   mRNA expression  Study Population  Samples  Reference_______________ 
Solute carrier SLC2A1  Glucose transport  Preg = not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
  family 2 member 1 
 
Solute carrier SLC2A4  Glucose transport  Preg = not preg  270 CC, 25 pts  Individual  Ekart et al. 2013 
  family 2 member 4 
 
SPHK1 interactor, SPHKAP  PKA signaling  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
  AKAP domain  
  containing 
 
Sprouty RTK SPRY2  Kinase inhibitor  Preg = not preg  MGC, CC, 18 pts ea Pooled   Hamel et al. 2008 
  Signaling 
  antagonist 2           
 
SplA/ryanodine SPSB2**  Signal transduction  Preg > not preg ns trend  38 CC, 22 pts   Individual  Fragouli et al., 2012 
  receptor domain  
  and SOCS box  
  containing 2 
 
Steroidogenic  STARD1  Steroidogenesis  Preg = not preg  MCG, CC, 111 pts  Pooled   Lee et al. 2016 
  Acute Regulatory 
  Protein 
 
Stanniocalcin 1 STC1  Hormone   Preg = not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
Preg = not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
Stanniocalcin 2 STC2  Hormone   Preg = not preg  99 CC, 33 ICSI pts  Individual  Wathlet et al. 2012 
 
Steroid sulfatase STS  Sulfatase   Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
  (microsomal),  
  isozyme S 
 
Synaptotagmin 11 SYT11  Protein trafficking  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
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Genes  Symbol  Function   mRNA expression  Study Population  Samples  Reference_______________ 
Transforming TGFB1  Growth factor  Preg = not preg  47 CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
  growth factor  
  beta 1 
 
Thrombospondin 1 THBS1  Adhesion protein  Preg = not preg  47CC, 47 ICSI pts  Individual  Wathlet et al. 2013 
 
THO complex 2 THOC2  Transcription factor  Preg = not preg  14 CC, 8 pts  Individual  Assidi et al., 2011 
 
Transmembrane TMEM64  Calcium signaling  Preg = not preg  39 CC, 41 pts  Individual  Burnik et al. 2015a 
  protein 64  
    
TNF alpha TNFAIP6  Hyaluronin binding  Live birth = not preg  38 CC, 38 pts SET  Individual  Gebhardt et al.  2011 
  induced protein 6      Preg = not preg  MGC, CC, 18 pts ea Pooled  Hamel et al. 2008 
Preg = not preg  108 CC, 8 ICSI pts  Pooled  Mckenzie et al. 2004 
Tumor protein p53 TP53I3**  Dehydrogenase  Preg = not preg  38 CC, 22 pts   Individual  Fragouli et al., 2012 
  inducible protein 3 
 
UDP-glucose UGP2  Glycogenic enzyme  Preg > not preg  MGC, CC, 18 pts  Pooled  Hamel et al. 2010b 
  Pyrophos- 
  phorylase 2           
 
Tryptophan rich WRB  Nuclear protein  Preg = not preg  39 CC, 39 pts  Individual  Burnik et al. 2015a 
  basic protein 
 
Tyrosine 3- YWHAZ  Signal transduction  Preg = not preg  MGC, CC, 18 pts   Pooled  Hamel et al. 010b 
 monooxygenase/           
 tryptophan 5- 
 monooxygenase 
 activation protein zeta  
____________________________________________________________________________________________________________________ 
*positive correlation with birth weight; ** overexpressed in chromosomally normal oocytes      
^ Two separate analyses were performed in the same study   
CC = cumulus cells; MGC = mural granulosa cells; ICSI = intra-cytoplasmic sperm injection   
SET = single embryo transfer; pts = patients; ea = each group; preg = pregnant, ns = not significant  
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